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Abstract
Gene therapy utilizing adeno-associated viral (AAV) vectors has experienced much success in the clinic
recently, culminating in the approval of Luxturna, the first AAV gene replacement product approved by the
FDA. However, many significant obstacles remain to the translation of AAV vectors into widely available
therapeutics, including immune responses to the capsid as well as a general lack of biochemical
characterization of the AAV capsid itself. Humoral immunity, generated in response to viral infection or
vector delivery, can reduce therapeutic efficacy due to AAV neutralization by neutralizing antibodies
(NAbs). To study these interactions and to inform the design of novel capsids able to evade NAbs, we
identified the novel and highly neutralizing antibody PAV9.1 from a panel of hybridoma clones and
mapped its epitope on AAV9 by cryo-EM. Mutagenesis efforts within this epitope established the minimal
changes required to confer evasion of both PAV9.1 binding and neutralization, but this evasion was not
found to extend to polyclonal, NAb positive samples from a number of sources, reflecting the complexity
of the NAb repertoire against AAV. To enable more complete study of this repertoire in a more
therapeutically-relevant fashion, we also established a pipeline for the unbiased cloning of novel α-AAV
antibodies from single memory B cells isolated from seropositive individuals. Using this approach, we
were able to isolate a panel of mAbs found to recognize AAV capsid, validating the use of this method for
further study of the polyclonal AAV Ab repertoire. Finally, to come to a better understanding of the
biochemical properties of the AAV capsid with the potential to influence critical aspects of vector
performance, including cellular transduction and interactions with the immune system, we evaluated AAV
by mass spectrometry for the presence of post-translational modifications. We established that there is
extensive deamidation of asparagine residues and through genetic deamidation mutagenesis determined
that these spontaneous events are a source of potentially undesirable heterogeneity that modulates
capsid protein charge, assembly, and in vitro and in vivo transduction. These studies highlight novel
findings that contribute to the greater understanding of AAV biology and will inform future efforts to
develop next-generation vectors.
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ABSTRACT
IMMUNOLOGICAL AND BIOCHEMICAL EVALUATION OF THE AAV CAPSID TO ADVANCE
NEXT-GENERATION GENE THERAPY VECTOR DESIGN
April Rose Giles
James M Wilson
Gene therapy utilizing adeno-associated viral (AAV) vectors has experienced much
success in the clinic recently, culminating in the approval of Luxturna, the first AAV gene
replacement product approved by the FDA. However, many significant obstacles remain to the
translation of AAV vectors into widely available therapeutics, including immune responses to the
capsid as well as a general lack of biochemical characterization of the AAV capsid itself. Humoral
immunity, generated in response to viral infection or vector delivery, can reduce therapeutic
efficacy due to AAV neutralization by neutralizing antibodies (NAbs). To study these interactions
and to inform the design of novel capsids able to evade NAbs, we identified the novel and highly
neutralizing antibody PAV9.1 from a panel of hybridoma clones and mapped its epitope on AAV9
by cryo-EM. Mutagenesis efforts within this epitope established the minimal changes required to
confer evasion of both PAV9.1 binding and neutralization, but this evasion was not found to
extend to polyclonal, NAb positive samples from a number of sources, reflecting the complexity of
the NAb repertoire against AAV. To enable more complete study of this repertoire in a more
therapeutically-relevant fashion, we also established a pipeline for the unbiased cloning of novel
α-AAV antibodies from single memory B cells isolated from seropositive individuals. Using this
approach, we were able to isolate a panel of mAbs found to recognize AAV capsid, validating the
use of this method for further study of the polyclonal AAV Ab repertoire. Finally, to come to a
better understanding of the biochemical properties of the AAV capsid with the potential to
influence critical aspects of vector performance, including cellular transduction and interactions
with the immune system, we evaluated AAV by mass spectrometry for the presence of posttranslational modifications. We established that there is extensive deamidation of asparagine
residues and through genetic deamidation mutagenesis determined that these spontaneous
v

events are a source of potentially undesirable heterogeneity that modulates capsid protein
charge, assembly, and in vitro and in vivo transduction. These studies highlight novel findings that
contribute to the greater understanding of AAV biology and will inform future efforts to develop
next-generation vectors.
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CHAPTER 1: Introduction
Introduction to gene therapy
Recent clinical efforts have demonstrated that gene therapy has tremendous potential to
address unmet need for a wide variety of conditions; initial gene replacement efforts focused
specifically on treating rare, monogenic diseases, but the technology has expanded to include
applications in infectious disease, autoimmunity, oncology, and chronic illnesses. This approach
functions by delivering nucleic acids (either RNA or DNA) encoding a transgene of interest to a
specific tissue or cell type where this transgene can then be expressed to replace a missing
protein, correct the host genome to endogenously produce functional protein itself, or even
introduce a novel protein able to fight pathogens or cancer. Many strategies have been taken to
deliver these recombinant nucleic acids, divided into two distinct groups: viral and non-viral
approaches. While non-viral approaches package nucleic acids into synthetic particles, often
liposomes, or inject naked plasmid DNA directly into a given tissue, viral approaches take
advantage of the natural ability of viruses to target, enter, and express genes in human tissues.
Early viral gene therapy efforts focused on the use of retroviral vectors designed to
integrate into the host genome for continuous expression of a therapeutic transgene. The first-inhuman trials utilizing retroviral vectors took place in 1990, but the first trial to demonstrate the
longevity and effectiveness of this approach was in 1999, in which a murine leukemia virus-based
retroviral vector encoding the interleukin-2 receptor ɣ-chain was used to transduce patient bone
marrow cells ex vivo for the treatment of X-linked severe combined immunodeficiency (1, 2).
However, a number of subjects in the trial developed leukemia that was linked to insertion of the
retroviral vector genome, raising serious concerns regarding the use of integrating viral vectors
for therapeutic purposes (3). Years of engineering efforts aimed at addressing the safety
concerns surrounding retroviral (and subsequently, lentiviral) vectors has led to the development
safer and more effective integrating vectors, resulting in many successful clinical trials and the
European approval of Strimvelis, the first ex vivo gene therapy product (4, 5).
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While integrating vectors were preferred for transduction of replicating cell populations,
the field also sought to develop vectors that could transduce non-replicating cells and whose
genomes could be easily manipulated to remove unnecessary viral components and be
maintained episomally. Initially, adenovirus was selected as an ideal candidate due to its ability
to transduce non-dividing cells in a large breadth of tissues, the ability of its genome to
accommodate large transgenes, and the ability to easily produce large quantities of vector;
however, adenoviral vectors proved to be more immunogenic than anticipated, resulting in
unanticipated severe adverse events in the clinic (6). As such, they are now more frequently
utilized as vaccines against a number of pathogens and cancers (7-9). Similarly to integrating
viral vectors, many safety concerns surrounding adenoviral vectors have been addressed and a
new generation of helper-dependent (HDAd) vectors are also currently being developed as both
in vivo and ex vivo gene replacement strategies (10, 11). Focus then shifted to, and largely
remained, on the use of adeno-associated virus (AAV) as the primary viral vector for gene
therapy applications.
The first clinical trial utilizing AAV was performed in 1995 for the treatment of cystic
fibrosis (12). Since then, over 200 clinical trials using these vectors have been initiated worldwide (13). Significant advances have been made towards the commercialization of AAV-mediated
treatment of a variety of indications, including inherited forms of blindness, hemophilia, and
lysosomal storage disorders (14, 15). This culminated in the EMA approval of the first gene
therapy product in Europe, Glybera for lipoprotein lipase deficiency, in 2012, followed by the FDA
approval in 2017 of the first AAV gene therapy product in the United States, Luxturna for the
treatment of RPE65-mediated Leber’s congenital amaurosis (16-18). While many unanswered
questions remain regarding AAV vector biology, the success of these recent ground-breaking
approvals demonstrate the tremendous potential of AAV gene therapy to address unmet need in
the rare disease community.
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Adeno-associated virus as a gene therapy vector
AAV was discovered in 1965 as a 20nm contaminant particle in a preparation of human
adenovirus (19). It is considered a “replication deficient” virus as it requires co-infection with a
helper virus, such as adenovirus or herpes simplex virus, to perpetuate its production and
subsequent spread of infection (20). As such, all AAVs are classified as belonging to the genus
Dependoparvovirus within the viral family Parvoviridae, the other members of which are
parvoviruses capable of replicating without the aid of a helper virus. While these other
Parvoviridae family members, such as parvovirus B19, are capable of causing significant disease
in humans and other mammals, AAV has not been reported to do so and is therefore considered
to be non-pathogenic (21, 22). Due, in part, to the lack of independent replication and subsequent
lack of pathogenesis, AAV has a low immunogenicity profile, especially when compared to the
immune responses generated to other DNA viruses such as adenovirus (23). Taken together,
these properties of AAV that qualify it as a defective virus also make it an ideal candidate for use
as a viral vector for gene therapy.
In addition to these inherent qualities of AAV that support the safety of its use as a gene
therapy vector, other properties contribute to the ease of its utility as a vector. AAV is a simple,
single-stranded DNA virus. Its genome is small when compared to that of other candidate viral
vectors (~4.6kb), which significantly limits its packaging capacity and therefore its use for certain
indications; however, this smaller size also allows for relatively straightforward engineering and
optimization of the vector genome (24). The wild-type AAV genome contains 2 main genes, rep
and cap, with a third open reading frame encoding the assembly-activating protein (AAP) (25).
The rep gene encodes for four non-structural proteins, Rep78 and Rep68 from the p5 promoter
and Rep52 and Rep40 from the p19 promoter (26). The Rep proteins perform a number of
essential functions throughout the course of the viral lifecycle, including genome replication,
transcriptional regulation, and the packaging of genomes into newly-formed AAV capsids (26,
27). The cap gene, through the use of the p40 promoter, splicing events, and a non-canonical
start site, encodes viral protein (VP) 1, VP2, and VP3, the three structural proteins required for
3

the formation of the icosahedral AAV capsid. VP1, VP2, and VP3 are unique in that they are all
expressed from an overlapping reading frame such that the entirety of the amino acid sequence
of VP3 is contained in the C-terminus of VP2, which is entirely contained in the C-terminus of VP1
(28). The N-terminus of VP1, called the VP1 unique region, or VP1u, contains a phospholipase
domain and performs additional, non-structural roles in viral infection, such as endosomal escape
following cellular entry (29). A fourth protein, AAP, is encoded from a secondary open reading
frame within the cap gene; AAP is required for efficient assembly of intact, viral particles for the
majority of AAV serotypes (30). The rep and cap genes are flanked at both the 5’ and 3’ ends by
double-stranded hairpin structures call inverted terminal repeats (ITRs) that play important roles
in second-strand synthesis as well as genome replication, transcription, and packaging (31, 32).
All genetic material located between these ITRs can be removed and replaced with a cassette
expressing a gene of interest, rendering the resulting vector void of most viral sequences and
unable to replicate even in the presence of helper virus. By providing rep and cap proteins in
trans as well as the necessary helper virus proteins, these AAV vectors can therefore be easily
produced in a variety of cell lines (33).
Sequence and structural variation of AAV
While most AAV vectors are produced using AAV2 ITRs and rep proteins because they
are the most characterized and are compatible with the production of all AAV vectors, the cap
proteins can be derived from the AAV best-suited for a given application (34). Approximately 10
serotypes of AAV have been identified (35, 36). These serotypes are defined not only by the
amino acid sequence of their cap gene but by the cross reactivity of sera isolated from animals
immunized with the given AAV capsids; if sera generated in response to an AAV does not
sufficiently cross react with a different AAV, the two are considered to be distinct AAV serotypes
(36, 37). In addition to these serotypes, over 200 variants of AAV have been identified that are
not serologically different from the previously identified serotypes but vary in both capsid amino
acid sequence and structure (36, 38, 39). As parvoviruses infect a variety of hosts, these AAV
variants have been isolated from tissues such as heart, lung, liver, and spleen from many
4

different sources, including humans, non-human primates, and pigs (36, 40, 41). These variants
are organized into clades based upon the DNA sequence of their native genomes, and it is
variation in the cap gene and the VPs it encodes that confers specific properties to each AAV
variant.
The shared VP1/VP2 region as well as the VP1u region of full length VP1 and/or VP2
perform functions essential for AAV transduction. The VP1 unique region (VP1u), located in the
capsid interior under most conditions, contains a phospholipase domain that is essential for
proper AAV trafficking following cellular entry, functioning to aid in the escape of the capsid from
the endosome following externalization (29, 42). Additionally, both the VP1u region and the
shared VP1/2 region contain a number of basic regions that function as nuclear localization
sequences that enable the AAV capsid to enter the nucleus (43). While there is natural variation
in the VP1/VP2 N-terminal regions of the AAV VPs, the majority of these motifs are conserved
between AAVs; most variation between AAVs originates from differences in the external capsid
structure itself (44).
VP1, VP2, and VP3 monomers assemble in a ratio of approximately 1:1:10 to form an
individual AAV capsid containing 60 VP monomers in total, with the shared VP3 portion of each
monomer contributing primarily to the capsid structure (28, 45). Each VP3 motif contains a core,
eight-stranded β-barrel motif as well as a conserved α-helix motif (Figure 1A) (46). The remainder
of the VP3 structure is less ordered, highlighted by nine flexible loop motifs called hypervariable
regions (HVRs) (Figure 1A). The resulting capsid is a classic icosahedron, with a 2-fold, 3-fold,
and 5-fold axis of symmetry (Figure 1B). The 2-fold axis is characterized by the two-fold
depression, which has been implicated in conformational changes during endosomal trafficking
(47). The 5-fold axis is characterized by the five-fold pore, comprised of HVR-II surrounded by a
highly conserved canyon region. The five-fold pore has been implicated in not only the loading of
the DNA genome into the capsid during packaging but also in extrusion of the VP1u region
following cellular entry to allow the phospholipase domain to access the endosomal membrane
during endosomal escape (48). The interaction site of three individual VP3 monomers at three5

fold axis forms the three-fold protrusions (or spikes). The three-fold protrusions are of particular
interest, as they are the sites of interaction of the capsid with cellular receptors as well as with
antibodies (49, 50).
Of the approximately 530 amino acids that comprise VP3, on average 85% of these
residues are highly conserved across all AAVs and form the rigid core of the capsid icosahedral
structure (51-54). The remaining 15% of residues are more variable between AAVs and are
largely located in the HVRs (55). HVRs I and III-IX are focused around the three-fold axis, with
HVR-IV, -V, and -VIII playing the largest role in the formation of the protrusions themselves.
Therefore, the majority of sequence and structural variation observed between AAV variants is
located at the three-fold axis within the HVRs. As the three-fold protrusions play important roles in
interactions with target cells and the immune system, the variation at these sites is what
determines tropism and confers unique transduction properties to each serotype.
Transduction properties of AAV vectors
Due to this natural range of tropism between the AAVs, the serotype that best transduces
a given target tissue can be selected for each potential gene therapy application. AAV2, which is
the most well-characterized AAV serotype to date, efficiently transduces photoreceptors following
subretinal administration and is therefore ideal for retinal gene therapy; development of this
vector lead to FDA approval of the first AAV gene therapy in the United States: Luxturna for
RPE65-associated Leber congenital amaurosis, a rare inherited form of blindness (18, 56). The
primary receptor of AAV2 has been identified as heparin sulfate proteoglycan (HSPG), and the
set of five basic amino acids determined to be largely responsible for this interaction (asparagines
484, 487, 585, and 588 as well as lysine 532) are located at the three-fold protrusions (57, 58).
Other serotypes utilizing HSPG include AAV3 and AAV6, but due to sequence and structural
differences these serotypes have different tropisms than AAV2, with AAV3B transducing liver and
AAV6 transducing skeletal muscle more efficiently than AAV2 (59-64).
Glybera, the first approved AAV gene therapy in the Western world, utilizes AAV1, which
is also a muscle-tropic serotype but does not utilize HSPG like AAV6 and instead recognizes
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sialic acid (17, 65). This interaction has also been mapped to the three-fold axis, specifically
N447, S472, and V473 in HVR-IV and N500, T502, and W503 in HVR-V (66). As is the case for
HSPG, additional serotypes utilize sialic acid as a receptor, including AAV4, AAV5, and AAV6
(66-68). AAV9, which targets many tissues following intravenous administration, including liver,
heart, muscle, and CNS, uniquely utilizes galactose; its galactose binding site has also been
mapped to the three-fold axis, specifically residues D271 and N272 in HVR-I and Y446, N470,
and W503 in HVR-V (69, 70). However, unique receptors have not been identified for all AAVs;
despite AAV8’s strong tropism for liver, the receptor responsible for this transduction profile has
not yet been elucidated.
In addition to the roles specific receptors play in conferring unique transduction profiles to
the AAV serotypes, recently a more universal receptor has been identified that plays a role in
transduction of most AAVs. The AAV receptor (AAVR) is a previously uncharacterized
transmembrane protein, KIAA0319L, that was initially determined to be essential for AAV2
transduction both in vitro and in vivo, and this has also found to be true for most other serotypes,
including AAV1, AAV8, and AAV9 (71, 72). However, recent studies indicate that more
structurally-divergent serotypes, specifically AAV4 and rh32.33, are AAVR-independent and
efficiently transduce target cells even in the absence of AAVR (73). While the binding site for
AAVR has yet to be elucidated for any AAV, given the structural divergence of AAV4 and rh32.33
from the other AAVs at the 3-fold axis and that all other receptor interactions occur at this site, it
is likely that the three-fold protrusions play an important role in AAVR binding, further evidence
that this site is critical for the distinct transduction properties of AAVs (55, 74).
Goals of the Dissertation
While the structure of the AAV capsid is well-characterized for the majority of commonlyused serotypes, as is the tropism of these serotypes following many routes of administration and
a number of receptors responsible for these unique transduction profiles, many critical aspects of
AAV gene therapy that pertain specifically to the capsid itself have yet to be fully explored.
Humoral immunity to the capsid itself is a significant concern with regards to determining what
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patient populations are eligible to receive AAV gene therapy and which previous recipients are
eligible for vector readministration. Study of the α-AAV antibody repertoire will lead to a better
understanding of AAV’s interaction with the immune system and inform future design of novel
capsids to address this concern. Additionally, while the basic structure of the external portions
AAV capsid has been extensively studied, the presence and potential impact of post-translational
modification has not been as extensively explored, particularly with respect to vector
manufacturing, transduction of target tissues, and interactions with the immune system. The work
described here aims to further explore these aspects of the development of AAV as a gene
therapy vector with the goal of leveraging these findings to develop next-generation gene delivery
platforms.

8

CHAPTER 2: AAV and the immune system
Interaction of AAV with the immune system
While unique cellular interactions provide numerous advantages of utilizing specific AAV
serotypes for targeted gene therapy approaches, interactions with the immune system are often a
significant hurdle in the translation of these novel viral vectors into the clinic. As AAV is a naturally
occurring virus, many individuals have been infected with at least one serotype by the time they
reach adulthood (75). Despite the fact that AAV is not considered to be highly immunogenic, it is
still recognized as a pathogen by the immune system, generating both innate and adaptive
responses against the viral capsid (76-78). Studies in animal models have established the role of
the innate immune system in generating immunity AAV, which involves TLR9-mediated activation
of the MyD88 pathway to activate CD8+ T cells and raise antibodies against both capsid and
transgene proteins (79, 80). Memory CD8+ T cells can also be detected in some individuals with
prior exposure to AAV (81, 82). Memory B cells produced in response to AAV have not been
extensively characterized directly, but the prevalence of circulating antibodies generated after
AAV infection is well-studied and is a primary concern in the field.
Up to 80% of the population is seropositive for antibodies against at least one AAV
serotype (83, 84). A subset of this seropositive population harbors not only binding antibodies
against AAV but also neutralizing antibodies (NAbs) that are capable of blocking AAV infection or
AAV vector transduction. NAbs are quantified by defining the NAb titer of a given sample, which
is the sample dilution at which transduction of an AAV vector (as measured by expression of a
reporter gene) is reduced by at least 50% relative to transduction in the absence of that
neutralizing sample: the more dilutions required to restore transduction, the higher the NAb titer
(85, 86). The serotype with the highest seroprevalence of NAbs in the general population is
AAV2, which is less commonly used in the clinic (84). Despite the lower prevalence of NAb titers
against more commonly used serotypes such as AAV8 and AAV9 (as well as closely related
variants), the percentage of individuals with NAbs against these serotypes at titers that can
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markedly reduce gene transfer efficiency is still significant. At a titer threshold of 1:20, studies
show that 20-40% of the population has NAbs against AAV8 and/or AAV9 (84, 87, 88).
The immune system’s generation of NAbs against AAV is its natural mechanism for
protection against reinfection with the virus. This preexisting immunity, however, also protects the
body against transduction by AAV vectors administered as potentially life-saving therapeutics.
This is of particular concern for gene replacement strategies requiring intravenous administration
of AAV vector. Mice that have previously been immunized or that have circulating NAbs due to
the passive transfer of NAb positive samples experience significantly lower levels of transduction
and therefore gene expression in target tissues relative to animals who are naïve to AAV and are
therefore NAb negative (89-91). Transduction following intravenous administration is generally
ablated at NAb titers of 1:20 with significant reduction observed at 1:10. This effect has also been
observed in the clinic, where individuals receiving intravenous AAV2 targeting liver for expression
of hFIX for the treatment of hemophilia B or intramuscular AAV2.5 (a hybrid vector between
AAV2 and AAV1) targeting muscle for expression of dystrophin for the treatment of Duchenne
muscular dystrophy with lower gene transfer efficiency were retrospectively determined to have
significant preexisting NAb titers relative to individuals who were later determined to be naïve for
AAV at the onset of the study (92, 93).
In addition to the likelihood of lower levels of transduction in NAb positive individuals
leading to reduced or complete lack of efficacy, there is also concern that clearance of AAV
vector from the bloodstream by preexisting NAbs and subsequent recall responses involving
+

CD8 T cells may lead to immune-related toxicities (86, 94). This concern also extends to
individuals with preexisting binding antibodies against AAV that are present in the blood but do
not neutralize AAV in either in vitro or in vivo assays; this is in spite of the fact that the presence
of these binding antibodies does not always correlate with the presence of NAbs and has not
been shown to negatively impact the efficacy of gene transfer (95, 96). To this end, the vast
majority of individuals with detectable NAb titers and many with detectable binding Ab titers are
excluded from clinical trials in which intravenous delivery of AAV vector is the chosen route of
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administration (ROA) (23, 97, 98). Additionally, despite the fact that circulating preexisting Abs
have been shown to have little to no impact on the efficiency of gene transfer following other
ROAs, such as intramuscular and intracerebroventricular, some clinical trials utilizing these ROAs
still exclude individuals with preexisting immunity out of concern for potential immune-related
toxicities (91). Therefore, preexisting immunity derived from prior exposure to AAV is largely
considered a contraindication for receipt of AAV gene therapy; for many rare diseases, this
significantly reduces the number of individuals eligible for trial participation and post-approval
therapy in an already small patient population, subsequently shrinking the overall potential of this
novel therapeutic to address an unmet need.
For most diseases, AAV gene therapy is designed to have a lifelong therapeutic impact.
However, this goal is not always achievable; some diseases, such as ornithine transcarbamylase
deficiency (OTCD), require newborn intervention, but the cells transduced by the initial dose of
AAV may divide as the patient ages. AAV genomes will therefore be diluted out over time, as the
AAV vector genome is maintained episomally, and expression of the transgene may be reduced
below the threshold required to maintain the desired therapeutic effect (99, 100). Therefore,
vector readministration may be required to prolong efficacy, but in cases utilizing the intravenous
ROA, readministration is likely impossible due to NAbs generated following the initial dose of
AAV.
Cellular immune responses mediated by AAV-specific T cells are also a concern for the
clinical use of AAV vectors. While natural infection with AAV productively elicits a humoral
response, the virus does not elicit an effective cytotoxic T cell response (78, 101). However, a
+

fraction of individuals who are seropositive for AAV harbor low frequencies of CD8 memory T
cells (81). It has been proposed that these preexisting memory T cells play a role in the rise in
liver transaminases that is often accompanied by a loss of transgene expression and an increase
in AAV-specific T cell populations following intravenous vector administration; however, this
hypothesis requires further study, as these responses could be elicited solely by the AAV vector
administration itself (78, 92, 102). As such, cell-mediated immune responses to AAV, both from
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viral infection and from vector administration, continue to be a serious concern for the field of AAV
gene therapy, and extensive experimentation is required to elucidate the mechanisms of this
aspect of AAV immunology.

Addressing humoral immunity to AAV
Many efforts have been made to evade these NAbs in either a preexisting immunity or a
readministration setting. Initial efforts focused on simply selecting a serotype that is less
seroprevalent or a serotype for which a given individual or population was seronegative. This
requirement helped drive the discovery of the second generation of AAV vectors, including AAV9
(36, 40). However, the structural variation that is responsible for the distinct serological profiles of
the AAVs also results in variation in tissue tropism (103). This reduces the likelihood that the
serotype selected due to an individual’s seronegative status will transduce the same target cells
as the serotype that was originally selected as the ideal therapeutic modality. This approach is
also likely unable to address both preexisting immunity and immunity generated in response to
vector administration. Historically, if an individual is seronegative prior to vector administration i.e.
AAV naïve, they will generate an antibody response that is limited to the serotype used and its
more closely related AAVs (104, 105). However, if that individual has a low binding or low NAb
titer and still receives vector, the immune response is broader, and the NAbs generated in
response to vector administration are cross-reactive with more divergent AAVs, narrowing the
pool of alternative serotypes (104, 106). Infection with wild-type AAV generates the broadest
immune response; individuals who are seropositive for one AAV due to a prior infection are
almost always positive for the vast majority of AAVs, making it even less likely that an alternative
serotype can be chosen (84).
Rather than changing the vector itself, approaches have also been taken to change the
way the immune system sees the vector of choice by utilizing a variety of immunomodulation
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techniques. Plasmapheresis globally reduces the concentration of total circulating antibodies in
the blood, reducing the quantity of AAV antibodies and therefore the titer of NAbs (107). This
approach has been shown to reduce both binding and neutralizing titers against AAV, but in order
to attain a titer below the benchmark 1:10 threshold an individual must have a relatively low titer
prior to plasmapheresis, with as many as five sequential rounds of plasmapheresis being
insufficient to reduce titers greater than 1:20 to below that threshold (108). Therefore, this
approach may be viable for only some individuals with preexisting immunity, as NAb titers
following natural infection are infrequently higher than 1:320, with the majority of individuals
having titers less than or equal to 1:80 for AAV2 and 1:20 for serotypes with lower
seroprevalence such as AAV8 and AAV9 (84, 87). Vector administration, due to the relatively
high doses required for intravenous applications, frequently generates NAb titers at least a log
higher than natural infection; as such, plasmapheresis is unlikely to be able to address a potential
readministration setting (104, 109).
More recent immunomodulation efforts have focused on pharmacological intervention in
order to block the body’s ability to produce antibodies in a specific window around the time of
vector administration. This approach, which utilizes various combinations of immunosuppressive
agents, has been shown to be effective in a number of models. One study explored the
administration of rapamycin and prednisolone to mice that had previously been injected with
AAV9 vector; this combination treatment reduced the frequency of total B cells and plasma cells
+

in the bone marrow as well as class-switched B cells and CD4 T cells in the spleen that
correlated with a significant reduction in circulating antibodies against AAV9 (70-80% reduction
after four weeks of treatment, 85-93% reduction after eight weeks of treatment) (110). This
approach potentially addresses vector administration in a preexisting immunity setting.
Another study explored the use of immune suppression prior to vector administration and
the resulting impact on the subsequent generation of AAV Abs. In a single human case study,
prophylactic administration of sirolimus and rituximab that continued following vector
administration (which was accompanied by a short course of methylprednisolone) prevented the
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generation of antibodies against both the AAV1 vector and the secreted transgene, an up to 155fold reduction in binding titer (111). The potential of this approach to therefore allow for
readministration is currently being evaluated preclinically for translation into the clinic (112). If
successful, it has the potential to address NAbs in a readministration setting by preventing their
generation entirely.
As the naturally occurring diversity between AAVs is not sufficient to address all aspects
of the obstacle presented by AAV NAbs, recent efforts have been made to engineer novel AAV
capsids that maintain the parental tissue transduction profiles while gaining the ability to evade
neutralizing antibody responses, either preexisting or vector induced. One such approach focuses
on the natural variation in the AAV capsid and attempting to combine domains from different
AAVs. AAV cap sequences are shuffled and/or recombined to generate a library of novel AAV
hybrid cap genes that are then made into a vector library (113, 114). Alternatively, saturating
mutagenesis can be applied to specific regions of a given capsid to generate a library of novel
AAV cap sequences (115, 116). These libraries can then be screened under a number of
selection pressures, including in vitro and in vivo transduction as well as binding to/escape from
AAV Abs. A highly complex pool of capsid variants can therefore be narrowed down to only
those with the desired properties, in this case, immune evasion. This approach has had moderate
success in generating novel AAVs able to evade NAbs from various sources, but in many cases
the selected motifs disrupt the domains required for characteristic tropism of any of the parental
AAVs (117, 118). While the new transduction profile of the shuffled variant may still include the
target tissue for a number of indications, it is not guaranteed.
While this approach has immense potential to identify novel capsids with unique
transduction and immune evasion properties, the identity of the optimal selection system is highly
debated. Ideally, a library would be interrogated with the polyclonal serum from an individual or
group of individuals with AAV NAbs that would be candidates to receive gene therapy. However,
the variation in immune repertoires generated in response to AAV is poorly characterized, making
the identification of the optimal selection pressure difficult and prompting the initiation of
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numerous studies with the goal of better characterizing the antibody repertoire generated
following exposure to AAV as well as how this response may vary between patient populations.
Studies attempting to map the breadth of the α-AAV immune response by evaluating the binding
and neutralizing ability of pooled IVIG to an extensive panel of AAV2 point mutants determined
that this pooled sample recognizes a sizeable portion of the AAV2 capsid, suggesting that the
anti-AAV repertoire is not limited to a small region of the capsid (119). Similar studies with
individual sera from a panel of normal human donors with preexisting AAV Abs have shown that
there are multiple subgroups of immune repertoires following AAV infection, raising questions of
the ability of this approach to globally address preexisting immunity (96). Additional studies
utilizing serum from patients that received AAV gene therapy for DMD came to similar
conclusions, as mutant vectors that escaped neutralization by one sample did not necessary
escape neutralization by a sample from other individuals despite being dosed with the same
vector (120). This raises additional questions of whether this approach can address AAV
immunity in a readministration setting.
These attempts to address the obstacle of NAbs against AAV shed light on the general
lack of understanding of how AAV interacts with the immune system. If more factors influencing
the immunogenicity of the capsid itself could be elucidated, vector engineering could be directed
only to the relevant regions of the capsid in a fashion that could provide maximal disruption of
antibody interactions for the largest number of individuals while still maintaining overall vector
function. To identify specific epitopes involved in the neutralization of AAV, individual antibodies
can be isolated and their epitopes mapped to generate an atlas of capsid immunogenicity from
which mutants can be rationally designed.
Prior efforts to study neutralizing responses to AAV
Traditionally, this epitope mapping approach has relied on the immunization of mice with
a selected AAV capsid, followed by splenocyte harvest and fusion to generate a panel of
hybridoma clones. The antibody produced by these clones and secreted into the media can then
be screened for desired properties, including AAV antigen recognition as well as the ability to
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neutralize vector transduction in vitro and in vivo. Following candidate identification, the epitope of
each antibody can then be mapped by one of a number of methods.
Early efforts focused on the epitope mapping of AAV2. These antibodies were initially
generated for use as reagents in studying basic AAV biology and as such not all antibodies
selected for evaluation were neutralizing. A combination of techniques was used to map these
early antibodies, including peptide mapping and scanning alanine mutagenesis of the AAV2
capsid (119, 121, 122). These techniques were sufficient to map the epitopes of a number of
mouse-derived AAV2 mAbs, such as B1 and A69, which recognize linear epitopes, as well as a
number of epitopes in the polyclonal repertoire of IVIG samples. However, for antibodies such as
A20 that recognize conformational epitopes that include residues from isolated portions of VPs
that form a complete epitope only in the intact AAV capsid, these approaches are often unable to
identify all residues that comprise a given epitope because they do not fully recapitulate the
epitope in its native state. Neutralizing epitopes, whose identification will provide most of the
information critical to the engineering of escape mutants, can often be conformational. Cryoelectron microscopy (cryo-EM) uses high resolution imaging techniques to determine the
structures of macromolecules as well as of protein complexes (123). Cryo-EM is therefore the
favored technique to map the epitopes of AAV Abs with conformational epitopes as the binding
site of the Ab can be determined while in complex with intact AAV capsid.
The first complex solved was the AAV2-A20 complex by McCraw et al. A20 is a
neutralizing mAb raised against AAV2 that cross reacts with the closely-related serotype AAV3B
(88% by sequence identity) (121). Cryo-reconstruction of the complex, refined to a resolution of
8.5Å, indicated that A20 binds AAV2 at the three-fold axis, and the footprint on the capsid is
comprised of residues from three separate three-fold related monomers, reflected in the fact that
it recognizes only intact capsid (124). The majority of residues in the A20 epitope are in variable
regions, specifically HVR-I, -III, -VII, and -IX, and the epitope was found to not overlap with the
heparin binding site on AAV2, indicating that A20’s neutralization mechanism is likely not directly
related to blocking receptor interactions. Additionally, all but three of the 17 residues identified by
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the cryo-reconstruction are shared between AAV2 and AAV3B, with these three being peripheral
sites, providing evidence for why A20 binds and neutralizes both serotypes.
As other AAV serotypes were discovered and began to be developed as gene delivery
vectors, these epitope mapping studies expanded to include many of these novel capsids. To
date, mAbs against AAV1, AAV5, AAV6, and AAV8 have been mapped: four against AAV1, three
against AAV5, and one each against AAV6 and AAV8 (125-127). However, not all are
neutralizing. All four AAV1 mAbs are neutralizing, as are those against AAV6 and AAV8, while
two of the three AAV5 mAbs bind but do not neutralize. Additionally, not all AAV mAbs map to the
three-fold axis, despite this site generally being considered to be the most likely site of antibody
binding due to its accessibility, sequence and structural variation, and important role in
transduction; mapped epitopes represent a broader spectrum of sites.
As previously stated, four neutralizing epitopes on AAV1 have been mapped. The
AAV1:4E4 complex was refined to a resolution of 12Å, and the 4E4 footprint was determined to
be comprised of residues from two HVRs: HVR-IV (residues 456-AQNK-459) and HVR-V
(residues 492-TKTDNNN-498), centered around the three-fold axis and oriented on top
of/extending outward from the three-fold protrusions (125). The second mAb, 5H7, is of particular
interest because, like A20, it recognizes and neutralizes both AAV1 and the closely-related AAV6.
Its structure in complex with AAV1 and AAV6 were refined to a resolution of 23Å and 15Å,
respectively, which, while not as high resolution as previous structures, was still sufficient to
identify the footprint of this antibody on the capsid surface; the epitopes on AAV1 and AAV6
largely overlap and include residues from HVR-V (T494 and 496-NNNS-499) and HVR-VIII (588STDPATGD-595), implicating additional residues in HVR-VIII (582-VN-583, H597) near the
footprint but not directly involved in mAb binding (126). All of these residues are shared between
AAV1 and AAV6 but are divergent in other serotypes, explaining the specificity of 5H7. Like 4E4
binding, 5H7 binds at the three-fold axis but is oriented on the inner faces of the three-fold
protrusions.
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A second set of NAbs against AAV1, ADK1a and ADK1b, has also been mapped, with
each AAV-Ab complex being refined to a resolution of 11Å (126). ADK1a binds similarly to 4E4 at
the three-fold protrusions, specifically residues R448, Q450, and 453-SGSAQ-457 in HVR-IV and
N500 in HVR-V, with additional occluded footprint residues in HVR-I, -III, and -VII. ADK1b
uniquely binds on the 2/5-fold wall and extends towards the five-fold pore, contacting a total of 19
residues in HVR-I, -III, -VII, and -IX while occluding additional residues in these HVRs in addition
to residues in the HI loop, which surrounds the five-fold pore and is essential for proper capsid
assembly (128).
While all mapped epitopes for AAV1 are neutralizing, representing multiple distinct
locations on the capsid, the mapped epitopes for AAV5 represent a mixture of both binding and
neutralizing epitopes. ADK5b is neutralizing and predominantly binds HVRs, similar to the NAbs
isolated against AAV1, specifically binding R248 (no HVR), 316-VQDS-319 (HVR-II), N443 (HVRIV), 530-NSQSPAN-535, 540-ATYL-542, G545, and N546 (HVR-VII) and Q697, D704, T706, and
708-EYR-710 (HVR-IX) while occluding additional residues in these regions as well as six
additional residues in the HI loop (126). The ADK5b density was located at the five-fold axis and
extended toward the three-fold axis, occluding residues not only in the 2/5-fold wall but also the
outer edge of the three-fold protrusions. ADK5a is not neutralizing, but its epitope mapped to
regions overlapping with the neutralizing epitope of ADK5b, specifically R248 and those in HVRVII (Q532, P533, 535-NPGTTVPSATYL-543, N546) and HVR-IX (Q697, F698, 704-DSTGEYR710). Epitope residues unique to ADK5a include N244, Q246, and E249, 250-IKSGSVD-256 and
Y263 (HVR-I), E377 and N378 (HVR-III), L453 and 456R (HVR-IV), and V652V, P654, and S656
in the HI loop; while these residues were not found to directly contact ADK5b, they were occluded
by ADK5b Fab binding and were therefore included in the ADK5b footprint. This provided further
evidence of epitope overlap between these two antibodies, one neutralizing and one binding.
The final antibody mapped to AAV5, 3C5, is also a binding but not neutralizing antibody;
two distinct binding sites were mapped for 3C5, one for the variable region and one for the
constant region of the 3C5 Fab (125). The variable region of 3C5 Fab (Site B) was found to bind
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HVR-VII (N530, 532-QPANPGT-538), HVR-IX (704-DSTGE-708), the HI loop (653-VP-654, 656SS-657), and Q246, while the constant region (Site A) was found to bind HVR-I (254SVDGSNAN-261), HVR-III (374-DN-375), and HVR-V (R483, 485-SVSAFATT-492, R494, E496,
and 499-GAS-501). Both sites, therefore, contact the 2/5-fold wall, with Site B extending towards
the five-fold pore. These data provide evidence for additional AAV neutralizing sites outside the
three-fold protrusions, and the overlap between binding and neutralizing epitopes indicates that
neutralization is not conferred to a given AAV NAb simply based upon its recognition site.
The structures of these AAV-Ab complexes were reconstructed to a high enough
resolution to provide reasonable confidence in the binding sites identified in these studies;
however, the number of both contact and occluded residues for the majority of Abs is relatively
large, and the epitopes themselves have not been validated by mutagenesis to confirm their
direct roles in antibody binding and neutralization (129, 130). The epitope for ADK8, the NAb
mapped to AAV8, has been functionally interrogated. Cryo-reconstruction of the AAV8-ADK8
complex to 18.7Å resolution identified binding at HVR-IV (456-GTANTQ-460), HVR-V (493TTTGQNNNS-501), and HVR-VIII (586-LQQQNT-591) at the top of the three-fold protrusions
(127). As ADK8 is specific for AAV8, domain swapping experiments with cognate sequences in
AAV2 followed by ADK8 binding analysis confirmed ADK8 usage of 586-LQQQNT-591 while
swaps of the 456-GTANTQ-460 and 493-TTTGQNNNS-501 regions had no effect on binding.
This demonstrates that the residues required by an NAb for neutralization of AAV may be as few
as six, suggesting that the residues relevant for neutralization (or binding) of the previouslymapped Ab described above may be far fewer than the total residues implicated previously by
cryo-EM.
Addressing gaps in knowledge
Taken together, these studies demonstrate the tremendous potential of traditional
hybridoma technology coupled with cryo-EM epitope mapping to identify regions on the AAV
capsid responsible for vector neutralization that could subsequently be engineered for the design
of novel escape mutants to address the obstacle of humoral immunity AAV. A number of
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residues that are conserved between AAV serotypes, such as the triple asparagine motif in HVRV, have been implicated in the epitopes of multiple mAbs, suggesting that the epitopes of different
AAVs share core features. Additionally, a number of shared capsid epitope locations with
divergent sequences have been identified between AAV mAbs despite these mAbs being specific
for a single serotype (or a few closely-related serotypes); this suggests that specific features of
the capsid are responsible for neutralization by NAbs independent of residue identity at that
location. However, the majority of these epitopes have not been validated, so the overlap that
exists between epitopes and therefore the regions considered to be common epitope motifs
between antibodies recognizing different serotypes may be overestimated. Assumptions about
the repertoire of antibodies generated against a given serotype such as AAV1, of which four
neutralizing epitopes have been mapped, are then extrapolated to other serotypes such as AAV8,
despite having mapped only one antibody against that serotype, as well as to other
therapeutically-relevant serotypes with no epitopes mapped, such as AAV9. More antibodies
need to be mapped and fully validated, for both AAVs with previously mapped epitopes and those
without, to come to a more complete understanding of the sites, both unique and shared, utilized
by NAbs to block vector transduction. Additionally, many residues have been identified that are
shared between neutralizing and binding epitopes; as such, the specific factors that constitute a
neutralizing versus a non-neutralizing epitope have yet to be identified. Taken together, this
indicates that further study is required to fully characterize the epitope repertoire for each relevant
AAV serotype, from initial mapping through validation, in order to better understand the antibody
response to AAV vectors and to use that information to rationally design vectors that can escape
neutralization.
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Chapter 3: Mapping an adeno-associated virus 9-specific neutralizing
epitope to develop next-generation gene delivery vectors
Abstract
Recent clinical trials utilizing AAV vectors, including AAV9, have demonstrated the
significant potential for these vectors to treat rare disease. However, there remain significant
barriers to their translation into widely-available gene therapy products. Specifically, exposure to
AAV, either by viral infection or vector delivery, can generate a neutralizing antibody response
that prevents successful administration (or readministration) of the vector. One approach towards
addressing this obstacle is to map which epitopes on the AAV capsid are responsible for this
neutralization using monoclonal antibodies and high resolution imaging techniques and to
subsequently rationally design a novel AAV variant able to evade this response. To design one
such AAV9 variant, we isolated an α-AAV9 monoclonal antibody following hybridoma generation
and screening from AAV9-immunized Balb/c mice. We determined that this antibody, PAV9.1, is
highly specific for intact AAV9 capsids and that purified PAV9.1 mAb has a high neutralizing titer
of >1:160,000. Cryo-EM reconstruction of AAV9 in complex with PAV9.1 Fab indicated that
PAV9.1 binds at the three-fold axis of symmetry, specifically to 496-NNN-498 in HVR-V and 588QAQAQT-592 in HVR-VIII. Targeted mutagenesis of these sites demonstrated that even a single
amino acid substitution is capable of markedly reducing capsid binding and neutralization by
PAV9.1. Subsequent in vivo studies of these variants demonstrated that mutations in the PAV9.1
epitope frequently confer a “liver-detargeting” phenotype (relative to wild-type AAV9 tropism),
indicating that the residues responsible for PAV9.1 activity are also responsible for vector
tropism. However, despite epitope mutations having a significant effect on PAV9.1 activity, we
observed minimal changes in binding and neutralizing titer when these mutant vectors were
tested for evasion of polyclonal samples. These studies therefore demonstrate the complexity of
incorporating both mapped neutralizing epitopes and knowledge of functional motifs into the
design of novel capsid variants able to evade NAb responses while performing efficiently as gene
therapy vectors.
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Introduction
Since its discovery, AAV9 has been the serotype of choice in the clinic for a variety of
indications due to its unique transduction profile. Following intravenous administration, AAV9
transduces not only the liver but also heart and skeletal muscle (62). Additionally, high dose
intravenous AAV9 has been shown to, through an unknown mechanism, cross the blood brain
barrier and transduce tissue in the central nervous system (131). AAV9 can also be administered
through other ROAs to transduce these tissues, particularly intramuscularly to target skeletal
muscle locally or intrathecally to target specific tissues in the central nervous system (CNS),
which does not require the higher doses needed to allow AAV9 to cross the blood brain barrier
following intravenous administration (132, 133).
Many clinical trials in various phases currently use AAV9 vectors. The most advanced is
AVXS-101, which is currently in phase III trial evaluation (ClinicalTrials.gov identifier:
NCT03306277) for the intravenous delivery of AAV9 expressing SMN1 protein for the treatment
of spinal muscular atrophy through transduction of cells in the CNS (SMA). SMA is characterized
by infant onset of motor neuron degeneration accompanied by immobility and respiratory failure,
with only a small percentage of affected individuals surviving past one year of age (97). The
phase I trial of this therapeutic (ClinicalTrials.gov Identifier: NCT02122952) has demonstrated the
ability of AVXS-101 to significantly improve mobility in these subjects as well as their ability to
breath without ventilatory assistance at a dose of 2e14 vg/kg delivered intravenously (97).
Intravenous AAV9 is also being used in the clinic to target other tissues. Solid
Biosciences recently initiated a Phase I/II dose escalation study to test its lead candidate SGT001, AAV9 expressing microdystrophin, an engineered, truncated version of dystrophin, for the
treatment of Duchenne muscular dystrophy in adolescents and children (ClinicalTrials.gov
Identifier: NCT03368742). Preclinical studies demonstrate efficient transduction of both cardiac
and skeletal muscle as well as long-term expression of microdystrophin in these tissues in both
rodent and dog models. Microdystrophin expression in these target tissues was sufficient to
improve muscle function in these models (134, 135). Intravenous AAV9 is also being evaluated
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preclinically for a wide variety of indications, such as lysosomal storage diseases (LSDs) that
require enzyme secretion from the liver (136-138).
While these indications require IV administration of AAV9 to successfully transduce all
target tissues for appropriate expression of the therapeutic transgene, this ROA is complicated by
immunity to the AAV9 vector itself. Between 20% and 50% of the population has circulating
antibodies against AAV9 generated following AAV viral infection earlier in life (87, 139, 140). Of
this population, 50-80% have neutralizing antibodies against AAV9 that are of high enough titer to
significantly inhibit vector transduction (87, 140). These individuals are often excluded from
participation in clinical trials and by extension from receiving an AAV gene therapy product due to
the expected reduction in potency of the vector in these individuals. Additionally, a large number
of indications for which AAV9 is being considered are pediatric disorders in that therapeutic
intervention early in life would be most beneficial (SMA, DMD, LSDs); however, the longevity of
IV AAV gene therapy has yet to be fully evaluated in humans. Additional doses of vector may be
required to provide therapy for the lifespan of these individuals, especially if they were initially
treated at a young age, but the initial vector administration acts as an immunization against AAV,
preventing IV vector readministration. Both preexisting and induced immunity to AAV, therefore,
present a significant obstacle to intravenous AAV gene therapy.
Investigators have taken many approaches to address this issue of AAV NAbs, including
generic circumvention of NAbs by global depletion of immunoglobulins by plasmapheresis or
immunomodulation to universally reduce production of immunoglobulins, careful selection of
alternate AAV variants that do not cross react with an individual’s NAbs, and capsid engineering
approaches including shuffling of existing AAV capsid sequences to generate chimeric capsids,
directed evolution, and rational capsid design (108, 110, 113, 141). This final approach involves
the isolation of monoclonal antibodies against a specific AAV capsid by hybridoma generation in
mice and characterization of these antibodies followed by epitope mapping, traditionally by cryoEM. Knowledge of these epitopes can then be utilized to rationally design capsids in which
interactions with these NAbs are disrupted such that they can efficiently evade neutralization.
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Ideally, this knowledge can be further combined with data regarding receptor binding sites and
other important capsid motifs involved in vector function (for capsids for which this information is
available) to engineer capsids that not only evade neutralization but also maintain the desired
transduction properties.
To date, a number of epitopes, both neutralizing and non-neutralizing (binding), have
been identified on AAV capsids, specifically on AAV1, AAV2, AAV5, AAV6, and AAV8 (124, 126,
127). The most epitopes have been mapped to AAV1 (4 in total). All four are neutralizing, and
these epitopes span the AAV1 capsid surface, utilizing residues in the three-fold protrusions, 2/5fold wall, and five-fold axis. The number of neutralizing epitopes mapped on the remaining
capsids is limited to 1-2 per serotype, and the vast majority of these have yet to be functionally
interrogated by mutagenesis and the resulting mutants evaluated for their ability to evade NAb
responses and successfully transduce target cells. These studies are essential for the complete
application of this approach to addressing the current obstacle posed by NAbs.
While the epitopes that have been mapped to various AAVs have, on average, a number
of features in common, particularly usage of the HVRs and the HI loop as binding sites, the ability
to extrapolate these results to other serotypes has yet to be established. AAV9 is an optimal
candidate for utilization by IV administration for many indications and is therefore highly
susceptible to neutralization by NAbs. Despite this fact, no studies to identify the immunogenic
epitopes on AAV9 and subsequent efforts to design next-generation AAV9-based vectors have
been performed.
In this study, we sought to address this gap in the literature through the isolation of a
panel of mAbs against AAV9 by immunization of Balb/c mice followed by hybridoma generation.
From this panel, we selected a highly potent NAb, PAV9.1, for further study. Cryo-EM
reconstruction of the AAV9-PAV9.1 Fab complex identified residues 496-NNN-498 in HVR-V and
588-QAQAQT-593 in HVR-VIII as directly involved in PAV9.1 binding and therefore
neutralization. Swaps of these regions with residues from divergent serotypes as well as alanine
replacement and site-directed mutagenesis were able to generate AAV9-based mutants with the
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marked ability to not only ablate PAV9.1 binding but also neutralization. However, this profound
effect was not found to translate to evasion of polyclonal samples from mice, macaques, and
human donors. Mutations in this epitope also modulated the transduction profile of AAV9. This
study highlights the complexity of overcoming the obstacle posed by NAbs against AAV vectors
and the need for a comprehensive approach that comprehensively addresses both immune
interactions and target tissue transduction.
Results
Identification of a novel, potent, α-AAV9 neutralizing antibody
We first sought to obtain antibodies specific to AAV9 for epitope mapping. We immunized
Balb/c mice repeatedly with AAV9 vector subcutaneously to elicit a potent immune response
against the vector capsid. Following hybridoma generation and culture, we screened a panel of
30 hybridoma clone supernatants for reactivity to AAV9 by ELISA as well as for AAV9
neutralization by NAb assay. While we found that all supernatants bound AAV9, one antibody,
PAV9.1, had the highest relative affinity for AAV9 of the samples tested. Following evaluation for
binding to additional AAV serotypes, PAV9.1 also exclusively recognized AAV9, while the
remaining 29 hybridoma supernatants broadly recognized other AAV serotypes, including AAV2,
AAV5, and AAV8 (Figure 2A, data not shown). While these antibodies with broad specificity
bound both native and denatured capsid, indicating that they likely recognize a linear epitope,
PAV9.1 exclusively bound native AAV9 capsid, indicating that it recognizes a conformational
epitope. These results were confirmed with purified PAV9.1 and 10 additional α-AAV9 mAbs
(data not shown). Finally, of all clones tested, we found that PAV9.1 was the only mAb able to
neutralize AAV9 transduction. We determined that the NAb titer of purified PAV9.1 was
1:163,840, indicating that this antibody is a highly potent neutralizer of AAV9. Passive transfer of
PAV9.1 mAb prior to intravenous vector administration in C57BL/6 mice confirmed the ability of
PAV9.1 to neutralize vector in vivo, as luciferase expression from the liver was ablated in animals
receiving PAV9.1 but not those receiving PBS or the non-neutralizing α-AAV9 mAbs PAV9.2 or
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PAV9.3 prior to vector administration (Figure 2B). For these reasons, we selected PAV9.1 for
further study, including epitope mapping, to come to a better understanding of the humoral
immune response against AAV9.
Epitope identification by cryo-reconstruction of AAV9 in complex with PAV9.1
After selecting PAV9.1 for epitope mapping, we generated PAV9.1 Fab particles by
papain digestion, incubated the purified Fab with AAV9 vector at a ratio of 600 Fab particles to 1
AAV9 capsid (or 10 Fab particles per potential binding site on the capsid surface, assuming a
maximum of 60 binding sites based on the icosahedral symmetry of the capsid), froze the
complex on cryo grids, and imaged using the FEI Talos Arctica electron microscope equipped
with a Gatan K2 Summit direct electron detection camera. AAV9-PAV9.1 complexes took on a
distinctly spiked appearance indicative of successful Fab binding (Figure 3A). From 1,100
images captured, we boxed 3,022 particles and used AUTO3DEM to generate a 4.2Å
reconstruction of PAV9.1 Fab in complex with AAV9.
From the cryo-reconstruction, we observed PAV9.1 Fab binding at the three-fold axis,
specifically on the inner face of the three-fold protrusions extending perpendicularly from the
spikes themselves (Figure 3B, C). This indicated likely interactions with HVR-IV, -V, and -VIII,
which comprise the top and interior of the three-fold protrusions; the residues of the HVRs at this
site are mostly charged residues able to participate in electrostatic interactions not only with other
three-fold related monomers but also non-viral proteins like receptors or, in this case, antibodies.
The PAV9.1 Fab complementarity determining regions (CDRs) were found to directly interact only
with HVR-V and HVR-VIII, specifically residues 496-NNN-498 in HVR-V and 588-QAQAQT-593
in HVR-VIII. The CDRs of the heavy chain are responsible for HVR-V binding while the CDRs of
the light chain are responsible for HVR-VIII binding in the same three-fold related monomer
(Figure 3D). In addition to the residues found to be in direct contact with the CDRs, the cryoreconstruction also indicated that PAV9.1 Fab binding occludes additional regions in HVR-IV,
HVR-V, and HVR-VIII, specifically G455 and Q456 in HVR-IV, T494, Q495, and E500 in HVR-V,
and N583, H584, S586, and A587 in HVR-VIII (Figure 3E, Table 1). While these residues do not
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directly contribute to PAV9.1 binding, they may still contribute to vector neutralization mediated by
PAV9.1 due to inaccessibility of cell surface receptors or other factors required for cellular
transduction.
Of the 60 potential PAV9.1 Fab binding sites, we found that at maximal occupancy,
PAV9.1 binds a total of 20 sites. We determined that the regions of the three-fold protrusions in
contact with PAV9.1 Fab had an average density of 2.5 sigma levels, which is comparable to
densities reported previously for other AAV-Ab complexes (127). We found the density of PAV9.1
Fab to be approximately 0.8 sigma levels, one third of the density of the AAV9 capsid at the
binding site. This indicates that only one Fab molecule can bind a given three-fold axis at any
time, likely due to the single bound Fab blocking binding of additional Fab molecules due to steric
hindrance.
Mutagenesis strategy for epitope validation and escape mutant engineering
We then selected specific residues for targeted mutagenesis for epitope validation and
escape mutant design. We chose to limit the number of residues mutated at a given site due to
the fact that previous efforts towards epitope validation in which large replacements were made
caused significant defects in capsid assembly, preventing further evaluation of these mutants
(127). Mutagenesis was therefore limited to five amino acids at a single site to increase the
likelihood that the resulting capsid mutant would tolerate the mutation.
We first chose to focus on HVR-VIII due to the high degree of sequence diversity in this
HVR between AAV serotypes based on the knowledge that PAV9.1 is specific for AAV9, and
therefore, regions unique to AAV9 are likely to be responsible for conferring this specificity.
Additionally, residues throughout HVR-VIII, most commonly aa582-591, have been implicated as
contributing to vector neutralization by monoclonal NAbs against AAV1, AAV2, and AAV8;
mutations in this region would allow for the comparison of the AAV9 epitope residues to those
that have been published previously (50). We selected 586-SAQAQ-590 specifically because the
residues in this region represent both residues that were determined to be directly interacting with
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PAV9.1 CDRs and residues simply occluded by PAV9.1 binding, allowing for the interrogation of
the junction between these two groups of residues (Figure 4).
In HVR-V, the cryo-reconstruction indicated PAV9.1 binding at 496-NNN-498. This is in
spite of the fact that PAV9.1 is specific for AAV9; this triple asparagine motif in HVR-V is
conserved between the vast majority of AAVs, with the exception of AAV4 and AAV5. This is not
to say that it cannot contribute to PAV9.1 binding, especially considering triple asparagine motifs
have been implicated in the epitopes of other serotype-specific mAbs, but it may not be
responsible for the AAV9-specific properties of PAV9.1 (127). We additionally selected 494-TQ495 for analysis as, despite the fact that they were found to be occluded and not directly involved
in Fab binding, these residues are variable between serotypes and could potentially contribute to
AAV9 specificity, and their inclusion, like in the 585-SAQAQ-590 HVR-VIII region selected for
evaluation, allows for the interrogation of the junction between binding and occluded residues.
Also as for 585-SAQAQ-590, these residues have been implicated previously in AAV-Ab
interactions (50), again allowing for comparison of epitopes from different AAV serotypes.
Establishing the role of HVR-VIII in the binding of AAV9 by PAV9.1
We first evaluated 586-SAQAQ-590 in HVRI-VIII due to the sequence and structural
diversity at this site. To evaluate this region as a whole, we designed swap mutants in which all
five residues from AAV9 were replaced with the corresponding residues from those of a panel of
different AAV serotypes representing clades outside of Clade F (Table 2). This included AAV2
from clade B (AAV9.RGNRQ), AAV3B from clade C (AAV9.SSNTA) and sequence representative
of the consensus of AAV8/AAVrh10 from clade D/E, respectively (AAV9.QQNTA). We selected
full direct swaps in order to maximize the likelihood that the resulting mutants would not display
assembly defects, as these motifs are naturally represented in the AAV repertoire, while also
taking advantage of the natural variation at this site. In the event that these swaps significantly
impacted capsid formation despite being naturally-occurring motifs, we included an additional
mutant, AAV9.AAQAA, as an intermediate between the wild type AAV9 sequence and the
AAV8/AAVrh10 sequence at this site (differing from AAV9 only at S586 and Q590) and would be
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less likely to disrupt capsid assembly. This mutant was also selected to help define the minimum
mutation required to disrupt PAV9.1 activity. We also evaluated a fifth mutant based on the
AAV2-derived mutant, AAV9.RGHRE, which is more diverse in sequence and amino acid
properties in order to determine the maximum amount of disruption of PAV9.1 that could be
achieved.
To evaluate capsid assembly efficiency, we first produced small scale vector preparations
by triple transfection and titered the resulting lysate by qPCR. The AAV8/AAVrh10 and AAV3Bderived mutants, AAV9.QQNAA and AAV9.SSNTA, assembled equivalently to AAV9.WT, as did
the intermediate mutant AAV9.AAQAA (Figure 5A). The two mutants based on AAV2,
AAV9.RGNRQ and AAV9.RGHRE, produced intact capsids approximately 2-fold less efficiently
than AAV9.WT. For further study of these mutants, we produced purified vector on a larger scale.
Titers of purified vectors from large scale preparations were similar to those observed in the small
scale lysates, with the reduced assembly efficiency of AAV9.RGNRQ and AAV9.RGHRE being
more profound at this scale (Figure 5B). Despite this modest defect in capsid assembly, titers
were sufficient for further evaluation.
We then evaluated the ability of each AAV9 mutant to disrupt PAV9.1 binding by AAV
capture ELISA. From the binding curves of varied concentrations of PAV9.1 with a constant
coating concentration of AAV9 (or AAV9 mutant), we calculated the effective EC50 of PAV9.1 for
each capsid, defined as the concentration of PAV9.1 mAb required to reach half-maximal binding
against that mutant, as measured by absorbance. An increase in EC50 is indicative of a decrease
in antigen binding. Each mutant markedly increased the EC50 of PAV9.1 for the respective
capsid when compared to the EC50 of PAV9.1 for AAV9.WT, indicative of reduced capsid binding
efficiency (Figure 6A). The degree of EC50 increase largely correlated with the degree of total
sequence divergence from AAV9.WT (based on full-length VP1 sequence) (36). The mutant
most similar to AAV9.WT, AAV9.AAQAA, disrupted binding the least, introducing a 45-fold
increase in EC50. AAV9.QQNAA and AAV9.SSNTA disrupted PAV9.1 binding to an intermediate
degree, increasing EC50 by 124- and 264-fold, respectively. Binding was disrupted the most by
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AAV9.RGHRE, increasing EC50 by almost 300-fold. The exception was AAV9.RGNRQ which,
while AAV2 is the most divergent serotype from AAV9 of those represented in this study when
comparing full-length VP1 sequences, at this site alone it is more conserved, sharing the Cterminal Q590 with AAV9.WT.
Since the S586A and Q590A mutations in AAV9.AAQAA were sufficient to significantly
reduce PAV9.1 binding, we then tested a number of point mutations at these sites to determine
the minimal change required to disrupt PAV9.1 activity. We tested each alanine replacement
(S586A and Q590A) independently as well as introduced more conservative mutations at these
sites to determine if a similar amino acid with slightly different properties was still able to disrupt
binding. Threonine was selected as a conservative change for S586, and asparagine was
selected as a conservative change for Q590. Small scale vector titers of AAV9.SAQAN and
AAV9.SAQAA were equivalent to AAV9.WT titers, while both mutations at S586 increased vector
production by 50% (Figure 5A). Following EC50 determination, neither an alanine nor a threonine
substitution at S586 had an effect on PAV9.1 binding, while Q590A and Q590N both increased
EC50 by 20- and 40-fold, respectively, indicating that Q590 is critical for PAV9.1 recognition of
the AAV9 capsid (Figure 6C).
Establishing the involvement of HVR-V in the binding of AAV9 by PAV9.1
After establishing the participation of 586-SAQAQ-590 in the PAV9.1 epitope, we focused
our mutagenesis efforts on 494-TQNNN-498 in HVR-V. We employed the serotype swapping
strategy to evaluate 494-TQ-495, which is a natural site of variation, mutating this motif to GQ
(AAV8 motif) and TD (similar to AAV2/AAV3B motif) in addition to replacing these two residues
with alanine. We could not employ a serotype swapping strategy to evaluate 496-NNN-498 as
these residues are highly conserved, choosing instead to simply replace all three asparagines
with alanine. Both AAV9.GQNNN and AAV9.TQAAA produced vector as efficiently as AAV9.WT,
while AAV9.TDNNN produced vector approximately 50% more efficiently and AAV9.AANNN
produced vector approximately 50% less efficiently (Figure 5A).
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After determining the EC50 for each HVR-V mutant by ELISA, we found that neither the
serotype swap mutants (AAV9.GQNNN and AAV9.TDNNN) nor the alanine replacement mutant
(AAV9.AANNN) at 494-TQ-495 had an effect on PAV9.1 binding (Figure 6B). This confirmed the
observation made from the cryo-reconstruction that residues 494-TQ-495 were occluded by
PAV9.1 binding and not directly involved in capsid interactions with the CDRs of PAV9.1 Fab.
Despite being conserved between AAV serotypes, the alanine replacement mutant at 496-NNN498, AAV9.TQAAA, increased the PAV9.1 for capsid by 15-fold, indicating that this triple
asparagine motif is involved in PAV9.1 binding and confirming the epitope determined by the
cryo-reconstruction.
Finally, we designed combination mutants based on the minimal mutations required to
modulate PAV9.1 activity in both HVR-V and HVR-VIII, AAV9.TQAAA/SAQAN and
AAV9.TQAAA/SAQAA, to determine if the effects of these individual mutations were additive.
AAV9.TQAAA/SAQAN increased the effective EC50 of PAV9.1 by 124-fold and
AAV9.TQAAA/SAQAA increased the effective EC50 by 83-fold, indicating that these combination
mutants are more effective at reducing binding than each mutant individually and establishing our
ability to finely tune PAV9.1 binding to AAV9-based capsids (Figure 6D, E).
Determining the impact of PAV9.1 epitope mutations on vector transduction
As all validated epitope residues lie in HVRs, established previously to be involved in
vector transduction, we then evaluated the ability of these mutants to transduce both HEK293
and Huh7 cells in vitro. In HEK293 cells, all mutants, with the exception of AAV9.RGNRQ,
displayed reduced transduction efficiency (Figure 7A). AAV9.AAQAA demonstrated the greatest
loss of transduction efficiency at a 3.75-fold reduction, indicating that the combination of S586
and Q590 is important for AAV9 transduction in vitro. AAV9.RGNRQ displayed a 2.3-fold increase
in transduction efficiency, modestly mirroring the ability of AAV2 to more efficiently transduce
cells in vitro than AAV9 (142). This could be due to the introduction of R586 and R589 (R585 and
R588 by AAV2 VP1 numbering) which have been established to be involved in AAV2 heparin
binding and therefore AAV2 transduction (57, 58). However, AAV9.RGHRE, which shares these
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two arginine residues with AAV9.RGNRQ, does not display increased transduction efficiency,
indicating that the other residues in this motif also play a role in the AAV2-like performance of
AAV9.RGNRQ or that there are other factors involved.
Loss of transduction efficiency was more profound in Huh7 cells and did not directly
correlate with an inability to transduce HEK293 cells (Figure 7B). AAV9.AANNN, which did not
affect PAV9.1 activity, was the most minimally affected, with a 2.8-fold loss in transduction.
AAV9.RGNRQ, the best performer in HEK293 cells, and its most closely-related mutant
AAV9.RGHRE, were most profoundly affected with an over 30-fold reduction in the ability to
transduce Huh7 cells, suggesting that the introduction of R586 and R589 do not confer increased
transduction efficiency in this system.
The effect of PAV9.1 epitope mutations on AAV9 neutralization
Having established which mutants reduce PAV9.1 binding and their ability to transduce
HEK293 cells sufficiently well for further in vitro analysis, we then evaluated all mutants by NAb
assay to determine if a loss in PAV9.1 binding translated directly into a loss of PAV9.1
neutralizing potential. We first evaluated AAV9.AANNN, which did not have an effect on PAV9.1
binding, as a negative control, expecting that this mutant with no effect on binding would likely not
change PAV9.1 neutralization. The NAb titer of PAV9.1 in the presence of AAV9.AANNN was
1:163,840, the same as for AAV9.WT (Figure 8A, H). All mutants that reduced PAV9.1 binding
were found to subsequently reduce PAV9.1’s ability to neutralize transduction by the
corresponding mutant vector (Figure 8B-J). We also found that the reduction in neutralizing
potential of PAV9.1 correlated strongly with the increase in EC50 due to a given mutation (Figure
9, Table 3). The two HVR-VIII point mutants, AAV9.SAQAA and AAV9.SAQAN, increased EC50
by 20- and 40-fold, respectively, and reduced the effective neutralizing titer of PAV9.1 by a
modest 4- and 16-fold, respectively. The HVR-VIII mutant that had the greatest impact on EC50,
AAV9.RGHRE, also had the greatest impact on PAV9.1-mediated neutralization, reducing
PAV9.1 NAb titer by at least 2048-fold. Again, AAV9.RGNRQ was the most divergent mutant
from this trend, with a 96-fold increase in EC50 only translating to a modest 8-fold decrease in
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effective NAb titer. Finally, there was no correlation between either an increase in EC50 or a
decrease in NAb and in vitro transduction efficiency.
Determining the tropism of AAV9-PAV9.1 mutant vectors
While this panel of AAV9-like mutants can effectively evade both PAV9.1 binding and
neutralization, in order to be viable vectors for addressing the obstacle presented by humoral
immunity to AAV, they need to also perform similarly to AAV9.WT in vivo. To study this, we
injected C57BL/6 mice intravenously with 1e11 GC/mouse of AAV9.WT.CMV.LacZ or one of the
PAV9.1 mutant vectors (n=3), collecting tissues at day 14 for genome copy analysis by qPCR as
well as for histology to evaluate β-galactosidase activity, a surrogate for gene expression. All
mutations conferring PAV9.1 evasion resulted in reduced liver transduction as measured by
vector GCs/µg liver DNA (Figure 10A). AAV9.QQNAA retained the most liver tropism, transducing
the liver 17-fold less efficiently than AAV9.WT, while AAV9.RGHRE nearly lost the ability to
transduce liver, doing so 1,110-fold less efficiently than AAV9.WT.
While all mutations in the PAV9.1 epitope resulted in a loss of liver transduction, this
profound effect was not observed for all tissues. With the exception of the AAV2-like mutants,
AAV9.RGNRQ and AAV9.RGHRE, the PAV9.1 mutants transduced heart and brain as efficiently
as AAV9.WT, suggesting that while these regions are important for AAV9 liver transduction, they
play less of a role in the transduction of other tissues. The trends observed for biodistribution
directly translated to β-gal expression and therefore activity levels; activity was highest in liver in
animals receiving AAV9.WT while it was equivalent between AAV9.WT and mutant groups in
heart, with the exception of the AAV2-based mutants for which no activity was detected (Figure
10B, C).
A subset of vectors was reevaluated at a ten-fold higher dose (1e12 GC/mouse, n=3) to
determine if these trends held true at multiple vector doses and to observe β-gal activity in
additional target tissues. While the trends previously observed did not reach significance, at this
dose AAV9.RGNRQ still performed poorly in all tissues tested, both by genome copy analysis
and β-gal activity staining (Figure 10D-G). The other AAV9 mutants tested, AAV9.SAQAA,
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AAV9.TQAAA, and AAV9.QQNAA, still transduced liver less efficiently than AAV9.WT, with
AAV9.QQNAA again performing most similarly to AAV9.WT measured both by biodistribution and
histology. As for the lower dose, at this dose these mutants performed equivalently to AAV9 in
other tissues tested, particularly heart and muscle, again both in genome copy analysis and
enzyme activity.
AAV9-PAV9.1 mutant vector binding and neutralization by polyclonal samples
Since all HVR-VIII swap mutants successfully evaded PAV9.1 binding and neutralization,
we then sought to determine if these mutants were also able to evade binding and neutralization
from antibodies in a more relevant, polyclonal sample. To simulate NAbs generated by an initial
vector dose, we utilized plasma from C57BL/6 mice (n=6) naïve prior to administration of
AAV9.WT vector intravenously at two doses, 7.5e8 or 7.5e9 GC/mouse. In these experiments, we
defined EC50 as the dilution of plasma required to reach half-maximal binding as determined by
absorbance by ELISA. Binding curves of plasma from mice in the low dose group against the
PAV9.1-based mutants were almost indistinguishable from the binding curve to AAV9.WT, with a
slight trend towards reduction in AAV9.RGNRQ and AAV9.RGHRE binding in two animals (Figure
11A, C). Binding curves of plasma from mice in the high dose group, in contrast, were markedly
more variable, with plasma binding to AAV9.AAQAA, AAV9.RGNRQ, and AAV9.RGHRE being
significantly reduced (Figure 11B, D). Neutralizing antibody assays of these plasma samples
performed using these mutant vectors, however, did not indicate that the use of these mutant
vectors measurably reduced the effective neutralizing titer of the plasma (data not shown).
To determine if the trends we observed using mouse samples were applicable to nonhuman primate (NHP) samples, we repeated these studies with serum from six rhesus macaques
that had previously received AAV9 vector (or a novel vector closely related to AAV9 with the
same VP3 sequence; this vector is considered to be comparable to AAV9 structurally and is
unrelated to PAV9.1 mutants). These macaques were confirmed to have AAV9 NAb titers of <1:5
prior to vector administration and were therefore defined as naïve. We observed some minor
variation in serum binding to the mutant vectors relative to wtAAV9 binding, but we did not
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observe any clear trend towards a significant reduction in binding as we did for a subset of
mutants in the high dose mice (Figure 12A, C). We did observe that, in fact, some mutants
actually increased serum binding. Regardless of serum binding, as we saw for all mouse
samples, no mutants reduced the effective NAb titer of these AAV9-injected NHP serum samples
(data not shown).
To assess the ability of these mutants to escape binding and neutralization by preexisting
immunity generated in response to an AAV infection, we obtained serum from a panel of NHPs
determined to be NAb positive for AAV9. Following EC50 determination, we found that the
binding curves for these sera were even less variable than those for sera from NHPs injected with
AAV9 vector, even with AAV9.RGNRQ (Figure 12B, D). As mutations in HVR-VIII did not reduce
serum binding to the AAV9 mutant capsids, we also found that they did not impact the NAb titer of
the serum samples tested (data not shown).
Finally, we evaluated binding and neutralization of the swap mutant panel by four serum
samples from normal human donors. Again, to model preexisting immunity, we selected donors
with NAb titers against AAV9 from a prior AAV infection. Similarly to the observations we made
from testing NHP serum samples with preexisting NAbs, these four human samples with
preexisting NAbs on average displayed minimal changes in binding between AAV9.WT and the
PAV9.1-based AAV9 vectors, with the exception of AAV9.AAQAA (Figure 13A, B). No changes in
the NAb titer of the polyclonal human serum were observed when testing the PAV9.1-based
AAV9 mutant vectors, indicating that even this significant change in AAV9.AAQAA binding failed
to modulate the neutralizing ability of the serum (data not shown).
Discussion
AAV9-PAV9.1 cryo-reconstruction defines neutralizing epitope and identifies shared features
Our successful cryo-reconstruction of AAV9 in complex with the highly potent neutralizing
mAb PAV9.1 to 4.2Å resolution allowed us to specifically define those residues that play a direct
role both in PAV9.1 binding to and neutralization of AAV9. The cryo-reconstruction indicated nine
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residues directly involved in binding, with the involvement of these residues being confirmed
through functional evaluation. We were able to define the epitope more specifically than previous
complexes that were of lower resolution and/or that did not narrow down the list of potential
residues through functional analysis. Therefore, it is difficult to make significant conclusions about
shared residues, as all residues of these other epitopes have not been validated. However, the
residues involved in the PAV9.1 epitope broadly agree with residues from other mapped
epitopes, either directly in sequence or in equivalent positions in the sequence alignment of AAV9
with other AAV serotypes. These include ADK8 (AAV8; 586-LQQQNT-591), E4E (AAV1; 492TKTDNNN-498), 5H7 (AAV1; 496-NNNS-499, 588-STDPATGD-595), and C37 (AAV2; 492SADNNNS-498, 585-RGNRQ-589) (125-127).
Despite the apparent shared binding sites between these neutralizing epitopes, the
orientations of each NAb following capsid binding are quite different. NAbs mapped against other
serotypes have been found to bind the top or the outer faces of the three-fold protrusions, which
allows for maximum occupancy of 60 Fab molecules in the complex due to a lack of steric
hindrance. In contrast, PAV9.1 uniquely binds the inner face of the three-fold protrusions and is
therefore limited to a maximum occupancy of 20 due to steric hindrance. The neutralization
mechanisms of each of these AAV NAbs have yet to be determined, and the functional
implications of these different binding orientations cannot be inferred. Therefore, while these
neutralizing epitopes have striking similarities, there may still be fundamental, uncharacterized
differences between them that require further study.
Minimal mutations required to affect mAb binding and neutralization
We were able to profoundly impact PAV9.1 activity by changing only five amino acids in
AAV9 HVR-VIII, reducing its neutralizing ability by up to 2,000-fold. Mutating only two amino acids
in this region still resulted in a significant reduction in PAV9.1 binding and a modest reduction in
neutralizing ability. Mutating only a single residue in this epitope, despite having a less profound
impact, still reduced PAV9.1 activity measured both by binding and by neutralization. Therefore,
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depending on the degree of NAb titer reduction required, minimal changes may need to be
introduced to a capsid engineered to evade, for example, preexisting NAbs.
We also determined that there was a direct correlation between the ability of PAV9.1 to
bind the mutant AAV9 capsids and its ability to neutralize them in vitro. This suggests that the
affinity of this and potentially other NAbs against AAV is largely responsible for conferring
neutralizing ability to these NAbs. However, the PAV9.2 antibody identified in our hybridoma
screen to strongly bind AAV9 does not neutralize AAV9 transduction. This is similar to what has
been observed with mAbs isolated against another parvovirus, canine parvovirus (CPV), in which
the affinity of a mAb for CPV did not correlate with an ability to neutralize virus (143). Additionally,
in individuals with preexisting immunity to AAV, we and others have found that binding Ab titer is
not always predictive of or correlates with NAb titer; some individuals have moderate binding
titers but are NAb negative, and some individuals with low binding titers have been found to have
moderate-high NAb titers (95, 96).
To determine the degree to which antibody affinity is a determinant of neutralizing ability,
further epitope mapping studies are required. In the catalog of mapped AAV epitopes, there are a
handful of binding (but not neutralizing) epitopes mapped, again against only a handful of
serotypes. A number of these epitopes overlap with neutralizing antibodies that were mapped to
the same serotype, suggesting that perhaps the differentiator between binding and neutralizing
could be the strength of which the antibody binds the capsid, but the affinity of these antibodies
has not been quantified. While the epitopes overlap, they are not identical, and perhaps NAb
binding to these unique regions, regardless of affinity, is what results in AAV neutralization. This
has been shown again to be the case for CPV, where mAbs that neutralize and mAbs that do not
shared binding sites on the relatively small capsid, indicating that other factors are involved in
determining neutralizing ability (143). Overall, the number of epitopes mapped is not sufficient to
come to any broad conclusions regarding the properties of binding vs. neutralizing epitopes. A
larger repertoire of antibodies of both types needs to be evaluated in order to focus engineering
efforts on either simply reducing effective affinity of NAbs in general or on ablating NAb binding to
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potentially unique, neutralizing regions completely in order to generate AAVs able to evade NAbs
in the future.

Translation of monoclonal antibody evasion to relevant polyclonal samples
Despite the dramatic ability of mutations in the epitope of PAV9.1 to reduce PAV9.1
binding as well as neutralization, this did not translate into an ability to significantly evade either
binding or neutralization by a number of different polyclonal samples that were surrogates for
either preexisting immunity from a prior AAV infection or induced immunity from AAV vector
administration. In the samples with induced immunity, we observed the largest change in binding
when evaluating the plasma from mice intravenously injected with a high dose of AAV9 vector
against AAV9.RGNRQ. This vector increased the effective EC50 of the plasma samples by
approximately 2-fold, which is much less than the increase in EC50 observed with PAV9.1 mAb
using the same vector (50-fold). AAV9.QQNAA, AAV9.SSNTA, and AAV9.RGHRE all increased
PAV9.1 EC50 more extensively than AAV9.RGNRQ but had little to no impact on the binding of
polyclonal mouse plasma. Not only did PAV9.1 mAb loss of binding to mutants not translate
significantly to polyclonal samples, but also the rank order of the impact of the mutations
changes. Taken together, these results suggest that while mutations in the 586-SAQAQ-590 motif
can have a potent effect on PAV9.1 activity, in vitro activity against a mAb does not predict
evasion of polyclonal samples. Additionally, as not all mutants behaved similarly against
polyclonal samples, there is the potential that a larger repertoire of antibodies utilizes this region
for binding that were disrupted by the AAV2 swap alone.
These findings were even less profound in both NHP and normal human donor samples
from individuals with preexisting immunity. Overall, the mutant binding curves from the samples
with preexisting immunity were, on average, even more similar to the AAV9.WT binding curves,
resulting in equivalent NAb titers for all samples in the presence of the mutant vectors compared
to AAV9.WT. These discrepancies between samples generated in response to an AAV infection
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and those generated in response to vector administration highlight potential fundamental
differences in the antibody repertoire following each route of exposure.
Based on the minimal changes in binding to the panel of AAV9 mutants in a handful of
polyclonal samples regardless of source, it was perhaps not surprising that these mutants did not
have any effect on the NAb titers of these samples. However, we were surprised that none of the
HVR-VIII mutants dramatically affected polyclonal activity, especially since this particular region
has been implicated in the mapped neutralizing epitopes of most serotype-specific NAbs. This
suggests that NAbs that recognize regions other than the three-fold protrusion also play an
integral role in AAV neutralization. This is supported by a recent study published by Tse and
colleagues in which they generated a library of AAV1 variants based on the epitopes of three
separate NAbs and identified a novel AAV1 variant, differing from the parental AAV1 by 20 amino
acids. This variant was able to evade the individual NAbs but also polyclonal samples from
vector-injected mice and NHPs and from normal human donors with natural immunity to AAV
(115). These data suggest that a larger percentage of amino acids on the capsid surface need to
be engineered in order to generate an AAV that can evade neutralization by polyclonal sera.
Additionally, these data suggest that some mutations can confer evasion to both preexisting and
vector-induced immunity and that the repertoire generated in response to these routes of
exposure does overlap, although to an unknown degree.
The effect of dose on immune evasion
It has been established that the magnitude of the NAb response to AAV varies widely
between routes of exposure. Individuals with preexisting, natural immunity rarely have NAb titers
against a given serotype that exceed 1:80 (humans) or 1:320 (macaques). In contrast,
intravenous vector administration regularly results in NAb titers exceeding 1:1000 at modest
vector doses (86, 91, 104, 144). In this study, we found that only mice receiving the higher vector
dose, resulting in higher NAb titers (data not shown), had measurable variations in AAV9 mutant
vector binding. This finding suggests that the magnitude of the native NAb response impacts the
ability of a specific mutation to confer evasion. The overall goal of designing AAV evasion
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mutants is to reduce an individual’s NAb titer to below the threshold that has been established to
significantly interfere with gene transfer, 1:10 for intravenous administration (90, 145, 146).
Mutant capsids that confer modest evasion only to high titer sera, bringing the titer down by a
dilution factor or two, will likely not be sufficient to reduce the titer below that 1:10 threshold.
Taken together with the fact that these capsids would not confer evasion to low titer sera, capsids
with these properties would not meet the ultimate goal of increasing the number of individuals
eligible to receive AAV gene therapy.
Evaluating the overlap of neutralizing epitopes and functional motifs on the AAV capsid
Maintaining parental tissue tropism is of utmost importance when designing immune
evasion capsids, particularly for the goal of readministration. Mutation of the HVR-V portion of the
PAV9.1 epitope reduced liver transduction, as did even a single mutation in HVR-VIII. Previous
studies have established the role of the three-fold axis, particularly HVR-V and HVR-VIII, in the
transduction efficiency of AAV9 (147). Therefore, while a reduction in in vivo mutant vector
performance was not necessarily unexpected, the magnitude of this reduction was quite profound
and outside the acceptable range to move forward as a candidate vector for therapies targeting
the liver. However, for indications where liver targeting is less critical and the focus is on the
transduction of other organs such as heart and muscle, evasion mutants with modified HVR-V
and HVR-VIII may still prove useful. These studies highlight the complexity of incorporating both
epitope mapping and functional data and collating this knowledge such that capsids can be
engineered that meet both sets of requirements.
Conclusions
By generating a 4.2Å resolution cryo-reconstruction of AAV9 capsid in complex with the
serotype-specific, potent neutralizing antibody PAV9.1, we precisely mapped the capsid
responsible for PAV9.1-mediated neutralization of AAV9 transduction. Using this information, we
engineered AAV9 capsid mutants able to evade not only PAV9.1 binding but also neutralization in
vitro. However, the resulting mutants were unable to appreciably evade binding and neutralization
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by polyclonal samples from a number of sources, indicating that this epitope, despite being a
conserved with other mapped AAV neutralizing epitopes, is likely not immunodominant following
AAV exposure in vivo. These mutations also interfered with the ability AAV9 to transduce liver, a
target organ for a number of indications. The results of these studies demonstrate the feasibility
of utilizing epitope mapping to design AAV escape mutants against α-AAV mAbs but also
highlight the complicating and confounding factors of addressing polyclonal immunity and
maintenance of other key vector properties, such as tropism.
Materials and Methods
Hybridoma generation: Balb/c immunization and hybridoma generation was performed at ProMab
Biotechnologies (Richmond, CA). Mice were immunized subcutaneously up to five times with
AAV9 vector. Following confirmation of seroconversion, splenocytes were harvested and
hybridomas generated according to ProMab’s standard custom mouse monoclonal antibody
hybridoma development protocol. Supernatants from thirty positive clones were screened for
AAV9 reactivity by ELISA and for AAV9 neutralization by NAb assay. Purified mAb of desired
clones was obtained from ProMab at a concentration of 3mg/mL.
o

AAV capsid ELISA: Polystyrene high bind microplates (Corning) were coated overnight at 4 C
with 1e9 GC/well AAV diluted in phosphate buffered saline (PBS). Coating solution was
discarded, and plates were blocked with 3% bovine serum albumin (BSA) in PBS for 2 hours at
room temperature followed by 3x wash with 300µL PBS+0.05% Tween. Sample (hybridoma
supernatant, purified mAb, serum, or plasma) was diluted in PBS with 0.75% BSA and incubated
o

at 37 C for one hour, followed by 3x was with 300µL PBS+0.05% Tween. Mouse samples were
then detected with 1:10,000 goat anti-mouse IgG HRP (Cat. 31430, Thermo Fisher Scientific,
o

Waltham, MA) in PBS with 0.75% BSA at 37 C for one hour followed by 3x wash with 300µL
PBS+0.05% Tween. Human and non-human primate samples were then detected with 1:10,000
goat anti-human IgG biotin-SP (Cat.109-065-098, Jackson ImmunoResearch Inc., West Grove,
PA) diluted in PBS at room temperature for one hour followed by 3x wash with 300µL
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PBS+0.05% Tween; secondary antibody was detected with 1:30,000 unconjugated streptavidin
(Cat.016-000-084, Jackson ImmmunoResearch Inc., West Grove, PA) diluted in PBS at room
temperature for one hour followed by 3x wash with 300µL PBS+0.05% Tween. All ELISAs were
then developed with tetramethylbenzidine.
Neutralizing antibody and vector transduction assays: All NAb assays were performed as
previously described with a few modifications (84). HEK293 cells were seeded at a density of 1e5
cells/well on black-walled, clear-bottomed, poly-lysine coated plates (Cat.08-774-256, Fisher
Scientific Company, Hampton, NH). A multiplicity of infection of wtAd5 of 90 particles/cell was
used. A working solution of 4e10 GC/mL AAV9.CMV.LacZ vector was utilized to achieve a final
concentration of 2e9 GC/well. Luminescence was measured with the SpectraMax M3 (Molecular
Devices, Sunnyvale, CA) according to the manufacturer’s protocol. NAb titer was defined as the
last dilution at which AAV transduction was reduced by >50% in the presence of sample
compared to AAV transduction in the presence of the naïve control.
HEK293 transduction experiments were performed as described above but in the
absence of neutralizing sera.
For Huh7 transduction experiments, Huh7 cells were seeded at a density of 5e4 cells/well
in DMEM low glucose media with 10% FBS and 1% penicillin/streptomycin. The next day, cells
were infected with wild type adenovirus at an MOI of 30 particles/cell for 2 hours followed by
AAV9.CB7.ffluc.RBG vector application at an MOI of 1e4 or 1e5 GC/cell (all in serum-free media).
Three days post-transduction, luciferase expression was determined by the injection of 50µL
0.3mg/mL D-luciferin (in complete media) (Promega, Madison, WI) using the Synergy 2
microplate reader and analyzed using Gen5 version 3.02.1 (BioTek, Winooski, VT).
Fab generation and AAV-Fab complexing: PAV9.1 Fab was generated using the Pierce Fab
Preparation kit (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer’s
instructions. Final PAV9.1 Fab concentration was 0.211 mg/mL. PAV9.1 Fab was then
complexed with AAV9 vector at a ratio of 600 Fab molecules: 1 AAV9 capsid (or 10 Fab
molecules: 1 potential binding site) at room temperature for 30 minutes.
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Cryo-EM sample preparation, data acquisition, and complex reconstruction: Sample preparation:
3µL of the PAV9.1-AAV9 complex was applied to a freshly washed and glow-discharged holey
o

carbon grid. Following blotting for 3-4 seconds with Whatman #1 filter paper at 22 C and 95%
relative humidity, the grid was rapidly frozen in liquid ethane slush using a Vitrobot Mark IV (FEI).
After freezing, grids were stored in liquid nitrogen. Grids were then transferred to an FEI Talos
Artica electron microscope operating at 200kV equipped with a Gatan K2 Summit direct electron
detection camera (Gatan, Pleasantan, USA).
Data acquisition: Data was acquired using the SerialEM software (148). Images were captured at
a nominal magnification of 22,000x (corresponding to a calibrated pixel size of 0.944Å) and a
dose rate of 2.21 electrons/Å/sec with a defocus range of 1.0-2.0µm (149). For each exposure, a
60-frame dose-fractionated movie stack in super-resolution mode was recorded for a total of 12
seconds. The movie frames were aligned using the “alignframes” program within the IMOD
software package (150).
Data collection and processing: All particle images were manually extracted from each
micrograph and processed using the e2boxer program in the EMAN2 suite (151). Boxed particles
were then transferred to AUTO3DEM for cryo-reconstruction and generation of an initial lowresolution model (30Å) based on 150 particle images (152). The program adopted a random
model generation procedure, and strict 60 non-crystallographic axes were applied. The lowresolution model was used for determining particle origin, conducting full orientation, refining
contrast transfer function of all images in AUTO3DEM. The reconstructed map’s quality was
improved by application of temperature factor correction and visualization in Coot and Chimera
(153, 154). A temperature factor 150-corrected map was used for model docking and
interpretation.
To generate the 4.2Å model, 3,022 boxed particles were extracted from 1,100
micrographs, resulting in a reconstructed map with a Fourier shell correlation of 0.15. A VIPER
database was used to generate the AAV9 60-mer model while applying strict icosahedral
symmetry axes (T=1) (155). The 60-mer copy of AAV9 capsid was docked into the cryo43

reconstructed electron density map using the FIT function of Chimera; this produced a correlation
coefficient of 0.9. The docked model was visualized and adjusted in Coot and Chimera for
accuracy. ABodyBuilder was used to generate the Fab model, which was then docked and
manually adjusted into the reconstructed density using Chimera (156). The model was then
visualized for interpretation of AAV9 capsid and antibody binding regions. All figures were
produced using Chimera and PyMOL (157). RIVEM was used to created two-dimensional
depiction of the asymmetric unit roadmap (158).
AAV9-PAV9.1 mutant trans plasmid construction: The AAV2 rep/AAV9 cap trans plasmid
construct was provided by the University of Pennsylvania Vector Core for AAV9 capsid
mutagenesis. All capsid mutants were generated using the QuikChange Lightning Mutagenesis
kit (Agilent, Santa Clara, CA) according to manufacturer’s instructions.
AAV vector production: Wild-type AAV9.CMV.LacZ.bGH and AAV9 mutant vectors were
produced by the University of Pennsylvania Vector Core by triple transfection in HEK293 cells
and titered used quantitative PCR against the bGH polyadenylation signal as previously
described (159).
Determination of EC50 of PAV9.1 mAb and polyclonal sera/plasma: Capsid capture ELISAs with
either AAV9.WT or AAV9 mutant vectors were performed as described above. EC50 values were
calculated using GraphPad Prism. Briefly, the concentration of PAV9.1 mAb in mg/mL was logtransformed and plotted on the x-axis. IgG concentration was defined as 5 mg/mL for mouse
plasma and as 10 mg/mL for non-human primate and human serum and was then logtransformed and plotted on the x-axis (160, 161). The maximum absorbance achieved for each
unknown was normalized to 100% and plotted on the y-axis. A dose-response curve (antibody
binding) was generated using GraphPad Prism’s “log(agonist) vs normalized response—Variable
slope” function. The EC50, or concentration mAb or sample required to reach half-maximal
binding, was then calculated from these dose-response curves.
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Animal studies: All animal protocols were approved and conducted in accordance with the
standards of the University of Pennsylvania’s Institutional Animal Care and Use Committee.
For passive transfer studies, male 6-8 week old C57BL/6 mice (n=3) were injected
intravenously by tail vein with 250µg PAV9.1, 9.2, or 9.3 mAb in PBS or PBS alone. Two hours
later, mice were injected intravenously by tail vein with AAV9.CMV.ffluc at a dose of
3e10GC/mouse. To determine luciferase expression, mice (~20g each) were anesthetized and
injected intraperitoneally with 200uL of 15 mg/mL luciferin substrate (Perkin Elmer, Waltham,
MA). Mice were imaged five minutes after luciferin administration via the IVIS Xenogen In Vivo
Imaging System. Luciferase signal was quantified using Living Image 3.0 in regions of interest.
Mice were imaged weekly for four weeks after vector administration.
To evaluate AAV9 mutant vector biodistribution, male 6-8 week old C57BL/6 mice (n=3)
were injected intravenously by tail vein with 1e11 GC/mouse AAV9.CMV.LacZ.bGH or AAV9
mutant vectors with the same transgene cassette. Animals were sacrificed 14 days after vector
administration. Organs were divided and were either snap frozen on dry ice for biodistribution or
embedded in optimal cutting temperature compound and frozen in liquid nitrogen for subsequent
sectioning and staining for β-galactosidase activity.
Vector biodistribution: DNA was extracted from tissues of interest using the QIAamp DNA Mini kit
(Qiagen, Hilden, Germany). DNA was analyzed for vector genome copies by qPCR against the
bGH polyadenylation signal as previously described (162).
β-galactosidase activity staining: Frozen tissue sections were fixed with 0.5% glutaraldehyde in
o

PBS for 10 minutes at 4 C and subsequently stained for β-gal activity. Following a wash with
PBS, sections were incubated in 1mg/mL X-gal substrate (5-bromo-4-chloro-3-indolyl-β-Dgalactopyranoside) in 20mM potassium ferrocyanide, 2mM MgCl2 in PBS (pH~7.3) overnight at
o

37 C. Sections were then counterstained with Nuclear Fast Red (Vector Laboratories),
dehydrated with ethanol and xylene, and cover slipped.
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Chapter 4: B cell biology and its utilization
B cell development and function
One of the body’s main defenses against infection with pathogens is the production of
antibodies. Antibodies are produced by B cells in response to these pathogens and function to
specifically bind to a target protein (or in some cases, glycan) on the pathogen in order to
interfere with its function through a process called neutralization. Antibodies can neutralize
pathogens by a number of mechanisms, including blocking receptor binding, induction or
blockage of conformational changes, opsonization, and complement activation (163, 164).
B cells, derived from lymphoid progenitor cells, develop in the bone marrow. In order to
generate immunoglobulin diversity, pro-B cells first undergo rearrangement of the heavy chain
variable (V), diversity (D), and joining (J) regions of the immunoglobulin locus facilitated by the
expression of recombination-activating genes (RAGs) that promote recombination at these sites
(165). The resulting intact, functional immunoglobulin heavy chain, utilizing the membrane
isoform of the IgM constant region, associates with the surrogate light-chain (SLC) forming a preB cell receptor (BCR). The resulting pre-B cells then internalize this protein and spontaneously
undergo recombination of the V and J regions of the light chain locus, again facilitated by RAG
protein activity.
It is during this process that the isotype of the light chain is selected. There are two light
chain isotypes, kappa (Igκ) and lambda (Igλ), their gene segments are encoded on different
chromosomes, and each B cell expresses antibody of a single light chain isotype (166). Gene
rearrangement at these two loci occurs independently, but, in humans, Igκ is initially evaluated for
productive rearrangement and incorporation into the BCR. If the cell is unable to produce a
functional BCR with Igκ, that allele is inactivated and Igλ is utilized (167).
The resulting BCR is again expressed on the surface of these immature B cells, where it
can encounter self-antigens expressed in the bone marrow and undergo negative selection (168).
B cells that are autoreactive undergo additional rounds of recombination in attempts to produce
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BCRs that do not recognize self-antigens; if this process is unsuccessful, they undergo cell death
to prevent the eventual circulation of auto-reactive B cells. Immature B cells that do not recognize
self-antigens then undergo positive selection in which accumulated tonic signaling by the
productive BCR triggers the upregulation of IgD, CD21, and CD23, driving the differentiation of
the immature B cell into a mature, naïve B cell (169). It is during this stage of development that B
cells traffic from the bone marrow to secondary, peripheral lymphoid organs such as the spleen
and lymph nodes (165).
Once in secondary lymphoid organs, naïve B cells encounter foreign antigens in the
+

primary B cell follicle (170). These B cells are then activated by CD4 T helper cells that have
been activated by antigen presentation by dendritic cells and costimulatory signaling in the T cell
zone (171). Some of these T helper cells become T follicular helper cells that then drive B cell
proliferation and further differentiation. Some B cells exit the germinal center and become
differentiated, short-lived plasma cells that secrete antibody in the early stages of infection. Other
B cells differentiate into long-lived memory B cells that encode the same antibody produced by
these short-lived plasma cells. A third subset of B cells migrates to the germinal center for class
switching and affinity maturation by somatic hypermutation.
The immunoglobulin heavy chain locus encodes many different constant regions,
allowing for the production of antibodies of different isotypes depending on the B cell subset
and/or desired function of the antibody. Mature, naïve B cells produce IgM and IgD antibody
isotypes; IgM assembles as a pentameric or hexameric molecule that is unable to migrate to most
tissues due to its size, and IgD is both secreted as well as produced as a cell surface receptor
(172). Class switch recombination of the constant region of the heavy chain locus facilitated by
the introduction of double-stranded breaks by activation-induced cytidine deaminase (AID) allows
for the utilization of alternative heavy chain constant segments whose expression result in the
production of immunoglobulins (Igs) of a different isotype, either IgG, IgA, or IgE, each with
different effector functions(173). Each of these Igs has distinct properties that render them more
effective against specific types of pathogens. IgA can be transported across mucosal membranes
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by the polymeric immunoglobulin receptor and is therefore ideal for combating bacteria at the
mucosa (174, 175). IgE, through its ability to bind the FCεRI and FCεRII receptors on basophils,
mast cells, and/or macrophages, is effective against parasitic pathogens (176). IgG is further
subdivided into four subclasses, with IgG1 and 3 being effective against viruses, IgG2 against
encapsulated bacteria, and IgG4, similar to IgE, being effective against parasites (177).
B cells are further matured by programmed mutagenesis of the variable regions of their
heavy and light chains in attempts to increase the ability of their immunoglobulins to recognize
their target antigen beyond what is conferred by the germline VH and VL loci (178). This process
of affinity maturation is mediated largely by somatic hypermutation. AID deaminates cytosines
within the VH and VL genes, converting them to uracil and introducing base pair mismatches.
Subsequent DNA repair and replication by low fidelity polymerases allow for the introduction of
mutations with the potential to antigen recognition and therefore antibody function (179-181).
These mutations, in addition to a number of surface markers and isotype-switched
immunoglobulin, are characteristic of antigen educated memory B cells.
-3

The mutation rate of B cells in the germinal center is approximately 10 mutations per
base pair per generation, which is orders of magnitude higher than the basal rate of mutation in
-8

somatic, higher-order eukaryotic cells, approximately 10 mutations per base pair per generation
(182-184) . These nucleotide substitutions are preferentially present in the complementarity
determining regions (CDRs) over the framework regions (FWRs) between them in both the VH
and VL loci (185). Functionally, the FWRs are more conserved regions and largely contribute to
the structural integrity of the antibody provide while the CDRs are responsible for antigen
interactions and therefore should be favorably targeted for mutagenesis to improve these
interactions, but the mechanism of this preference has not been established (186). Not only do
these nucleotide changes occur more frequently in the CDRs (defined per base pair in a given
region), but a greater percentage of the substitutions additionally result in an amino acid
substitution (replacement mutation) than in the FWRs (187). The degree of somatic
hypermutation and by proxy affinity maturation can further be defined by the ratio of replacement
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mutations to silent mutations (R/S) in both the CDRs and the FWRs and also by the ratio of these
ratios (R/S CDR: R/S FWR).
Studies of total human memory B cell populations that differentiated from germinal center
+

B cells that have undergone affinity maturation estimate that, on average, a mature, IgG memory
B cell harbors 18 mutations in its VH chain, 9.7 mutations in its VL chain if it utilizes a kappa light
chain, and 7.7 mutations in its VL chain if it utilizes a lambda light chain (188). In a study by Tiller
and colleagues, VH CDRs were found to have a mutation frequency between 10 and 13% while
VH FWRs have a mutation frequency of 3 to 5% of total base pairs. VL CDRs, regardless of
isotype, have a mutation frequency of 5-8% with the associated FWRs having a lower frequency
of <1-3% (188). Additionally, CDR R/S ratios ranged from 2.6-10.5 while FWR R/S ratios 0.9 to
1.8, clearly indicating a preference for replacement mutations in the CDRs. Studies from other
groups evaluating somatic hypermutation in antigen-specific memory B cells have found similar
results, establishing hallmark characteristics for this mature, antigen educated B cell population
(189).
Surface markers of B cell populations
In addition to their functional differences, different B cell populations have corresponding
sets of experimentally determined protein markers that allow for identification and isolation of
these populations. In humans, B cells (as well as dendritic cells/DCs, natural killer/NK cells, and
monocytes) can be distinguished from T cells by the absence of CD3, which is a co-receptor for T
cell activation via the T cell receptor (TCR) (190, 191). B cells are then distinguished from DCs,
NK cells, and monocytes by the presence of CD19, which is present on the surface of all B cells
(with the exception of differentiated plasma cells) and modulates both BCR-dependent and independent signaling (192). B cells expressing CD27, which is thought to contribute to B cell
differentiation, expansion, and antibody production, are considered to be part of the memory B
cell population while B cells lacking CD27 are generally considered to be naïve B cells (193, 194).
CD27 can also be found on some T cell populations (195)
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The utility of single B cell cloning
This natural, iterative process used to produce highly potent antibodies has recently been
harnessed to study the B cell repertoire generated in response to many pathogens, including
human immunodeficiency virus (HIV), dengue virus (DENV), and influenza, as well as
abnormalities in humoral immunity. Specific B cell populations, including antigen-specific memory
B cells, can be isolated via cell sorting utilizing the markers described above. Techniques have
been developed to isolate the paired immunoglobulin genes from these sorted cells for highthroughput study of the phylogenetic relationships of B cell lineages within the larger repertoire as
well as production and characterization of fully-human, recombinant antibodies against an antigen
of interest.
This strategy has allowed for the evaluation of aberrations in the immunoglobulin
repertoire proposed to be involved in autoimmunity. Sequence analysis, production, and
evaluation of antibodies from healthy individuals established the percentage of circulating
memory B cells that produce low-affinity anti-self antibodies and that, as a whole, the
immunoglobulin genes in this auto-reactive population do not share any defining sequence
characteristics (188, 196). When applying this approach to specific diseases, however, it has
defined some fundamental features of auto-antibodies against specific targets. Single cell studies
of patients with systemic lupus erythematosus indicated abnormal levels of Igλ usage relative to
healthy controls, which suggests above-normal levels of receptor editing, as well as an
abnormally low frequency of Vκ3-20 gene usage (197). While the exact mechanism of
pathogenesis is not clear from these studies, this approach has the ability to identify particular
disease phenotypes for further evaluation.
B cell cloning has also been used in HIV research to study a population of individuals that
are uniquely able to raise broadly neutralizing antibodies (bNAbs) against the constantly evolving
virus as determined by the ability of their sera to neutralize a diverse panel of viruses (198).
Many of these bNAbs have been sequenced and evaluated following single memory B cell
cloning from PBMC samples from these individuals (199-201). While these bNAbs do not
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significantly impact viral load following initial infection, their evaluation has led to breakthroughs in
the HIV prophylaxis efforts (202). Passive immunization, either by intravenous delivery of
recombinant bNAbs or by their vector-mediated expression, is currently being explored as a way
to prevent initial HIV infection (203-205). Additionally, epitope mapping of these bNAbs has led to
efforts to develop vaccination strategies that direct the immune response to the regions of the HIV
envelope protein that are susceptible to neutralization by these cross-reactive antibodies (206).
Similar approaches have been taken to develop immunization strategies against other
pathogens. bNAbs capable of neutralizing even pandemic strains of influenza have been
identified, and vector-mediated delivery of these bNAbs as a method of passive immunization is
currently being pursued as an alternative to the seasonal influenza vaccine (207-209). Single B
cell cloning is also being used to better understand correlates of protective immunity against
infection with DENV. There are four major serotypes of DENV, and infection with one serotype
provides significant protective immunity against that serotype, but this immunity is also correlated
with more severe disease if subsequently infected with one of the other serotypes (210). This
technique is therefore being utilized to study this phenomenon and how to develop a vaccine that
elicits broad immunity to prevent infection with all DENV serotypes (211, 212). As such, B cell
cloning techniques can provide a better understanding of the way the immune system interacts
with various pathogens and how this interaction can be leveraged to provide a therapeutic
benefit.
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Chapter 5: Isolation of novel, human α-AAV antibodies from single memory
B cells
Abstract
With the advent of single B cell cloning technology, antibody against virtually any antigen
can be isolated in a high-throughput fashion in order to study immunological repertoire against a
given pathogen and to develop novel therapeutic strategies. Antibodies against the AAV capsid
are a significant obstacle towards the use of AAV as a gene delivery vector in the clinic, as they
can block vector transduction and are derived either from prior exposure to AAV or previous
administration of AAV vector. Epitope mapping efforts utilizing mouse monoclonal antibodies
generated through AAV vector immunization have provided critical but limited information
regarding capsid immunogenicity with the goal of engineering AAV capsids able to evade these
neutralizing antibodies. In addition to the limited number of epitopes mapped using this method,
these studies are unable to address potential differences in the α-AAV antibody repertoire
following AAV infection compared to AAV vector administration due to the method of mAb
generation and isolation. Here, we utilize single memory B cell cloning, originally designed to
identify approaches to prevent viral infection, to study the human antibody repertoire generated in
response to AAV with the goal of leveraging this knowledge to design escape mutants able to
transduce target tissues even in AAV seropositive individuals.
Introduction
While the traditional approach of mouse immunization followed by hybridoma generation
for the isolation of mAbs for epitope mapping can significantly contribute to the understanding of
the immunogenicity of the AAV capsid, it fails to address aspects unique to the use of AAV as a
gene therapy vector. The repertoire of NAbs generated following a wild-type AAV infection,
resulting in preexisting immunity, may be fundamentally different than the repertoire generated in
a naïve individual following AAV vector administration, and it is currently unknown how these
differences may impact efforts to design vectors to evade these distinct types of immunity. Mice
often require repeated immunization with AAV in the presence of an adjuvant to raise sufficient
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responses for hybridoma fusion, and the doses of AAV may be significantly higher than those
required for most indications that seek intervention by AAV gene therapy. This repeated
immunization with vector does not precisely mirror either a single dose of AAV vector or infection
by replicating AAV. It is, however, more similar to vector dosing, as animals are naïve prior to
immunization and generate immunity that is often limited to the immunizing capsid as well as
potentially closely related serotypes (104, 213). This is not to say that this setting does not
recapitulate preexisting immunity. However, evidence from infectious disease demonstrates that
vaccination with an attenuated or replication-deficient pathogen does not always generate
protective immunity comparable to that following an active infection (214, 215). Therefore, the
source of antibodies and the setting under which they are generated must be carefully considered
and further explored.
With the advent of single B cell cloning techniques that allow for the isolation of B cells
recognizing a specific antigen in a native setting and sequencing of their paired heavy and light
chains, we are now able to study immune repertoires in response to various stimuli in a highthroughput fashion. This approach has been applied frequently in vaccine research to identify
families of antibodies able to block infection by specific pathogens and to use that information to
design more effective vaccines (206, 207). It has also been used to identify auto-antibodies and
contribute to the understanding of the pathogenesis of autoimmune disorders (216, 217).
Here, we chose to leverage single B cell cloning techniques to evaluate the repertoire of
antibodies elicited by AAV exposure. Traditional hybridoma isolation can be more cumbersome
and is most commonly utilized in mouse models, making it difficult to study the complete antibody
repertoire and capture its complexity in a larger variety of biological systems. In most models, it
requires immunization with the antigen of choice, often repeatedly and/or in the presence of an
adjuvant. Single B cell cloning allows for the enrichment of a specific cell population such that
native immune responses can be studied even if the frequency of antigen-specific cells is low. It
also allows for the study of natural responses to infection. Responses generated in different
individuals, populations, or under different conditions can be evaluated and compared. This
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makes it an ideal approach for studying immune responses to AAV that prevent either initial
vector dosing or readministration; the epitopes responsible for neutralization can be fully
characterized, and potential variations in immunodominant epitopes between individuals, type of
exposure, route of administration, vector dose etc. can be more completely evaluated.
In this study, serum from a panel of normal human donors was screened for NAbs
against a number of AAV serotypes. The donor with the highest titer against AAV2 with significant
NAb titers against additional serotypes was selected for further study. From this donor’s total
PBMCs we isolated bulk switched memory B cells, cultured them for two weeks, and screened
their supernatants containing secreted antibody for AAV reactivity. Memory B cells were chosen
for isolation as it allowed us to use samples from donors previously exposed to AAV and did not
require identification and acquisition of samples from individuals with an active or recent AAV
infection. Additionally, cells were sorted in an antigen-independent fashion to avoid selection bias.
cDNA was synthesized from RNA harvested from positive clones, and VH and VL chains isolated
by nested PCR. These sequences were evaluated for evidence of a memory B cell lineage.
Isolated VH and VL sequences were also cloned into an expression plasmid for production of
recombinant Abs, which were then again screened for AAV reactivity and neutralization. We
identified over 100 positive B cell clones using this method, and produced and confirmed the
reactivity of over 15 novel, human α-AAV mAbs, supporting the use of this approach for further
isolation of novel α-AAV mAbs.
Results
Selecting AAV NAb positive donors
To select a donor for memory B cell isolation, we obtained a panel of 31 normal human
donor samples of separated serum and matched whole blood, from which we isolated PBMCs
using a Ficoll gradient. As the seroprevalence of AAV2 is highest in the normal human
population, we first screened the sera for NAbs against AAV2, identifying 18 of the 31 samples as
having detectable NAb titers, ranging from 1:5 to 1:320 (Table 4). This percentage (58%) is
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comparable to what we have seen previously for the prevalence of AAV2 NAbs in the human
population. We then determined the NAb titers of these samples for AAV8, AAV9, and AAVrh10,
whose seroprevalences have also been established previously. We determined that 11 of
31(35%), 11 of 31(35%), and 12 of 31(39%) samples were NAb positive for AAV8, AAV9, and
AAVrh10, respectively. On average, NAb titers against these three serotypes were lower than
those against AAV2, suggesting that these individuals were likely exposed to AAV2 and
generated an immune response primarily against AAV2 that is cross-reactive with additional AAV
serotypes. We also evaluated serum samples from individuals that were strongly positive for
AAV2 and positive for the other three serotypes tested for NAbs against AAV3B to determine the
crossreactivity of their sera. We were particularly interested in NAbs against AAV3B due to the
potential of its use for intravenous, liver-directed gene therapy in humans (60). As expected, all
10 samples screened for AAV3B NAbs were determined to be NAb positive, while the magnitude
of the AAV3B NAb titer did not necessarily correlate with AAV2 NAb titer, despite being the most
closely-related serotype to AAV2 of the serotypes in the panel. Based on these results, we
selected Donor 7 for memory B cell isolation, as this sample had the highest AAV2 NAb titer, was
highly positive for all serotypes tested, and had one of the highest titers against AAV3B.
Isolation, culture, and identification of AAV-specific memory B cells
+

+

-

We then isolated bulk memory B cells, defined as CD19 /CD27 /IgM , from donor 7’s
purified PBMCs by negative column selection using magnetic bead sorting. We first evaluated
this approach using PBMCs from additional screened donor samples, as PBMCs from donor 7
+

were limited. Prior to staining and column selection, 5-20% of bulk PBMCs were CD19 . Of these
+

+

CD19 cells, the majority were CD27-/IgM naïve B cells (data not shown). Following staining with
a panel of biotinylated antibodies against non-memory B cell markers and magnetic bead sorting,
+

>90% of cells in the column flow-through were CD19 , and of these cells, almost all were
+

-

CD27 /IgM , demonstrating that these cells are a highly enriched population of switched memory
B cells. Relatively few memory B cells were retained on the column, as a very small fraction of
+

+

-

the CD19 cells retained were CD27 /IgM .
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Following isolation, we diluted the bulk switched memory B cells in IMDM+Glutamax
media to a concentration calculated to result in a maximum seeding density of one viable cell per
well following seeding into 96-well culture plates for clonal expansion. We supplemented the
media with IL-2 and IL-21 to promote memory B cell survival, expansion, and antibody secretion.
These functions were further supported by co-seeding with irradiated 3T3-msCD40L feeder cells,
providing CD40 receptor engagement. We seeded a total of 5,400 wells and therefore 10,800
total cells, assuming a maximum of one viable cell/well.
Following 14 days in culture, we harvested supernatant and froze the plates containing
the clonal memory B cell colonies after the addition of lysis buffer for future RNA harvest. To
approximate cellular viability following 14 days in culture, we selected a random subset of
supernatants from those harvested to quantify secreted antibody by protein A ELISA. Antibody
was detected in 33% of supernatants, suggesting that at most one in three wells contained a
viable B cell colony actively secreting detectable quantities of antibody. Viability could also be as
low as 16.5%, if each of these three wells was successfully seeded with two memory B cells.
We then screened all supernatants for reactivity against AAV2 and AAV3B by ELISA, as
NAbs against AAV2 and AAV3B were the primary donor selection criteria. 61 supernatants were
identified as positive for antibodies against AAV2, and 60 supernatants were identified as positive
for antibodies against AAV3B. Of these 121 positive supernatants, 21 were shared between
AAV2 and AAV3B; in total, 39 supernatants were positive for AAV2 only, 40 were positive for
AAV3B only, and 21 bound both AAV2 and AAV3B. Based on 101 unique positive hits and a
viability of 16.5-33%, we estimated that the frequency of AAV-specific memory B cells in this
donor with preexisting immunity is 2.8-5.5%. Based on degree of positivity, we selected clonal B
cell colonies from which to produce cDNA and clone variable heavy and variable light chain
sequences by nested PCR.
Cloning and evaluation of recombinant, human α-AAV mAbs
From these positive wells, we obtained and cloned VH sequences and at least one
cognate chain (in some cases, more than one light chain sequence was isolated) from 14. We
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also obtained sequences from 15 additional positive wells but were unable to recover both heavy
and light chain sequences for evaluation or, in the case of well 2.8F9, isolated too many
sequences for one chain to efficiently test all possible combinations. Following cloning of the
paired positive variable chain sequences into an expression cassette utilizing IgG1 constant
heavy and constant light chains and production in HEK293 cells, we confirmed binding of the
recombinant mAbs to AAV2 and AAV3B as well as compared relative affinity of these mAbs for
AAV by evaluating AAV binding at two fixed concentrations, 100ng/mL and 250ng/mL (Figure
14A, B). Two clones, 2.46F4 and 2.86D7, did not express sufficiently to evaluate the supernatant
at 100ng/mL and were therefore evaluated neat. Three additional clones, 2.46C11, 2.92G6c3,
and 2.92G6c9, did not express sufficiently to evaluate binding at 250ng/mL and were therefore
evaluated exclusively at 100ng/mL. Despite representing raw culture supernatants that tested
positive for AAV2, AAV3B, or both AAV2 and AAV3B, all clones, with the exception of 2.46F4,
were determined to bind both AAV2 and AAV3B at all dilutions tested. 2.46F4 binding to either
AAV2 or AAV3B was undetectable, indicating that its identification was either a false positive or
that we were simply unable to express a sufficient quantity to detect binding.
In addition to evaluating mAb binding to AAV2 and AAV3B, we additionally evaluated
binding to the other serotypes against which we determined Donor 7 was NAb positive, AAV8,
AAV9, and AAVrh10, at a concentration of 100ng/mL. We found that all Donor 7 mAbs bound all
serotypes tested. Binding preference was determined relative to AAV2 binding, and we found that
some mAbs, such as 2.46D10 and 2.81G5, bound all serotypes with similar relative affinity while
others, such as 2.15G3 and 2.51B6, showed a preference for some serotypes over others (Figure
14C). These binding profiles indicate that the isolated antibodies are cross-reactive but diverse
population of novel α-AAV mAbs. However, despite all isolated mAbs having the capacity to bind
AAV, following NAb assay with recombinant mAb, we found that these mAbs were not capable of
neutralizing AAV transduction. We therefore identified a panel of cross-reactive but simply binding
mAbs.
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Analysis of isolated variable region sequences
To confirm memory B cell phenotype, identify the germline gene usage, and evaluate the
degree of maturation of our isolated clones, we further analyzed the variable heavy and variable
light chain sequences of both the clones produced and validated as AAV binding as well as total
sequences isolated from AAV-positive wells. One hallmark of memory B cells is affinity
maturation by somatic hypermutation, which introduces mutations into the variable regions of
immunoglobulin genes in B cells already established to be reactive against a given antigen in
attempts to further improve antigen recognition and antibody functionality. We utilized IgBLAST to
map our variable chain sequences back to their germline sequence, to define the boundaries of
the framework regions (FWRs) and the complementarity determining regions (CDRs), and to
quantify the number of nucleotide and amino acid substitutions from the germline sequence. For
the validated antibody population, the VH gene harbored an average of 31.6 nucleotide
substitutions, the Vκ gene harbored an average of 14.4 nucleotide substitutions, and the Vλ gene
an average of 8.9 nucleotide substitutions (Figure 15). When including all isolated sequences in
the analysis, these values were slightly higher, with an average of 35.5, 19, and 10.6 nucleotide
substitutions per VH, Vκ, and Vλ, respectively, but this difference was not significant. Based on
the total number of nucleotide substitutions in each chain and the length of the predicted germline
sequence, we calculated the mutation frequency for each chain (excluding CDR3). For validated
mAbs, the average mutation frequency/nucleotide was 10.9% for VH, 5.7% for Vκ, and 3.3% for
Vλ. When including the non-validated sequences in the analysis, the average mutation
frequency/nucleotide was found to slightly higher for VH, Vκ, and Vλ at 12.3%, 7.4%, and 4%,
respectively. These frequencies are orders of magnitude above the average rate of genomic
somatic mutation, and the average number of mutations per chain and average mutation
+

+

frequency are in agreement with previously published values for CD27 IgG memory B cell
populations (178, 182, 188, 200, 218-220).
Another hallmark of the VH and VL sequences of memory B cells is that mutations are
more focused in the CDRs relative to the FWRs, as the CDRs are generally responsible for
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antigenic interactions. As such, we evaluated FWRs 1-3 and CDRs 1 and 2 separately to
determine the average mutational frequency in these regions. For VH and Vλ in both the
validated and the total sequence dataset, the average mutation frequencies of both CDR1 and
CDR2 were higher than those of any FWR or the mean mutation frequency for each chain as a
whole, with the exception of Vλ-CDR1 and Vλ-FWR2 (Figure 16A, B, E, and F). This was not true
for all Vκ samples; for both the validated and total sequence datasets, Vκ-CDR1 had a higher
mutation frequency than the average or any FWR while Vκ-CDR2 did not, largely due to the
higher percentage of Vκ sequences that had no mutations in CDR2 (Figure 16C, D).
In addition to having a higher frequency of mutations in the CDRs relative to the FWRs, a
greater percentage of these mutations result in an amino acid replacement than resulting in a
silent mutation when occurring in the CDRs in the variable regions of the immunoglobulin gene in
memory B cells. This can be quantified by defining the R/S ratio, or number of replacement
mutations per silent mutation. We determined this ratio for total variable chain sequences
(excluding CDR3) as well as individually for FWR1-3 and CDR1 and CDR2 (Figure 17A-F). For
validated sequences, the R/S ratios were 0.9, 1.7, and 1.7 for total VH, Vκ, and Vλ, respectively
(Table 5). After incorporating the non-validated sequences, the R/S ratios were 0.9, 1.2, and 1.9
for total VH, Vκ, and Vλ, respectively. We compared the R/S ratios for CDRs to those for FWRs to
observe enrichment for replacement mutations over silent mutations in the CDRs. While the R/S
ratios for FWRs of all chains ranged from 0.32 (VH-FWR1, validated) to 1.76 (Vκ-FWR3,
validated), most FWR R/S ratios were around 1. The R/S ratios for the CDRs, however, ranged
from 1 (Vκ-CDR2) to 6.5 (Vλ-CDR2), with all CDRs favoring replacement mutations. While overall
R/S ratios for FWRs and CDRs trended towards being lower than published averages, particularly
when compared to average values in IgGs generated in response to some specific pathogens,
CDR R/S was consistently higher than FWR R/S as would be expected based on the isolated cell
population, and the ratio of CDR R/S: FWR R/S was similar to published values (188, 220-223).
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Discussion
While the majority of efforts utilizing single B cell cloning aim to better understand and
therefore prevent disease, including microbial and immunological pathogenesis, our efforts here
leverage that technology to generate permissive viral vectors able to transduce target tissue even
in the presence of an immune response. Here, we demonstrate the ability of this approach to
isolate paired heavy and light chain variable region immunoglobulin sequences from single
memory B cells with reactivity to an AAV vector of choice, using a moderately seropositive
individual as a donor. We established the frequency of memory B cells against AAV in this
individual to be approximately 2-5% of the total memory B cell population, an aspect of AAV
immunity that had not been previously quantified. Significantly lower frequencies would potentially
hinder further high-throughput screening efforts due to low positive hit rate; however, this range is
acceptable, and we predict that this frequency will be higher for individuals who have received a
bolus of AAV vector, as those doses can reach over 1e14 GC/patient.
Epitope mapping of human α-AAV mAbs
The ultimate goal of this endeavor is to map the epitopes of the mAbs isolated from this
donor and others using traditional cryo-reconstruction of the Fab in complex with AAV capsid.
We did generate Fab molecules from a number of purified α-AAV mAbs produced by transfection
of 293 cells and made initial attempts to complex these Fab molecules with AAV3B using the
same protocol we have used previously to complex AAV9 and the mouse mAb PAV9.1 (see
Chapter 3: Materials and Methods). However, we were unable to fully optimize the complexing
conditions and have thus far been unable to freeze grids suitable for cryo-imaging (data not
2

shown). We plan to continue optimization efforts, perhaps utilizing F(ab’) molecules rather than
Fabs. As we determined that this panel of human antibodies all recognize both native and
denatured capsid (data not shown), we may also opt to utilize peptide competition assays to map
these epitopes as well, as this approach, while not as precise as cryo-reconstruction, has been
used to hone in on residues of AAV mAb epitopes previously (121).
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Requirement for the isolation of novel neutralizing antibodies
Additional isolation experiments, either from additional clones from this donor or from a
larger cohort of donors, will be required to isolate a neutralizing antibody for further study, as we
were unable to do so in this first screen, suggesting that the frequency of neutralizing antibodies
relative to binding antibodies is relatively low in normal human donors. While mapping
neutralizing epitopes is highly desired in order to direct the engineering of novel AAV NAb escape
variants to address dosing individuals with preexisting immunity and the potential for
readministration, much can be learned from mapping epitopes that confer antibody binding but
not neutralization. Binding antibodies are still of concern in the clinic, and the mapping of binding
epitopes and their comparison to neutralizing epitopes will lead to a better understanding of how
AAV interacts with the immune system and establish potential mechanisms of neutralization
based on which structural motifs are involved (for further discussion, please see Chapter 3,
Discussion).
Single cell antibody cloning as a technique to study α-AAV immune repertoires
Utilization of this approach will also allow for the comparison of AAV humoral responses
generated in different individuals and in response to different routes of exposure. Most vector
engineering programs, irrespective of approach, make the assumption that the resulting variant
will be sufficient to evade NAbs in the vast majority of individuals for which its use is intended,
despite evidence that this is likely not the case. Peptide competition studies of sera from 14
human donors seropositive for AAV2 with detectable NAb titers were unable to identify even a
single peptide that correlated with neutralization by all sera, and numerous unique peptide
binding profiles (independent of neutralization) were found within this relatively small number of
donors (122). Studies of targeted peptide insertion at predicted neutralizing epitopes on AAV2
and the effect this insertion had on serum binding and neutralization of samples from 29 donors
also demonstrated significant diversity in the antibody profiles of these donors (96). While similar
studies have not been performed for additional serotypes, these data provide evidence that there
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is significant variation in the anti-AAV antibody repertoire between individuals but the extent of
this variation is not entirely clearly. Complete study of individual repertoires from subjects with
preexisting immunity using a B cell cloning approach will provide a more comprehensive
evaluation of the diversity in AAV antibody repertoires and subsequently aid in the evaluation of
the feasibility of engineering broadly-applicable next-generation AAV vectors. If potential gene
therapy recipients can be organized into a small number of groups based on shared neutralizing
epitopes, it may be feasible to design an AAV variant able to evade the NAbs of individuals within
that group, while designing a variant for each individual, if it is determined that there are not
enough shared epitopes, is not practical nor sustainable long-term.
In addition to repertoire diversity between individuals, little work has been done to
evaluate potential differences in the repertoire of antibodies generated in response to AAV
infection vs. AAV vector administration, potentially due to the historically limited number of
samples from individuals who had received AAV vector. However, with the ever increasing
number of individuals receiving AAV vector, these studies can now be performed. The impact of
route of administration (ROA) on antibody repertoire can also be explored using our approach.
Not only can it be used identify shared and divergent epitopes of the antibodies produced by
these α-AAV B cells, but sequence analysis of the variable heavy and variable light chains of that
B cell population isolated from individuals that had been infected with AAV compared to those
from individuals who had received AAV vector from one of a selection of ROAs will allow for the
study of the unique interaction of AAV with the immune system (as a non-pathogenic, replicationdefective virus requiring helper functions) and how this interaction changes when the AAV that is
encountered is a replication-deficient vector and not a replicating virus.
Conclusions
These studies demonstrate the ability of modern B cell cloning technologies to be used
as a critical tool in the field of AAV vector engineering. While we have not yet mapped the
epitopes of these novel human antibodies, we clearly show the potential of this approach to not
only identify and evaluate novel α-AAV immunoglobulins but also to further study AAV
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interactions with the immune system in a variety of patient populations and methods of AAV
exposure. In the future we hope to utilize this approach to come to a better understanding of
basic AAV biology and to use that understanding to design next-generation AAV therapeutics.
Materials and Methods
Human donor sample acquisition: Matched human donor serum and whole blood samples were
obtained from Bioreclamation (now BioIVT, Westbury, NY). Peripheral blood mononuclear cells
(PBMCs) were isolated from whole blood as previously described (224). Isolated PBMCs were
frozen at a concentration of 1e7 cells/mL and stored in liquid nitrogen.
Determination of neutralizing antibody titer of donor serum: Neutralizing antibody titers of donor
sera were determined against AAV2, AAV3B, AAV8, AAV9, and AAVrh10 as previously
described (84)
o

Switched Memory B cell sorting: Frozen PBMCs were thawed briefly in a 37 C water bath then
diluted in 10mL complete media (RPMI+ L-glutamine, 10% FBS, 2 mM glutamine, 10 mM
HEPES, 50 g/ml gentamicin sulfate, and penicillin-streptomycin) with 20U DNase I (Cat. 776-785,
Roche Scientific, Indianapolis, IN) and pelleted by centrifugation at 300xg for five minutes. The
cell pellet was then washed with an additional 10mL complete media with DNase I and pelleted
again with final resuspension in 10mL complete media.
Recovered cells were then sorted using the Switched Memory B Cell Isolation Kit
(Cat.130-093-617, MACS Miltenyi Biotec, Auburn, CA). PBMCs were then again pelleted and
resuspended in chilled PBS, pH 7.2 with 0.5% BSA and 2mM EDTA (resuspension buffer). 100µL
of biotin-antibody cocktail (containing biotin-conjugated α-CD2, -CD14, -CD16, -CD36, -CD43, CD235a, -IgM, and -IgD) was added to resuspended PBMCs, which were then incubated with
o

gentle agitation for 10 minutes at 4 C. Cells were then pelleted and resuspended in resuspension
buffer. 200µL of α-biotin MicroBeads was then added to the resuspension, and cells were
o

incubated with gentle agitation for 15 minutes at 4 C. Cells were again pelleted and resuspended
in resuspension buffer then applied to an LS column (pre-rinsed with 3mL resuspension buffer).
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The flow-through containing enriched, switched memory B cells (initial suspension plus three
additional washes) was collected, and cell density was calculated by cell counting.
Validation of memory B cell population: Cellular fractions of interest were spun down at 1700rpm
for five minutes, supernatant decanted, and cells resuspended in remaining volume by gentle
agitation. Cells were then stained with desired antibody at concentrations recommended by the
manufacturer (α-CD19-APC, Cat.IM2470U, Beckman Coulter, Sharon Hill, PA; α-CD27-PE, Cat
555441, Beckman Coulter, Sharon Hill, PA; α-IgM-FITC, Cat. 555782, BD Biosciences, Franklin
Lakes, NJ) for 12 minutes at room temperature while protected from light. Then, 2mL staining
buffer (1%FBS in PBS, sterile-filtered) was added and cells were again spun down and
resuspended by agitation. 200µL Cytofix (Cat. 554655, BD Biosciences, Franklin Lakes, NJ) was
added to each sample, which was then incubated for 20 minutes on wet ice followed by the
addition of 2mL staining buffer, spinning to pellet, decanting of the supernatant and resuspension
by agitation. Samples were further resuspended with additional staining buffer as desired. Data
was collected using an FC500 flow cytometer (Beckman Coulter, Sharon Hill, PA) and analyzed
in FlowJo.
Expansion and irradiation of 3T3-msCD40L cells: 3T3-msCD40L cells were obtained from the
NIH AIDS Reagent Program (Cat.12535). Cells were thawed and expanded in DMEM with 10%
FBS, 1% L-glutamine, and 0.1% gentamicin. Cells were harvested and resuspended at a density
of 1e7 cells/mL in culture medium and irradiated with 5000 rads (50 Gy) with an X-RAD irradiator
(PXi, North Branford, CT). Cells were then pelleted, cryo-preserved in 1-2mL vials with 3.5e7
cells/vial, and stored in liquid nitrogen. This protocol was derived from Huang 2013 et al (225).
Seeding of memory B cells with 3T3-msCD40L feeder cells: Five vials of 3.5e7 irradiated 3T3msCD40L cells were thawed and resuspended in 7.5mL Iscove’s Modified Bubecco’s Media with
Glutamax (IMDM, Cat.31980030, Thermo Fisher Scientific, Waltham, MA) with 4000U benzonase
(EMD Millipore, now Millipore Sigma, Burlington, MA), incubated for 15 seconds then pelleted and
resuspended in 10mL IMDM. Cellular suspension was made for seeding first by adding 17,500U
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IL-2 (Cat. 11147528001, Roche Diagnostics, Indianapolis, IN), 87.5µg IL-21 (Cat.PHC0215, Life
Technologies, Carlsbad, CA), and 1.75e8 irradiated 3T3-msCD40L cells to 1680mL complete
IMDM. Outer wells on edge of 96-well culture plates were filled with 250µL sterile H2O to prevent
evaporation. 250µL of initial cell suspension was added to remaining wells in column B to act as a
negative-control for future assays. Sorted memory B cells were then added to the remaining cell
suspension at a concentration of eight cells/mL to achieve a seeding density of two cells/well
(maximum of one viable cell/well based on previous viability experiments). This final suspension
was then added to all remaining wells at a volume of 250µL /well, and plates were incubated at
o

37 C and 5% CO2 for 14 days. Colonies of expanding B cells were visualized as early as day 10
after seeding, and supernatants were screened for total antibody production as early as day 12.
o

Fourteen days after seeding, supernatant was removed and stored at -80 C. Cells were then
lysed by the addition of 20µL/well lysis buffer (2mL 1M Tris-HCl pH 8.0, 1.7mL RNAse inhibitor,
Cat.M0314L, New England Biolabs, Ipswich, MA, per 132mL DEPC-treated H2O); plated were
o

then stored at -80 C. This protocol was derived from Huang 2013 et al (225).
Determination of total antibody concentration by ELISA: High binding polystyrene 96-well plates
(Corning) were coated with 5µg/mL protein A (Cat.P6031, Sigma Aldrich, St. Louis, MO) in PBS
o

overnight at 4 C. Plates were then 8x washed with PBS with 0.05% Tween (wash buffer) and
blocked with 1% BSA in PBS for one hour at room temperature. Blocking solution was discarded,
and samples and mAb standard (B12 α-gp120, Cat.IT-001-b12, Immune Technology Corp., New
o

York, NY) were applied and incubated for one hour at 37 C followed by 8x wash with wash buffer.
Plates were then blocked again with 1% BSA in PBS for one hour at room temperature followed
by 8x wash with wash buffer. Samples were then detected with Biotin-SP-conjugated goat αhuman IgG (Cat.109-065-098, Jackson ImmunoResearch, West Grove, PA) diluted 1:10,000 in
PBS for one hour at room temperature (followed by 8x wash) and streptavidin-HRP (Cat.ab7403,
Abcam, Cambridge, United Kingdom) diluted 1:30,000 in PBS for one hour at temperature
followed by a final 8x wash. Plates were developed with TMB and antibody quantified by
comparison to recombinant B12 mAb control.
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Screening and selection of α-AAV memory B cell clones: High binding polystyrene 96-well plates
(Corning) were coated with 1e9 GC/well AAV vector (University of Pennsylvania Vector Core)
o

diluted in PBS overnight at 4 C. Coating solution was then discarded, and plates were blocked
with 3% BSA in PBS for two hours at room temperature followed by 3x wash with PBS with
o

0.05% Tween (wash buffer). Supernatant samples were then applied and incubated at 37 C for
one hour followed by 3x wash. Samples were then detected with Biotin-SP-conjugated goat αhuman IgG (Cat.109-065-098, Jackson ImmunoResearch, West Grove, PA) diluted 1:10,000 in
PBS for one hour at room temperature (followed by 3x wash) and streptavidin-HRP (Cat.ab7403,
Abcam, Cambridge, United Kingdom) diluted 1:30,000 in PBS for one hour at temperature
followed by a final 3x wash. Plates were developed with TMB. Clones were identified as positive if
absorbance was determined to be higher than that resulting from supernatant samples from 3T3msCD40L cell-only culture wells.
PCR amplification and isolation of immunoglobulin loci of positive clones: Plates containing
positive wells were thawed on ice, and cell lysate was mixed by pipetting. Reverse transcription
was performed by adding 4µL of cell lysate to 3.5µL of RHP mix (150ng random hexamer
primers, Cat 11034731001, Roche Diagnostics, Indianapolis, IN; 1.5% Igepal CA-630, Cat. I8896,
Sigma Aldrich, St. Louis, MO; 5U RNAsin, Cat. N2511, Promega, Madison, WI, in nuclease-free
o

water). Mixture was incubated for one minute at 68 C and placed back on ice. Reverse
o

o

o

transcription was performed at 42 C for 5 minutes, 25 C for 10 minutes, 50 C for 60 minutes, and
o

94 C for 5 minutes after the additional of 7µL reverse transcription mix (15mM dithiothreitol; 5U
RNAsin, Cat. N2511, Promega, Madison, WI; 1.75mM each dNTP, Cat. CB4420-4, Denville
Scientific, Holliston, MA; 2.3X First Strand buffer and 50U SuperScript III, Cat. 18080044, Thermo
Fisher Scientific, Waltham, MA; in nuclease-free water).
Immunoglobulin gene amplification was performed according to the protocol described in
Wardemann 2013 et al, with the exception that only 1µL cDNA was used for first PCR
amplification due to the increased amount of RNA used for cDNA synthesis (226). Second PCR
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products were analyzed by 1% agarose gel in TAE for the presence of a 450bp (heavy), 510bp
(kappa light), or 405bp (lambda light) band.
Positive bands were extracted using the QIAquick Gel Extraction Kit (Qiagen, Hilden,
Germany) and cloned using the TOPO-TA cloning kit (Cat.K450001, Life Technologies, Carlsbad,
CA) and transformed into TOP10 competent cells for bacterial plasmid expansion, purification,
and sequencing.
Immunoglobulin sequence analysis: Sequences obtained from TOPO cloning were queried using
the IgBLAST database (http://www.ncbi.nlm.nih.gov/igblast/) to identify the most closely-related
germline sequence. The IMGT database was selected for all searches. Total nucleotide and
amino acid substitutions were determined by comparison to the IgBLAST-selected most likely
germline sequence for each chain (CDR3-excluded). Framework regions (FWRs) and
complementarity determining region (CDRs) boundaries were determined by IgBLAST using the
IMGT definition for each region. Mutation frequencies were determined by dividing the number of
mutations over the length of each individual chain (or region) to calculate the likelihood that a
mutation occurs at a given position.
Recombinant immunoglobulin production and evaluation: The consensus amino acid sequence
for each B cell clone variable chain was determined by alignment of all sequenced TOPO clones
and subsequently codon-optimized for expression in human cells using the default GeneArt
optimization scheme. Paired heavy and light chain variable regions were cloned into a coexpression vector with IgG1 constant regions. The expression cassette was under the control of
the CMV promoter, contained the PI intron and SV40 polyadenylation signal. Heavy and light
chain were separated by a furin cleavage site/F2A linker. The resulting recombinant mAbs were
produced in HEK293 cells by transfection with PEI; supernatants were harvested three days posttransfection. mAb concentration was determined by protein A ELISA (described above). Binding
to AAV2, AAV3B, AAV8, AAV9, and AAVrh10 was determined by AAV capture ELISA (described
above). mAbs were also evaluated for their ability to neutralize AAV2 and AAV3B vector as
previously described (84).
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Chapter 6: Post-translational modifications and their impact on gene
therapy vector product development
QC requirements for biologics
The development of biopharmaceuticals, or biologics, drove the rise of the biotechnology
sector, expanding the pharmaceutical portfolio beyond small molecule drugs. Unlike small
molecules, which can be synthesized in a highly-controlled and uniform fashion using wellcharacterized chemical processes, biologics are most often protein products that originate from or
are produced in a complex biological system, whether isolated from a native source or
manufactured in vitro (227). Regulatory agencies therefore adopted new guidances for the
chemistry, manufacturing, and controls (CMC) component of investigational new drug
applications (INDs) and biologics license applications (BLAs) for biologics to address this
complexity.
Many assays are now required to define the complex physical characteristics of biologics
and to demonstrate that these characteristics are well-defined and consistent between different
production lots (228). The primary sequence of amino acids must be confirmed, generally by
protein sequencing as well as mass spectrometry confirmation of protein identity. Protein size and
purity are to be established by SDS-PAGE gel, and the protein charge characterized by
isoelectric focusing. Basic chemical modifications, such as oxidation and deamidation, are to be
quantified, as are larger post-translational modifications (PTMs) such as glycosylation and
phosphorylation to confirm that they are of the correct composition to allow for proper product
performance. Studies are also to be performed that establish that the product is properly folded
and has not aggregated, such as evaluation of disulfide bonds. Additionally, as these biologics
are produced in biological systems such as cell culture, utilizing other biological materials for
manufacturing, the sterility and of the product as well as the components used to produce the
product must be established, and removal of host cell DNA and proteins must be demonstrated to
an acceptable degree (229).
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QC requirements for AAV vectors
While viral vectors are considered biologics alongside monoclonal antibodies and other
recombinant protein therapies, they are a unique and distinct therapeutic modality not only in
function but also in formulation. Each viral vector particle is a highly complex macromolecule
comprised of significantly more individual subunits than any “traditional” biologic. Each monomer
or protein subunit needs to come together in a specific fashion to produce a functional, vector
particle. Many of the regulatory requirements for “traditional” biologics have also been applied to
viral vectors due to commonalities in production systems and protein makeup (230). However,
due to the lack of precedent for these novel therapeutics with unique structural components as
well as therapeutic modalities, current guidances often do not address these aspects unique to
viral vectors. Additionally, there remain many gaps in knowledge regarding the basic biology of
these vectors both structurally and mechanistically that, once characterized, will need to be
addressed by regulatory agencies as these discoveries arise (231).
Basic quality control requirements for all drugs are requirements for AAV vectors (232).
The process chosen for vector production must be demonstrated to produce a sterile product,
free not only of bacterial and fungal contaminants but also of replication competent vector. The
purity of both the genetic material and the protein of the product must also be established.
IND applicants must also provide confirmation of the identity of their product, but specific
assays are not required. For AAV, the identity requirement is two-fold, requiring both confirmation
of the identity of the vector genome, generally by sequencing of the cis plasmid used in
production and also the vector genome following production, but also the capsid itself. As the final
vector contains no viral protein genes, the capsid itself must be identified. This assay could be an
ELISA, a Western blot, or a mass spectrometry-based serotype identity assay, which provides the
most comprehensive analysis of the capsid proteins themselves.
Potency of the vector must also be established, and these assays are dependent on the
specific disease indication. However, should potency be lower than desired or expected, it is
historically difficult to attribute that loss of function to a specific characteristic of the vector
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preparation. Overall, AAV vectors are not as well-characterized as monoclonal antibodies on the
protein level. While the overall utility of AAV as a delivery vector for genetic material is relatively
well-studied, the basic biological mechanisms of this delivery and capsid performance have not
been fully elucidated. For example, an almost universal receptor for AAV, AAVR, was identified
only recently despite the fact that AAV has been in development as a gene therapy vector for
decades (71). Due to this general lack of characterization of the capsid and how various
production and purification methods could potentially affect the protein component of the final
vector product, QC requirements may not be as extensive as needed to provide consistent levels
of product characterization.
Post-translational modification of AAV capsids
Many groups have performed studies to identify PTMs on the AAV capsid both in
attempts to better understand basic AAV vector biology as well as to define the native state of the
AAV capsid to provide for better vector characterization and subsequent quality control. As is the
case for most studies of basic AAV biology, AAV2 has most commonly been evaluated for the
presence of PTMs. Based on the reports of other capsid viruses, such as adenovirus and
rotavirus, being glycosylated at multiple sites, Murray et al evaluated AAV2 for putative
glycosylation sites and for glycosylation events. They identified eight sites predicted to be
consensus glycosylation (either N-linked or O-linked) sites. They then produced AAV2 in HeLa
cells for biochemical and mass spectrometry analysis but were unable to detect any significant
glycosylation events by either approach (233). While this does not disprove the present of AAV
glycosylation, especially when vector is produced in other cell types using other methods, it
suggests that even if AAV glycosylation does occur, it is likely at levels below that of the limit of
detection of the assay (estimated to be able to detect 1% VP3 glycosylation and 10% VP1/VP2
glycosylation).
This finding was also reported more recently by Jin et al, specifically for AAV2 despite
other serotypes being evaluated elsewhere in the study (234). However, mass spectrometry data
presented at a recent meeting by Paulk et al alludes to the identification of glycosylation events
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on a variety of AAV serotypes (135). As these data have not yet been published, it remains to be
seen what the impact of these potential findings will be on the understanding of AAV vector
biology and QC.
Recombinant protein products are also frequently evaluated for phosphorylation events.
Previous studies identified the ubiquitin-proteasome pathway as playing a role in AAV2
transduction efficiency, specifically the EGFR-PTK signaling pathway (235, 236). Further studies
identified tyrosine phosphorylation of the AAV2 capsid following cellular entry, indicating that AAV
is capable of being phosphorylated, but these studies do not address the phosphorylation status
of purified vector prior to cellular transduction (237). The preliminary data presented by Paulk et
al again alluded to phosphorylation of purified AAV vector preps, but no definitive results have
been published.
Deamidation as a post-translational modification
One PTM commonly evaluated in the quality control of recombinant protein products,
particularly monoclonal antibodies, but that is not addressed in these previous studies of AAV
capsids is deamidation. Deamidation is the process by which an amide amino acid (either
asparagine or glutamine) undergoes amide loss, resulting in the conversion of that residue to the
acid form of the amino either (aspartate or glutamate) (238). Deamidation can be enzymaticallycatalyzed or spontaneous. For example, viral homologs of glutamine amidotransferase and
phosphoribosylformylglycinamidine synthetase function to actively deamidate RIG-I, a receptor
involved in innate immunity, to prevent antiviral cytokine production (239). Spontaneous
deamidation occurs in the absence of enzyme catalysis. Specifically, the carbonyl carbon of the
amide R group undergoes nucleophilic attack by the main chain nitrogen atom of the adjacent,
N+1 amino acid (Figure 18A). This attack and subsequent loss of an ammonia molecule results in
the generation of a succinimidyl intermediate. This succinimidyl intermediate then undergoes
hydrolysis at one of the carbonyl carbons in the ring structure. This resolves the intermediate into
a mixture of aspartate and isoaspartate, or glutamate and isoglutamate. Studies have determined
that the ratio of aspartate to isoaspartate in this mixture is approximately 3:1 (240). This change
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in amino acid identity also changes the properties of the protein at this site through the
introduction of an amino acid with a negatively-charged R group where there was previously a
polar, uncharged side chain.
Many factors have been established to play a role in spontaneous deamidation. First, the
identity of the amino acid itself plays a large role, as glutamine residues undergo deamidation
approximately 100-fold less efficiently than asparagine residues (241). Another such factor is the
identity of the N+1 residue. Nucleophilic attack by the neighboring nitrogen of the protein
backbone requires a certain degree of flexibility of the N+1 residue due to a lack of steric
hindrance from the neighboring R group; residues with smaller R groups provide adequate
flexibility in the main chain to allow for this interaction. For this reason, it has been established in
many studies that N+1 glycines, on average, provide the most favorable conditions for
deamidation, followed by serine, alanine, and histidine (242). This flexibility requirement also
extends beyond the N+1 residue to the local protein structure. Asparagines located in flexible,
disordered motifs are more likely to undergo deamidation than are asparagines in rigid motifs with
many hydrogen bond interactions, such as α-helices and β-sheets (240, 242). Another factor
influencing deamidation based on protein sequence and therefore structure is solvent
accessibility; the hydrolysis of the succinimidyl intermediate requires that the water molecules in
the solvent be able to access the residue itself (243). Therefore, buried residues are less likely to
be frequently deamidated, unless deamidation occurs prior to proper protein folding, which is
unlikely as the half-time of deamidation is usually measured in days while protein folding occurs
much more quickly.
Other factors that influence the rate of deamidation that are not directly dependent on
protein structure include pH and temperature. Increases in temperature increase deamidation
rates (and therefore decrease the half-time of the reaction) due to the increase in thermal
vibration (240, 244). Both pH and buffer composition have been shown to have an impact on
deamidation, and the magnitude and direction of this impact is often dependent on both the pH
and identity of the buffer. For example, increasing the pH of buffers containing carbonate or
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ammonia more profoundly increases deamidation rates than pH increases in other buffers;
therefore, pH-dependent deamidation is highly dependent on the buffer composition (240, 245).
The ionic strength of the buffer has also been implicated in determining deamidation rates, but, as
for pH, the applicability of this observation is largely dependent on buffer identity (240, 244).
Deamidation and its functional impact
Due to the introduction of an amino acid that is not encoded in the gene of a given
protein, deamidation has the potential to impact many aspects of a protein’s performance. First,
this new primary protein sequence can change how its peptides could be loaded onto major
histocompatibility complex (MHC) proteins on antigen presenting cells, modifying its presentation
to T cells and modulating the host immune response to the recombinant protein (246, 247).
Second, it has the potential to change the structure of the parent protein, which could introduce
non-native epitopes that the immune system would recognize as foreign. This has been
documented for constant region of the immunoglobulin heavy chain, where multiple sites have
been established to be susceptible to deamidation (243, 248). While endogenous antibodies have
also been found to be deamidated, this may still be a concern for biologics if a given mAb is
particularly susceptible to deamidation due to a novel engineered sequence or production
process such that levels vary widely from those found endogenously (249). This is also a concern
for enzyme replacement therapies where there is a significant effort in all cases to reduce the
potential immunogenicity of the protein (250, 251).
In addition to concerns over eliciting a detrimental immune response and calling into
question the safety of the protein product itself, deamidation also has the potential to significantly
impact protein function. This has been documented for a number of recombinant protein products
such that, in most cases, these deamidated residues are engineered out of the protein when
possible (252, 253). Deamidation in the CDRs of mAbs, which are responsible for antigen
recognition, has been shown to significantly reduce antigen binding and therefore reduces the
functionality of the mAb (254-256). For the recombinant protective antigen (rPA) protein-based
anthrax vaccine, in which function is directly tied to immunogenicity, deamidation of a number of
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residues is directly linked to a loss of vaccine potency as measured by anti-rPA antibody titer,
likely due to a lack of T cell help that is proposed to be due to a loss of MHC class II peptide
loading (257-259). Deamidation of endogenous proteins such as RNase A and αA-crystallin has
been shown to negatively affect enzymatic or native chaperone activity, and this is therefore a
concern for recombinant protein therapies, including enzyme replacement therapy (250, 260,
261).
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Chapter 7: Identification and implications of spontaneous deamidation of
the AAV vector capsid
Abstract
The presence of post-translational modifications on the AAV vector capsid is an important
but poorly understood aspect of the development of these vectors as gene therapy products. We
sought to contribute to the understanding of AAV post-translational modification (PTM) by
subjecting AAV8 vector to two-dimensional gel electrophoresis, discovering substantial charge
heterogeneity in the populations of each viral capsid protein. Mass spectrometry indicated that
this heterogeneity is due to deamidation of asparagine residues in these proteins, a spontaneous
PTM that has not been previously described for AAV. Distribution and extent of deamidation was
largely consistent between purification methods, suggesting that deamidation occurs
independently of vector processing. Genetic deamidation of select asparagine residues indicated
that the introduction of an aspartic acid at these sites can not only negatively impact capsid
assembly but also performance in vitro and in vivo. De novo modeling of these residues revealed
evidence of deamidation in the AAV8 structure as well as an explanation for why the capsid
tolerates this PTM. We additionally observed similar patterns of deamidation after evaluating the
AAV9 capsid, suggesting that this phenomenon is not serotype specific. This study therefore
illustrates a novel aspect of AAV capsid biology, highlighting a previously unidentified source of
vector heterogeneity impacting product development.
Introduction
Following its discovery as a contaminant in a adenovirus prep, adeno-associated virus
was established to be a single-stranded DNA virus with an icosahedral capsid comprised of 60
viral protein (VP) monomers (VP1, VP2, and VP3) in an approximately 1:1:10 ratio (19, 51).
Analysis of the viral genome established that the entirety of the VP3 protein sequence (~520
amino acids) is contained within the C-terminus of both VP1 and VP2 (28, 45). The crystal
structures of a number of AAV serotypes have been determined, but due to the presumed
structural flexibility of the VP1/2 unique regions as well as their low monomeric representation in
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the assembled capsid (relative to VP3 monomers), VP3 (or the VP3 shared region) is the only
capsid protein that is resolved in these structures (51). Comparison of both the primary
sequences and structures of numerous AAV serotypes has identified nine, flexible hypervariable
regions (HVRs) in VP3 that are the primary source of variation between the AAVs. Given their
location on the capsid surface, studies have shown that the HVRs are largely responsible for
interactions with target cells as well as with the immune system (69, 72, 145, 262).
While many of the structures of different AAV serotypes are published (PDB IDs 1LP3,
4RSO, 4V86, 3UX1, 3KIC, 2QA0, and 2G8G), these structures are based on the primary amino
acid sequence encoded by the cap gene and do not provide any information regarding possible
post-translational modifications (PTMs) of capsid proteins. Previous studies suggest that
intracellular phosphorylation of the AAV2 and AAV8 capsids occurs at specific tyrosine,
threonine, and serine residues and may impact transduction efficiency (237, 263-265). While
putative glycosylation sites have been identified in the primary VP3 sequence of AAV2, mass
spectrometry and enzymatic deglycosylation experiments have been unable to identify any
glycosylation events (233, 234). Other AAV serotypes have not been evaluated for glycosylation.
The presence and identification of PTMs on the AAV capsid with the potential to affect
vector performance could significantly impact the development of AAV as a gene therapy product,
as sources of product heterogeneity pose significant barriers to quality control and maintenance
of product consistency. One modification with the potential to introduce significant vector
heterogeneity is the deamidation of asparagine and/or glutamine residues in the capsid VPs.
Asparagine and glutamine deamidation in proteins is a naturally occurring process. In some
cases it is catalyzed by viral or bacterial deamidases that deamidate host cell proteins to
modulate signaling pathways and innate immune responses (266, 267). More commonly, protein
deamidation is an enzyme-independent, spontaneous process (268). While the molecular
purpose of deamidation is not entirely understood, studies suggest that it acts as a molecular
clock to track relative protein “age” and therefore regulate protein turnover (241). This process
also occurs during the production of recombinant biological products and has complicated their
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development due to its impact on product performance (269, 270). For example, in the
recombinant protective antigen-based anthrax vaccine, the deamidation of select amino acids
significantly modulates the stability of the vaccine itself as well as its ability to efficiently elicit the
proper immune response (257, 258).
Deamidation occurs when the amide group of asparagine residues (or less frequently
glutamine residues) undergoes nucleophilic attack from an adjacent nitrogen atom on the protein
backbone, resulting in the loss of the amide group and the formation of a succinimidyl ring
intermediate (271). Following hydrolysis of this intermediate, the ring resolves into a mixture of
aspartic and isoaspartic acid (or glutamic and isoglutamic acid); studies of this process in short,
synthetic peptides estimate that this resolution results in a 3:1 mixture of iso- to aspartic acid
(272, 273). A number of biophysical factors determine the kinetics of this process including, but
not limited to, the identity of the N+1 residue, local flexibility/temperature factor of the protein
backbone, structural motif, solvent accessibility, buffer identity, pH, and temperature (238, 241,
274). The size and charge of the N+1 residue greatly influence the ability of the backbone to
perform a nucleophilic attack on the residue of interest and is therefore of particular importance.
Due to its size and lack of charge, N+1 glycine is most permissive and encouraging of
spontaneous deamidation reactions and therefore greatly reduces the half-time of deamidation;
histidine and serine are the next most-permissive (241). The overall flexibility and thermal
vibration of the local protein backbone is also important, as deamidation rates have been shown
to be greatly reduced when the residue of interest is located in regions of highly ordered and rigid
secondary and tertiary structural motifs, sterically hindering nucleophilic attack (273).
Here, we sought to characterize AAV8 capsid PTMs by two-dimensional gel
electrophoresis, mass spectrometry, and de novo structural modeling. AAV8 was chosen due to
its current extensive development for use in the clinic for a large number of indications. We
identified extensive deamidation at a number of sites on the capsid surface and evaluated the
impact of these deamidation events on capsid structure as well as function both in vitro and in
vivo. Finally, we additionally analyzed AAV9, another commonly-used serotype, by the same
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approach to determine if other AAVs are also deamidated, finding that this phenomenon is not
serotype-specific.
Results
Two-dimensional gel analysis of AAV8
In order to qualitatively assess potential heterogeneity in the total AAV8 VP population as
well as to evaluate the presence of PTMs on these proteins, we evaluated AAV8 vector produced
in HEK293 cells by triple transfection and purified by iodixanol gradient by one-dimensional (1D)
and two-dimensional (2D) gel electrophoresis. When analyzed by 1D gel under reducing
conditions, AAV8 VP1, VP2, and VP3 resolve as single bands of the expected sizes,
approximately 87kDa, 73kDa, and 62kDa, respectively (Figure 18B) (275). However, when the
AAV8 capsid proteins are resolved by isoelectric focusing prior to SDS-PAGE (2D
electrophoresis), we determined that each VP population is actually comprised of different
isoform subpopulations, each with a distinct isoelectric point (pI), indicating that each isoform
carries a different total charge (Figure 18D). The pIs of these isoforms ranged from pH 6.3 to
pH>7.0 depending on the VP. Each isoform spot was separated from the neighboring spot by a
discreet interval of 0.1 pI units, as measured by migration relative to internal isoelectric point
standards. This suggested that each isoform differs from its neighbor by a single charge (Figure
18C). Additionally, the presence of many isoforms suggested that each VP has the potential to
undergo many modifications that additively affect overall charge.
Identification of AAV8 post-translational modifications by mass spectrometry
To identify modifications potentially responsible for the generation of the AAV VP
isoforms, we subjected purified AAV8 vector to tryptic digest followed by mass spectrometry
analysis. Sequence coverage was high, as we detected >95% of the predicted tryptic peptides for
VP1, VP2, and VP3. A subset of these peptides were found to have an approximately 1 Da
increased in their observed mass as compared to predicted mass based on the coding sequence
of the peptide (Figure 19A-D). This 1 Da increase is due to protein deamidation, as the loss of an
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–NH2 group and subsequent replacement with an –OH increases the apparent mass of a given
peptide by this 1 Da. We detected deamidation of a large number of asparagine and glutamine
residues spanning not only the shared VP3 region but also the VP1 and VP2 unique regions of
the representative VPs (Figure 20). Heterogeneity in the number of deamidation events in a given
VP could be responsible for the different VP isoforms observed by 2D gel, as the deamidation of
an amide to an acid introduces a single negative charge, corresponding to the 0.1 pI differences
between spots of the same molecular weight.
We then sought to evaluate possible heterogeneity in deamidation frequency at a given
site between AAV8 vector lots made using the same purification method as well as across other
methods. Vectors were produced by triple transfection in 293 cells and purified by cesium
chloride gradient, iodixanol gradient, or affinity chromatography. Vector genomes were also
varied both in promoter and in transgene. We also evaluated an AAV8 prep made in the absence
of cis plasmid (producing empty capsids only) and purified by iodixanol gradient to determine if
the presence or absence of a vector genome had an impact on deamidation.
The average degree of deamidation for a given residue ranged widely, from undetectable
levels of deamidation to over 99% of the asparagines at a single position being deamidated to an
aspartic (or isoaspartic) acid. We observed the highest degree of deamidation (>75%) at
asparagine residues where the N+1 residue was glycine; AAV8 has five of these ‘NG’ motifs. We
also observed significant deamidation of other asparagine residues with N+1 residues that were
not glycine but to a lesser degree (up to 17%). We found that at asparagine residues, the average
percent deamidation for a given position was largely consistent between preps, purification
method, genome presence, and genome identity. The largest prep-to-prep difference was
observed at N499, with some preps having <1% deamidation while others had up to 50%
deamidation. We were also able to detect deamidation of a number of glutamine residues but
these residues were deamidated much less frequently than asparagine residues; the glutamine
with the most deamidation, Q467, was deamidated in less than 2% of peptides.
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Identifying potential factors responsible for AAV deamidation
The number of residues undergoing deamidation as well as the degree to which these
residues underwent deamidation was expected when compared to typical deamidation rates of
other recombinant proteins. We therefore performed a number of experiments to determine if
sample preparation for mass spectrometry or general sample manipulation following vector
purification could be responsible for the remarkable levels of deamidation in AAV8. As changes in
temperature and pH have been shown to impact deamidation rates, we sought to determine the
ability of these conditions to induce additional deamidation and to what extent. We exposed AAV8
o

vector to high temperature (70 C) for three or seven days, or to low or high pH (2 or 10,
respectively) for seven days, evaluated deamidation percentages, and compared these
percentages to those obtained previously. We selected these conditions based on the
assumption that any deamidation induced by the more moderate conditions encountered during
standard vector manipulation would certainly introduce less deamidation than these extremes.
We observed an overall trend towards a higher degree of deamidation following vector
incubation at high temperatures (Figure 21A). The largest change observed was an increase of
5.6% at N653. We also observed a trend towards increased deamidation following incubation at
extreme pH, but on average, the increase was even more modest than that observed following
high temperature (Figure 21B). The largest increases observed were 2.7% at pH 2 for N305 and
2.7% at pH 10 for N540. Based upon these results, we concluded that standard storage
o

conditions (-80 C followed by a brief thaw, near neutral pH) alone could not be responsible for the
extensive deamidation we observed, as conditions previously shown to force deamidation in vitro
introduced minimal additional deamidation.
To ensure that sample processing for mass spectrometry did not induce deamidation, we
processed AAV8 in the presence of heavy water, as residues incorporating the label would
indicate that deamidation of that residue occurred during preparation. We detected minimal
incorporation of the O18 label (Figure 21C). This indicates that the deamidation events are not
artifacts of sample processing required for mass spectrometry.
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Evaluating ability to identify deamidation events
We also sought to ensure that our workflow was able to efficiently and accurately identify
deamidation events. Therefore, we obtained and analyzed two non-AAV recombinant proteins for
deamidation, human carbonic anhydrase 2 and rat phenylalanine-4-hydroxylase. Both of these
proteins are homologous to those that have been previously evaluated for deamidation and also
contain canonical NG motifs, which we expected would be highly deamidated. Both NG sites in
human carbonic anhydrase, N12 and N25, were highly deamidated relative to other asparagines
(as well as glutamines), in agreement with previous studies (Figure 22A) (276). Similarly, both NG
sites in rat phenylalanine-4-hydroxylase, N8 and N32, were also highly deamidated relative to
other potential sites of deamidation; N32 with an N+1 glycine is conserved in human
phenylalanine-4-hydroxylase and deamidation levels at this site were also consistent with
previous reports (Figure 22B) (277).
We additionally submitted a subset of our raw data to a mass spectrometry core facility at
a secondary institution to determine if the same conclusions regarding deamidation percentages
could be drawn. All but one asparagine identified using our pipeline was identified in this
secondary analysis and the majority of percentages were equivalent; the largest difference was
observed at N499 (Figure 23). The minimal variation in deamidation percentages can be
attributed to variations in peak detection and area calculation between software packages,
resulting in small discrepancies between relative abundance calculations.
Structural analysis of AAV8 structure for evidence of deamidation
The crystal structure of AAV8 has been solved and is published and available for
analysis; we therefore analyzed the AAV8 capsid for evidence of structural motifs favorable for
spontaneous deamidation of asparagine residues (Figure 24A, Table 6). From the crystal
structure data, we also calculated the temperature (or B) factor values for each of the asparagine
residues of interest. The B factor of an atom is a measure of the displacement of that atom from
its mean position; higher values are indicative of a larger displacement from the mean position
81

and therefore higher thermal vibration. These values can be averaged for all atoms of a given
residue, again with higher values indicating higher thermal vibration and therefore increased
flexibility when compared to residues with lower B factor values.
The majority of highly deamidated asparagines are located in or near the AAV8 HVRs,
which are surface-exposed, making these motifs more favorable for deamidation as they are
comprised of flexible loops with a high degree of solvent accessibility. This is in direct comparison
to deamidated residues located in regions that are more structurally restrained such as α-helices
and β-strands; these residues were deamidated much less frequently than those in HVRs. For
example, both N263 and N514 are part of NG motifs and were therefore predicted to be highly
deamidated based purely on protein sequence. N263 is located in HVR-I and therefore has a high
temperature factor and is therefore highly flexible, due in part to HVR-I lacking direct interactions
with other capsid protein motifs. As a result, N263 was found to be deamidated >98% of the time.
N514 is also located in an HVR, HVR-V, but has a low temperature factor relative to that of N263
due in part to the interaction of HVR-V with other VP monomers, resulting in less frequent
deamidation of N514 (~85%). A number of other deamidated asparagines were also located on
the flexible HVRs but had much lower frequency of deamidation due to less-favorable N+1
residues as well as relatively low local temperature factors. N517, also in HVR-V, has a
temperature factor that is equivalent to the highly-deamidated N514, but was determined to have
a much lower deamidation percentage (4%), likely due to the N+1 serine rather than glycine.
A number of asparagines of interest were not located in HVRs and were therefore
predicted not to be favored for deamidation. This is reflected by the fact that, on average, these
residues were deamidated much less frequently than those located in HVRs, but deamidation
was still detected at these sites. For example, the AAV8 crystal structure indicates that N630 is
partially buried but deamidation is still detectable at this site, despite the N+1 residue being the
unfavorable phenylalanine. The presence of this phenylalanine suggests that this region could
potentially be a site of non-enzymatic autoproteolytic cleavage. This has similarly been described
previously for AAV2, where four residues undergo a conformational change following exposure to
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acidic pH (mimicking the endosome) that results in autolytic cleavage of the VP3 protein
backbone (275).
In addition to analyzing the AAV8 structure for conditions favorable for deamidation, we
also evaluated the crystal structure for direct evidence of deamidation, as an asparagine should
resolve differently from an aspartate or isoaspartate due to the differences in the identity of their
R groups. However, the resolution of the available crystal structure is 2.7Å, which is not of high
enough resolution to not only show but also identify individual atoms and therefore distinguish
between an –NH2 and an –OH group. Since the primary product of deamidation is isoaspartate,
formed in a 3:1 ratio with aspartate, we can use the length of the electron density of the
corresponding R group at this position as a surrogate for residue identity; when the succinimidyl
intermediate resolves into isoaspartic acid, the beta carbon of its R group is incorporated into the
main chain of the protein, resulting in a markedly shorter R group and distorting the predicted
structure of the main chain that is distinct from the structure of an asparagine at that same
position.
We first performed a refinement of the AAV8 structure to obtain a capsid electron density
that was generated independently of the VP3 sequence encoded by the cap gene. We then
examined this non-biased refinement for evidence of residues predicted to be asparagine by
sequence but have a shorter-than-expected R group electron density. When compared to the
electron density at position 410, determined to be an asparagine by sequence and not found to
be deamidated, the electron densities corresponding to R groups at positions 263, 385, 514, and
540, all part of highly deamidated NG motifs, were found to be shorter and wider, indicating that
the majority of the amino acids at these positions are indeed isoaspartic acid rather than
asparagine (Figure 24B-E). The resulting AAV8 VP3 models with isoaspartic acid instead of
asparagine at these positions were comparable to the electron densities and subsequent models
generated of other proteins known established to be deamidated, supporting the validity of our
analysis (278-280). These structural analyses provide independent confirmation of the
deamidation phenomena identified and quantified by mass spectrometry.
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Functional evaluation of genetically deamidated AAV8 capsid mutants
To evaluate the impact of deamidation on AAV capsid structure, assembly, and
performance, we selected five of the 12 deamidated VP3 asparagines residues for permanent,
genetic deamidation by mutation of these asparagines to aspartic acids: N254, N514, N517,
N540, and N630. These residues represent a wide range of average percent deamidation (from
2% to 98%), of structural motif (located in an HVR or more structurally-conserved regions), and of
local structure (surface-exposed or buried). We additionally included N255 due to the detected
deamidation at N254 on the same peptide and the possibility that deamidation at position 255
could be incorrectly assigned to N254.
The genetic inclusion of the acid form of these residues should, as a deamidation event
does, introduce a negative charge to every VP and therefore increase the isoelectric point of each
VP isoform by 0.1 pH units, supported by the prediction of this increase by ExPASy. We therefore
compared the isoform migration patterns of two of the deamidation mutants, N255D and N517D,
to those of wtAAV8 by 2D gel. Each of the major spots of VP1, VP2, and VP3 in the mutant
vectors were shifted one position more acidic relative to the major spots of wtAAV8,
corresponding to a 0.1 pI unit decrease in isoelectric point and suggesting that deamidation
events are indeed responsible for various VP isoforms (Figure 25A-D). The genetic deamidation
of these sites did not, however, change the number of isoforms or the relative spot intensities of
these isoforms, suggesting that the heterogeneity in isoelectric point is a product of the average
distribution and number of deamidation events in the VP population.
We then evaluated the impact of all six deamidation mutations on capsid assembly,
titering vector after small-scale triple transfection. All mutants located in HVRs (N254D, N255D,
N514D, N517D, and N540D) all had titers equivalent to wtAAV8, indicating that these mutations
had no effect on capsid assembly and suggesting that deamidation at these sites does not impact
capsid structural integrity (Figure 26A). N630D mutant capsids produced 10- to 15-fold less
vector than wtAAV8, indicating that it had a significant impact on capsid assembly likely because,
unlike the other mutants, N630 is located in a buried and structurally rigid capsid motif.
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As all mutants produced vector of sufficient titer, we then evaluated the impact of
permanent deamidation on vector transduction efficiency in Huh7 cells in vitro. As measured by
luciferase expression, we found that the majority of deamidation mutant vectors transduced Huh7
cells less efficiently (Figure 26B). Genetic deamidation of the residues of interest with the lowest
levels of deamidation (N254, N255, N517, and N630) significantly reduced the ability of these
mutants to transduce Huh7 cells, indicating that extensive deamidation beyond endogenous
levels negatively impacts vector performance. Interestingly, genetic deamidation of residues with
high levels of endogenous deamidation, N514 and N540, also significantly impacted transduction
despite introducing minimal additional deamidation, as the endogenous levels of deamidation of
these residues are already 84% and 79%, respectively; N514D transduction was reduced by 73%
and N540D transduction was reduced by a more modest 18%. This suggests that these
additional “deamidations” at the small population of asparagines at these locations not
endogenously deamidated can still have a significant impact on AAV8 vector performance.
To further study the impact of genetic deamidation, we selected those mutants that
produced sufficiently and demonstrated a substantial loss of in vitro transduction for in vivo
evaluation (N254D, N255D, N514D, N517D, and N630D). Vectors expressing firefly luciferase
were administered intravenously to C57BL/6 mice (n=3), and luciferase expression was
evaluated weekly or biweekly by in vivo imaging (Figure 26C, D). On day 7 following vector
administration, we observed reduced luciferase signal from liver in mice receiving N255D and
N630D mutant vectors. By day 14, luciferase expression in animals receiving N630D rebounded
to wtAAV8 levels while expression in animals receiving N255D remained significantly lower than
wtAAV8 levels throughout the remainder of the study (p<0.05, linear mixed effects model, run in
R).
After the in-life phase of the study, we analyzed liver for vector genome copies as an
additional measure of transduction efficiency. On average, we found that mutants that resulted in
luciferase expression equivalent to that of wtAAV8 also had equivalent genome copies/diploid
genome in the liver (Figure 26E). Genome copies in liver DNA from animals receiving N255D
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were two logs lower than in animals receiving wtAAV8, reflecting the luciferase expression levels,
although these results were not significant. Genome copies in mice receiving N254D or N630D
also trended towards a decrease compared to wtAAV8 GC/diploid genome (also not significant),
which was consistent with the reduction observed in in vitro transduction efficiency.
Evaluation of deamidation of the AAV9 capsid
Having established the presence of deamidation of AAV8 vector and evaluated its
potential impact on vector performance, we sought to determine if this phenomenon is applicable
to other AAV capsids. We chose to similarly evaluate AAV9 due to its current development as a
therapy for a number of indications, including spinal muscular atrophy and Duchenne muscular
dystrophy (97, 134). 2D gel analysis of AAV9 vector demonstrated that the populations of AAV9
VP1, VP2, and VP3, like AAV8, are comprised of a number of isoforms with distinct isoelectric
points (Figure 27A). Mass spectrometry revealed extensive deamidation at all four NG sites in the
total AAV9 VP1 sequence; two of these sites, N57 and N512, are evolutionarily conserved with
AAV8 and a number of other AAV serotypes, and two, N329 and N452, are unique to AAV9 (not
found in AAV8) but are deamidated to a similar degree as the other NG motifs (Figure 27B).
Consistent with our AAV8 findings, a number of other motifs, particularly NS, NN, NH, and ND,
are deamidated in AAV9, although to a lesser degree than the NG motifs. We repeated the forced
deamidation studies with high temperature and low and high pH and found that no condition
appreciably had an impact on deamidation (Figure 28A, B).
Structurally, at a number of AAV9 residues, such as N329 and N452, high temperature
factor corresponded to high levels of deamidation; however, other residues, such as N704, had
relatively high temperature factors but were not highly deamidated (Table 7). As was the case for
AAV8, this indicates that additional factors such as N+1 residue identity contribute to the
likelihood of a given residue undergoing deamidation. We also generated a non-biased
refinement of the AAV9 crystal structure and evaluated the electron density at asparagine
residues of interest, finding that isoaspartic acid fits the R group electron density at positions 329,
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452, and 512, better than asparagine, again providing independent confirmation of the presence
of deamidation on the AAV9 capsid (Figure 27C).
Discussion
Deamidation of the AAV capsid is extensive and not serotype specific
Here we establish that the natural phenomenon of spontaneous deamidation, which has
been previously established to occur in a variety of proteins both in vivo and in vitro with many
structural and functional implications, occurs on AAV vectors as well. We confirmed this through
numerous methods, including 2D gel electrophoresis, mass spectrometry, de novo protein
modeling, and functional studies. Consistent with what has been established in the literature, we
observed asparagine deamidation much more frequently than glutamine deamidation. We also
establish the importance of the identity of the N+1 residue on the deamidation of asparagine on
the AAV capsid. All NG sites located in in both AAV8 and AAV9 were found to be highly
deamidated (>75%). No sites with N+1 residues that were not glycine were found to be
deamidated greater than 20% of the time. Additionally, of these 9 NG sites, 7 are located in VP3
regions for which structures have been determined, with the remaining 2 being located in the
VP1u region (for which structural information is not available). The available structures indicated
that they were also all located in flexible loop regions, further facilitating their extensive
deamidation beyond that of other asparagine residues located in or near more structurally
constrained motifs.
We then sought to address the potential effects of this deamidation on the performance
of AAV as a gene therapy vector, doing so in a comprehensive fashion. We selected a number of
different asparagines for evaluation, each with a unique set of properties, in order to evaluate the
implications of deamidation in each of these scenarios. As a surrogate for determining the
biological activity of the acid “version” of these residues as well as to assess vector performance
should the remaining amide residues be lost, we genetically deamidated these residues by
mutating them to aspartic acid. While this is not a perfect representation of spontaneous
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deamidation, which was expected to result in a mixture of aspartic acid and isoaspartic acid, this
approach still allowed us to evaluate the effect of the introduction of a positively-charged residue
at each site.
The impact of deamidation on AAV vector production is limited
As may have been expected, genetic deamidation of asparagines in surface-exposed
regions and/or the generally flexible hypervariable regions had little to no effect on capsid
assembly/integrity, as evidenced by equivalent vector production. As none of these sites are
integral parts of ordered structural motifs, such as alpha helices or beta sheets, or participate in
critical VP monomer-monomer interactions, it follows that the capsid would tolerate these
deamidations from a structural perspective, especially considering that flexible regions such as
the HVRs have been established to be relatively tolerant of mutations (46, 281). Genetic
deamidation of N630, however, introduced a production defect, indicating that introduction of
additional deamidation beyond the native low levels present in AAV8 preps could negatively
impact total vector yield. While these studies do not pinpoint if deamidation occurs prior to or after
capsid assembly, we propose that the majority of deamidation events likely occur after capsid
assembly simply based on the average half-times of deamidation at various sequence motifs
(274). Genetic deamidations that reduce vector yield could prevent assembly due to this
deamidation being “introduced” prior to capsid formation when native deamidation is introduced
after capsid formation, where low average deamidation rates at those sites after assembly are not
sufficient to significantly destabilize the capsid and are therefore tolerated from a stability
standpoint. Alternatively, these native deamidation events could occur prior to assembly, but low
levels are below the threshold that would be required to block capsid formation. A third possibility
is that these mutant capsids may still assemble but the stability of the resulting capsid is
significantly reduced, reducing vector yield. Further study will be required to determine when in
the vector production process deamidation of the AAV capsid occurs.
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Vector performance is modulated by deamidation
Functionally, genetic deamidation had a varied impact. N540D had minimal impact on the
vector’s ability to transduce Huh7 cells in vitro, perhaps due to it being surface exposed on a VP3
monomer but not on the assembled capsid, and therefore the native N540 already has a minimal
role in transduction. It could also mean that as the majority of asparagines at this site are already
deamidated, that the conversion of the residual asparagines to aspartic acids had no additional
impact on function beyond what the native levels of deamidation potentially introduce. This was
not the case for N514D, as the conversion of the approximately 15% residual asparagines to
aspartic acids markedly reduced in vitro transduction, suggesting that these residual nondeamidated asparagines may play an important role in vector performance; this could be partially
explained by the participation of N514 in hydrogen bond interactions with D531 from a three-fold
related monomer that could disrupt functionality of this region (53). Despite the fact that this
observation did not translate to in vivo experiments, it demonstrates that the residual asparagines
at highly deamidated NG motifs can play a critical role in vector functionality.
Genetic deamidation of lower percentage sites, like for the NG motifs, had a varied effect
on vector performance both in vitro and in vivo despite the fact that the introduction of aspartic
acid at these sites represents a greater change from baseline deamidation levels and therefore
might be expected to introduce larger functional changes. Also as was the case for the NG motif
mutants, the effects of genetic deamidation at these lower percentage sites are highly position
dependent, as loss of in vitro and in vivo function was much more profound for N255D than for its
immediately adjacent neighbor, N254D. In summary, these studies indicate that we cannot draw
conclusions about the global effects of spontaneous deamidation other than it has the potential to
negatively impact performance and that each residue must be specifically evaluated to determine
if deamidation at that site has any impact on AAV assembly or functionality.
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Deamidation introduces significant and undesired heterogeneity into AAV viral protein population
Having demonstrated the ability of deamidation to interfere with vector performance and
that this phenomenon is not limited to AAV8 but extends to other AAVs, questions are therefore
raised regarding vector heterogeneity and its impact on AAV vector quality control. As the
introduction of an aspartic acid resulted in a discreet shift of the distinctive AAV8 VP spotting
pattern, we are confident that the presence of multiple isoforms of these VPs is due to
heterogeneous deamidation within the overall pool of VPs, likely between VPs in a given capsid
particle. This suggests that the intact capsids themselves also represent a heterogeneous
population. Mass spectrometry studies indicated that while there were no significant differences
in percent deamidation of any given residue based purely on purification method, there were
certain sites with a higher degree of variation between preps tested, such as N499, whose
percent deamidation ranged from 0-53% with a mean of 17%. As we established that these
deamidation events occur during the process of vector production, it is possible that more subtle
differences between production runs are responsible for this variation.
Regardless of the source of this apparent heterogeneity in deamidation, its presence
brings attention to gaps in the current expectations of AAV vector quality control. Deamidation is
a fairly standard concern for other biologic products, such as recombinant mAbs. For these
products, extensive testing is performed during product development to identify sites that are
potentially susceptible to deamidation, particularly in the CDR regions responsible for antigen
recognition (256) (254). Even sites that are deamidated less than 10% of the time are of great
concern and are generally avoided in the final product by engineering variants of the mAb that do
not include that site; this is because it has been well-established that PTMs, including
deamidation, in the CDRs can significantly impact mAb performance (256). Despite AAV’s recent
rise in use in the clinic, thorough annotation of functional regions of each AAV serotype being
used is not complete and it is therefore difficult to fully define physical QC requirements as we do
not fully understand which, if any, PTMs are innocuous and are an acceptable source of
heterogeneity and which are a concern for product development. Based on our findings here, we
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would recommend that 2D gel and mass spectrometry analysis be performed regularly on new
AAV vector preps and compared to a reference lot such that, despite further work being required
to fully characterize the impact of heterogeneous deamidation on vector performance, at
minimum consistency between different preps could be established to rule out deamidation
heterogeneity as a potential source of unexpected vector performance. The establishment of
standard vector characterization will only become more critical in the future as more therapies
enter the clinic and are approved, with many groups utilizing modified or completely unique
methods of manufacturing vector with the potential to produce AAV vectors that vary in their
biochemical properties.
Conclusions
While these studies do not comprehensively evaluate the functional implications of
deamidation of all asparagines that were determined to be deamidated, they provide significant
evidence of this deamidation on two clinically-relevant AAV serotypes, AAV8 and AAV9, as well
as numerous examples how deamidation has the potential to be significantly detrimental to vector
performance. As deamidation was not found to be serotype-specific, all vectors in clinical
development should be evaluated for deamidation, and this evaluation should be included as a
standard measure of quality control as these vectors are commercialized. Future studies should
expand the mutagenic evaluation of the functional implication of deamidation as well as explore
possible methods to ensure consistency in deamidation levels to reduce prep-to-prep variation as
well as approaches to reduce deamidation rates in attempts to improve vector performance.
Materials and Methods
1D and 2D gel electrophoresis: For one-dimensional SDS-PAGE analysis, AAV vectors were
o

denatured in the presence of lithium dodecyl sulfate and reducing agent for 20 minutes at 80 C.
They were then run on 4-12% Bis-tris gels for 90 minutes at 200V and stained with Coomassie
blue for protein visualization. 2D gel electrophoresis for Figure 1 was run by Kendrick
Laboratories, Inc. (Madison, WI). Subsequent experiments were performed in-house. 3e11 GCs
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of AAV vector was combined with 500U turbonuclease as an internal marker (Accelagen, San
Diego, CA) in 150µL phosphate buffered saline (PBS) with 35nM NaCl and 1mM MgCl2 and
o

incubated for 10 minutes at 37 C. Nine sample volumes of absolute ethanol was then added,
o

samples were vortexed, and placed at -80 C for at least two hours. Samples were then incubated
o

on ice for five minutes and then centrifuged at maximum speed for 30 minutes at 15 C. After the
supernatant was decanted, the pellet was air-dried and then resuspended in resuspension buffer
#1 (0.15% SDS, 50mM dithiothreitol (DTT), 10mM Tris pH 7.5, and 1 µL pH 6-9 ampholytes,
Thermo Fisher ZM0023, added day-of, in ddH2O) and left undisturbed at room temperature for 30
minutes. 1µg chicken conalbumin marker (Sigma Aldrich, St. Louis, MO) was added and samples
o

were incubated at 37 C for 30 minutes, flicking to mix at 15 minutes. Samples were then
o

o

incubated at 50 C for 15-20 minutes, vortexed, incubated at 95 C for 2.5 minutes and allowed to
cool prior to centrifugation at maximum speed for 1 minute. 10-15µL of each sample was mixed
with 140µL resuspension buffer #2 (9.7M urea, 2% CHAPS, 0.002% bromophenol blue, and
0.05% ampholytes, described above, in ddH2O) and incubated at room temperature for 10
minutes. The resulting mixture was applied to pH 6-10 immobilized pH gradient (IPG) strips
(Thermo Fisher, Waltham, MA) and run on the ZOOM IPGRunner system according to
manufacturer’s instructions. The following ramping parameters were used for isoelectric focusing:
100-1,000V for 120 minutes, 1,000-2,000V for 120 minutes, and 2,000V for 120 minutes, limited
of 0.1W and 0.05mA per strip run. IPG strips were then reduced and loaded in a single-well 412% Bis-tris gel and run in 1D according to manufacturer’s instructions. Gels were stained with
Sypro Ruby (Thermo Fisher, Waltham, MA) according to manufacturer’s instructions. Relative
migration of AAV VPs were determined by comparison to internal control proteins turbonuclease
(Accelagen, 27kDa) and chicken egg white conalbumin (Sigma Aldrich, 76kDa, pI 6.0-6.6).
Vector production: 1D, 2D gel electrophoresis and mass spectrometry: Vectors purified by either
cesium chloride or iodixanol gradient were produced by the University of Pennsylvania Vector
Core as previously described (40, 159). Vectors that were affinity purified were produced as
follows: HEK293 cells grown in ten 36-layer hyperstack vessels (Corning) were co-transfected
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using PEIpro (PolyPlus) with a mixture of vector genome plasmid (pAAV-LSP-IVS2.hFIXcoWPRE-bGH), trans plasmid containing AAV2 rep and AAV8 cap genes, and adenovirus helper
plasmid. Five days post-transfection, supernatant was harvested, clarified through Sartoguard
PES Midicap filters (Sartorious Stedim), and treated with benzonase (Millipore), and salt was
added to bring concentration to 0.6M. The clarified bulk harvest material was concentrated tenfold by tangential flow filtration (TFF) and then diafiltered against four volumes of affinity column
loading buffer. Vectors were then captured by POROS CaptureSelect (Thermo Fisher) affinity
column, and the vector peak was eluted at low pH directly into neutralization buffer. The
neutralized eluate was then diluted into high pH binding buffer and loaded into an anion exchange
polishing column (Cimultus QA-8; Bia Separations) to enrich for genome-containing particles.
These particles were then eluted with a shallow salt elution gradient and neutralized. Vector was
then subjected to a second round of TFF for final concentration and buffer exchange into
formulation buffer (PBS+0.001% pluronic F-68).
In vitro assays: Deamidation mutant vectors were produced by small-scale triple
transfection of HEK293 cells in six-well plates. 5.6µL of a 1mg/mL polyethylenimine solution in
90µL of serum-free DMEM with 5.6ug polyethylenimine was mixed with 90µL of serum-free
DMEM with plasmid DNA (0.091µg cis plasmid, 0.91µg trans plasmid, and 1.82ug deltaF6 Adhelper plasmid), incubated at room temperature for 15 minutes, and added to cells in 1.5mL fresh
serum-free DMEM. Vector was harvested three days post-transfection by 3X freeze/thaw cycles
followed by centrifugation and supernatant harvest. The cis plasmid contained a transgene
cassette encoding firefly luciferase under the control of the chicken beta-actin (CB7) promoter
with the Promega chimeric intron and rabbit beta-globin (RBG) polyadenylation signal. The trans
plasmid encoded the wtAAV8 cap gene. To generate AAV8 cap mutants, we used the
Quikchange Lightning Mutagenesis kit (Agilent Technologies, Wilmington, DE). Vector was titered
as previously described (159).
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In vivo assays: AAV8 (deamidation mutants and wild-type) vectors for in vivo experiments
were produced as previously described with a transgene cassette including the CB7 promoter, PI
intron, firefly luciferase transgene, and RBG polyadenylation signal (159).
Mass spectrometry sample preparation and analysis: Materials: Ammonium bicarbonate, DTT,
iodoacetamide (IAM), and 18O-enriched water (97.1% purity) were purchased from Sigma (St.
Louis, MO); acetonitrile, formic acid, trifluoroacetic acid (TFA), 8M guanidine hydrochloride
(GndHCl), and trypsin were purchased from Thermo Fisher Scientific (Rockford, IL).
Trypsin Digestion: Stock solutions of 1M DTT and 1.0M IAM were prepared. AAV vectors
o

were denatured and reduced at 90 C for 10 minutes in 10mM DTT and 2M GndHCl. Samples
were allowed to cool to room temperature and were then alkylated with 30mM IAM at room
temperature while protected from light. Alkylation was then quenched with the addition of 1mL
DTT. 20mM ammonium bicarbonate (pH 7.5-8.0) was added to the denatured protein solution to
dilute the concentration of GndHCl to 200mM. Trypsin was added in a ratio of 1:20 trypsin:protein
o

and incubated overnight at 37 C. TFA was then added to a final concentration of 0.5% to quench
protein digestion.
For 18O-water experiments, vector was first buffer exchanged into 100mM ammonium
bicarbonate prepared in 18O-water using Zeba spin desalting columns (ThermoScientific,
Rockford, IL), doing so twice to ensure complete water removal. Stock solutions of 1M DTT and
1M IAM were also prepared in 18O-water. Digestion was otherwise performed as described
above.
Liquid chromatography tandem-mass spectrometry: Online chromatography was
performed with an Acclaim PepMap column (15cm long, 300um inner diameter) and a Thermo
UltiMate 3000 RSLC system (Thermo Fisher Scientific) coupled to a Q Exactive HF with a
o

NanoFlex source (Thermo Fisher Scientific). Column temperature was maintained at 35 C
throughout online analysis. Peptides were separated with a gradient of mobile phase A (MilliQ
water with 0.1% formic acid) and mobile phase B (acetonitrile with 0.1% formic acid). The
gradient was first run from 4% B to 6% B over 15 minutes, then to 10% B over 25 minutes, and
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finally to 30% B over 46 minutes (86 minutes total). Samples were loaded directly onto the
column, which was 75cm x 15µm I.D. and was packed with 2µm C18 media (Acclaim PepMap).
Total run time was approximately two hours, including sample loading, lead-in, and wash steps.
Mass spectrometry data was acquired using data-dependent top-20 method on the Q
Exactive HF mass spectrometer, dynamically choosing the most abundant not-yet-sequenced
precursor ions from the survey scans (200-2000m/z). Sequencing was performed via higher
energy collisional dissociation fragmentation with a target value of 1e5 ions determined with
predictive automatic gain control. The isolation of precursors was performed with a window of
4m/z, and survey scans were acquired at a resolution of 120,000 at 200m/z. The resolution for
HCD spectra was set to 30,000 at 200m/z with a maximum ion injection time of 50ms and a
normalized collision energy of 30, and the S-lens RF level was set to 50 to give optimal
transmission of the m/z region occupied by the peptides from sample digest. Precursor ions with
single, unassigned, or six and higher charge states were excluded from fragmentation selection.
Data processing: BioPharma Finder 1.0 software (Thermo Fisher Scientific) was used to
analyze all data. Peptide mapping was performed by searching using a single-entry protein
FASTA database with carbamidomethylation set as a fixed modification and oxidation,
deamidation, and phosphorylation set as variable modifications using a 10ppm mass accuracy, a
high protease specificity, and a confidence level of 0.8 for tandem-mass spectrometry spectra.
Deamidated peptides were identified by a mass shift of +0.984 Da from the parent, intact, nondeamidated molecule, which is the mass difference between –OH and –NH2 groups. The percent
deamidation of a peptide was determined by dividing the mass area of the deamidated peptide by
the sum of the area of the native and deamidated peptides. Due to the number of possible
deamidation sites, isomeric species that were deamidated at different sites may co-migrate in a
single peak. As such, fragment ions originating from peptides with a number of potential
deamidation sites can be used to differentiate multiple sites of deamidation, using the relative
intensities of the observed isotope patterns to determine the relative abundance of the different
deamidated peptide isomers. This assumes that the fragmentation efficiency for all isomeric
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species is independent of the deamidation site and allows for the definition of specific sites as
well as potential combination of sites involved in deamidation.
Secondary data processing: The following method was used for secondary analysis of
raw mass spectrometry data at the University of Maryland, Baltimore County. Peaks Studio v5.3
software (Bioinformatics Solutions Inc.) was used for analysis. The following parameters were
used to perform data refinement of the raw files: precursor m/z tolerance of ≤10ppm and
precursor charge state of a minimum of 2, maximum of 4. De novo sequencing of the input
spectrum was performed using the Peaks algorithm (precursor ion error tolerance of 10ppm,
product ion error tolerance of 0.1Da). Trypsin was set as the digestion enzyme, oxidation,
phosphorylation, and deamidation were set as variable modifications, and cysteine
carbamidomethylation was set as a fixed modification.
Structural analysis: AAV8 atomic coordinates, structural factors, and associated capsid model
were obtained from the RCSB Protein Data Bank (PDB, ID:3RA8). Structure refinement was
performed to generate a capsid electron density independent of the primary amino acid sequence
of AAV8 VP3 for use in three-dimensional structural analysis of the AAV8 capsid. This analysis
was performed into order to observe the isoaspartic acid electron density in a structure of AAV8
that was not biased by the primary sequence of VP3. The four asparagines in the AAV8 VP3
primary sequence with N+1glycines were modeled as isoaspartic acids and the resulting
structures were refined using the Crystallography and NMR System (CNS) software by strictly
imposing the icosahedral non-crystallographic matrices using the standard refinement protocol
(282). A structural model of isoaspartic acid was obtained from the HIC-UP database, and a
molecular dictionary was generated in PRODRG for structure refinement (283). The average
electron density map of the AAV8 capsid was then calculated in CNS and visualized in COOT,
and minor adjustments of the model were made to fit the modeled isoaspartic acid residues into
the electron density map (154). This protocol was repeated to similarly model N512 in the AAV9
VP3 primary sequence (PDB ID:3UX1). All figures were generated using COOT, PyMol, and
UCSF Chimera (153, 154, 157). A number of structures of proteins previously structurally
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characterized and identified as deamidated were obtained for comparison of their electron density
maps of deamidated isoaspartic acid residues with modeled isoaspartic residues from AAV8 and
AAV( (PDB IDs: 1DY5, 4E7G, 1RTU, 1W9V, 4E7D, and 1C9D) (278-280).
Temperature factors for deamidated residues were determined by averaging the
temperature factors for each atom of the selected residue in the AAV8 or AAV9 crystal structure
atomic coordinates (PDB ID: 3RA8, 3UX1).
Animal studies: All animal procedures were approved by the Institutional Animal Care and Use
Committee of the University of Pennsylvania.
Vector performance was evaluated by injecting eight-week-old C57BL/6 mice (n=3)
intravenously vial tail vein injection with 3e10 GCs of wtAAV8 or capsid mutant vector in a total
volume of 100µL (vector was diluted in PBS). All groups (with the exception of N514D) were
sacrificed 56 days after vector administration, with liver tissue being harvested for genome copy
analysis. Animals in the N514D were euthanized prior to study day 56 due to a water supply
malfunction; viable liver tissue was obtained for genome copy analysis from one of the three
animals in this group.
Evaluation of vector performance by luciferase expression: In vitro studies: Huh7 cells were
seeded at a density of 5e4 cells/well in black-walled 96-well plates in complete DMEM (10% fetal
bovine serum, 1% penicillin/streptomycin). The next day, media was removed and replaced with
100uL of complete media containing 1e10 GC/mL AAV vector. Twenty-four hours posttransduction, all media was removed and replaced with 50uL fresh complete media. Seventy-two
hours post-transduction, luciferin substrate (Promega, Madison, WI) was prepared in complete
media at a concentration of 0.3µg/µL, and 50uL was added to each well containing transduced
cells. Luminescence was read on the Clarity luminometer (Biotek).
In vivo studies: Mice (~20g each) were anesthetized and injected intraperitoneally with
200uL of 15mg/mL luciferin substrate (Perkin Elmer, Waltham, MA). Mice were imaged five
minutes after luciferin administration via the IVIS Xenogen In Vivo Imaging System. Luciferase
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signal was quantified using Living Image 3.0 in regions of interest. Measurements were taken
weekly to day 14 post-injection and then bi-weekly until study completion at day 56.
Biodistribution: DNA was extracted from liver samples using the QIAamp DNA Mini Kit (Qiagen,
Hilden, Germany) and analyzed for vector genome copes by real-time PCR as previously
described using a primer/probe set against the RBG polyadenylation signal of the transgene
cassette (162).
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Chapter 8: Future Directions and Perspectives
The work described here attempts to address a number of unanswered questions
surrounding the immunology and biochemistry of AAV vector capsids, and, in the process, raises
many more questions regarding how we approach engineering AAV capsid proteins. Many
engineering efforts focus primarily on vector performance from a transduction perspective,
looking to enhance entry into a target cell, increase the number of cell types transduced,
modulate clearance from the bloodstream, or reduce the time between administration and onset
of expression. Focus on transduction efficiency is paramount, as vectors unable to transduce the
relevant tissues to the required degree and in the required period of time are not viable
therapeutics. However, these new vectors may interact differently with the immune system or
have modified biochemical properties; conversely, capsid engineering to modulate immune
interactions or biochemical properties has been shown here and elsewhere to often interfere with
vector transduction. To increase the ultimate productivity of engineering efforts, screens to
evaluate physical vector characteristics as well as a number of measures of functionality,
including immunogenicity and immune evasion, should be incorporated early on in product
development. Additionally, the selection process for these engineered vectors must be carefully
considered.
The results of the PAV9.1 epitope-based engineering of AAV9 provide information critical
to future escape mutant engineering. The significant degree to which PAV9.1 activity can be
ablated by a small number of engineered mutations provides evidence that the mouse hybridoma
approach is viable for generating mAbs against AAV for proof of concept studies. However, the
fact that only a fraction of predicted footprint residues are required for PAV9.1 binding and activity
confirms the requirement for retrospective, mutational analysis of previously determined mAb
footprints. As the PAV9.1 epitope shares a number of features with larger footprints from other
mouse mAbs, this approach could be used in the future to further evaluate epitope similarities
between different mAbs or AAV serotypes through the isolation of additional candidate mAbs.
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Doing so has the potential to identify common epitope features that could be applied to
engineering of a larger subset of AAVs.
Despite the potential throughput of hybridoma screening, however, a relatively small
collection of mAbs have been characterized in this way. This could be due to a low percentage of
isolated clones producing the more commonly desired neutralizing antibodies or due to only a
small fraction of isolated mAbs being suitable for complexing with AAV and structural modeling by
cryo-EM. Of 30 clones screened in the PAV9.1 study, only one was found to be appropriate for
evaluation. This could be rectified in the future by simply screening additional candidates or
improving immunization protocols such that more suitable mAbs can be identified and applied to
the study of both previously isolated AAV serotypes as well as novel variants that have yet to be
discovered.
However, several pitfalls of the AAV9 vector engineering effort described here became
clear following the conclusion of the study. The first and most obvious is that while rational
engineering of the PAV9.1 epitope ablated mAb activity, it did not translate to evasion of binding
or neutralization by polyclonal samples from more relevant sources. It therefore served as a proof
of concept study to demonstrate the feasibility of this approach to identify epitopes on AAV9 and
established the minimum mutations required to prevent the specific epitope from interacting with
its corresponding mAb but made it clear that epitopes mapped in this fashion are not always
applicable to the polyclonal responses for which we are attempting to introduce evasive
properties. This supports the further development of strategies similar to that described in
Chapter 5 to isolate more relevant mAbs for study in a more high-throughput fashion. This
approach can be applied to a variety of relevant human samples, from individuals with preexisting
immunity to those receiving AAV vector from one of a number of potential routes of administration
(more feasible now due to the increased number of active clinical trials utilizing AAV vectors). It
could also be used for individuals with neutralizing antibodies against a single AAV serotype for
the isolation of serotype-specific mAbs or for those individuals with broad, cross-reactive
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immunity in an attempt to isolation neutralizing antibodies with broad specificity whose study may
inform evasion engineering efforts for a larger number of serotypes.
In the short term, we could isolate mAbs from additional donors from the 31 screened
with different NAb titer profiles, such as Donor 11, who had a high NAb titer against AAV9. We
could then evaluate IgG variable sequences to quantify AAV-specific memory B cell maturation
and compare mutation frequencies between individuals as well as compare the frequencies of
neutralizing antibodies as well as broadly binding antibodies in these individuals. In the long term,
we would ideally apply this approach to individuals who have received vector, which would likely
entail inclusion of sample collection for this purpose in clinical trial study protocols. One drawback
of this approach is that it requires the identification and access to a population of individuals who
have either previously received vector (if isolating memory B cells) or will be receiving vector in
the near future (if isolating cells that are part of a more acute response, such as plasmablasts)
and therefore limits this approach to capsids that have advanced to the clinic.
This strategy could also be adapted to obtain mAbs from non-human primates utilizing
species-specific memory B cell sorting protocols as well as the appropriate primers for IgG gene
amplification from these animal models. As such, the humoral response to AAV could be studied
in a more controlled fashion. If adapted to non-human primate models, humoral responses to
novel vectors could more feasibly and quickly be evaluated rather than waiting for clinical
evaluation. However, the species of NHP selected will determine if there is significant
optimization required, as the markers and reagents for some B cell subsets are not as well
characterized for certain species; similar optimization may be required to determine the optimal
primer mix for amplification of the immunoglobulin sequences of interest.
Engineering efforts other than rational design based on epitope mapping of individual
mAbs, such as library approaches using capsid shuffling, error-prone polymerases, or saturating
mutagenesis of regions predicted to be involved in antibody binding, could also benefit from more
comprehensive and rigorous evaluation in the presence of polyclonal sera. Normal human donor
blood samples are readily accessible, and there are resources for obtaining panels of NHP
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samples; these samples can all easily be screened for binding to and neutralization of a capsid of
interest. Patient or NHP samples from individuals receiving AAV vectors are harder to acquire,
but the steady rise in the number of clinical trials as well as preclinical studies utilizing AAV
vectors should increase their availability to support these studies. Sample collection is relatively
non-invasive, and screening by ELISA, NAb assay or even in vitro transduction assays do not
require gratuitous volumes of sample and can be performed in a relatively high throughput
fashion to evaluate vector performance, especially if assays can be miniaturized.
Tse and colleagues incorporated this approach into their 2017 study of AAV1 saturating
mutagenesis libraries, evaluating their candidate vector CAM-130 (selected for ability to
transduce cells in vitro followed by evasion of 3 αAAV1 mouse mAbs) in the presence of 10
different NHP and 10 different human sera with preexisting immunity as well as against 3 serum
samples from NHPs that received AAV1 vector (115). These studies demonstrated the potential
of CAM-130 to successfully evade these relevant samples, but these sample sizes should be
dramatically increased to fully learn the potential of CAM-130 to evade the variety of humoral
responses observed in the overall population. Such information could also be used to potentially
categorize humoral responses to AAV from different individuals and to provide information about
the clonality of these responses.
The saturating mutagenesis strategy used to generate CAM-130 was designed based not
on the epitope of a single mAb against AAV1 but a group of three mAbs whose epitopes
minimally overlapped. Cumulatively, their mapped Fab densities covered the majority of the AAV1
capsid surface at maximum occupancy. Interestingly, while the sites of mutagenesis were based
on mAb epitopes, variants were selected based on their ability to transduce HeLa cells in the
absence of sera. In spite of this initial lack of immune selection, the top candidates, including
CAM-130, still escaped neutralization. This suggested that, at a minimum, combinatorial
mutagenesis of three neutralizing epitopes can successfully generate a significant escape
phenotype. However, it is likely a requirement that these epitopes do not largely overlap and, as
these mAbs do, span the capsid surface. It is unknown how many mAbs were screened to
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identify these candidate mAbs and how long this screening process took, but it likely represents
years of work. Adopting the aforementioned B cell cloning approach could significantly increase
the efficiency of this process and also determine if the minimum requirement of three mutated
epitopes to generate escape mutants for AAV1 is true of other serotypes/combinations of mAbs
or if it is a surreptitious exception to the rule; if so, high-throughput methods to identify relevant
mAbs will be even more critical to engineering efforts.
Introducing mutations to serve one function has the potential to interfere with other
functions, such as receptor binding and therefore transduction. As such, the known sialic acid
binding site on AAV1 was excluded from the saturating mutagenesis in this study. This is likely
why the escape mutants generated maintained a transduction profile similar to that of the parental
AAV1. In the work described in this dissertation, parental AAV9 tropism was not maintained,
despite no known disruption of the previously-characterized galactose binding site due to the
mutations in the PAV9.1 epitope. This could potentially be due to disruption of capsid interactions
with AAVR (71). This is likely not the case for the majority of mutants, as most tissues were still
efficiently transduced, but it remains a possibility. However, it is still possible or even would
logically follow that some neutralizing antibodies would function to block AAVR binding, but as
this site has not yet been identified/characterized, it cannot be actively excluded from such
studies. Similarly, there are a number of AAVs for which receptors have not yet been identified,
such as AAV8, and therefore their binding sites cannot be consciously avoided. This calls
attention to the fact that significant gaps in our understanding of basic AAV biology actively
interfere with our efforts to design better AAVs and provide support for research efforts to more
thoroughly address these critical gaps.
In addition to inadvertently interfering with the ability of capsid to interact with receptors,
capsid engineering to evade humoral immune responses also has the potential to introduce new
but undesirable qualities to the capsid proteins themselves. In the studies here, some NHP sera
actually bound the PAV9.1 mutants better than wtAAV9, suggesting that attempts to mutate one
epitope may actually introduce a second. Mutations may also enhance peptide binding to MHC
103

and therefore enhance capsid antigen presentation to the immune system and T cell responses
to transduced cells. Alternatively, peptide binding to MHC may also be reduced and potentially
interfere with the induction of tolerogenic Tregs, particularly after liver gene transfer (284).
Introduction of additional asparagine residues may also introduce additional deamidation
sites and therefore additional sites of heterogeneity within each AAV capsid and within all
particles in the prep. This is of particular concern when introducing these asparagines adjacent to
a glycine, serine, or histidine residue. Additionally, mutations at N+1 sites or that affect the
flexibility of the protein backbone or surface exposure can also change the deamidation status of
native asparagine residues, which we have shown can negatively impact vector performance.
These same concerns are applicable to engineering efforts to avoid or control
deamidation. A logical step following the identification of these charge isoforms of AAV capsid
proteins due to deamidation would be to evaluate methods by which deamidation could be
minimized or controlled for quality assurance purposes or to optimize vector performance. A
number of approaches have been taken to minimize heterogeneity in biochemical properties and
subsequently improve performance in biologics, particularly in monoclonal antibodies; these
approaches could be applied to AAV vectors in the future (285).
. A first step would be the replacement of the asparagine of interest with a different amino
acid altogether. This could be replacement with glutamine, which has a similar R group to
asparagine but has been shown to deamidate approximately 100-fold less efficiently (268). It
could also involve permanent, genetic deamidation, which would remove all biochemical
heterogeneity at the given site. All possible amino acid replacements could also be screened to
determine which most closely retains wtAAV efficiency. However, we have clearly demonstrated
that conversion to aspartic acid can be detrimental to vector performance, and our studies with
PAV9.1 epitope-based AAV9 vectors show that even conservative point mutations can
significantly change vector tropism.
Another possible approach to reduce deamidation would be to replace the N+1 residue
that is favorable for deamidation with one that is less favorable. This would likely be most
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effective for the highly deamidated NG motifs, as an exchange of the N+1 glycine to an alanine
should dramatically reduce deamidation. As previously discussed, such an approach would have
to be thoroughly evaluated for its impact on capsid formation and vector performance as it not
only changes the identity of the N+1 residue but also the functional identity of the asparagine
itself.
As previously mentioned, mutations or even aberrant deamidation due to vector
processing or handling conditions could also interfere with receptor interactions or interactions
with the immune system. The only partially characterized receptor for AAV8 is LamR, and aa491557 and aa593-623 of AAV8 VP1 have been implicated in these interactions (286). We identified
a number of deamidated asparagines within these regions, and while we cannot confirm at this
time that those residues are involved in LamR interactions due to the lack of further
characterization of its binding site, engineering efforts in this region could hinder the ability of
AAV8 to recognize this co-receptor. The same concern applies to AAV9, in which we found a
single asparagine, N515, to be deamidated that is also part of the putative galactose binding site
g(69). However, two additional asparagines, N272 and N470, in the galactose binding site were
not found to be deamidated. In general, deamidated residue involvement in or proximity to known
receptor binding sites should be determined and taken into consideration prior to engineering
efforts to modulate deamidation status of the AAV capsid.
Taken together, the studies described here highlight a number of obstacles to
successfully engineering AAV capsids, both those that are able to evade humoral immune
responses as well as those that are biochemically homogeneous. They also highlight a number of
previously unexplored aspects of basic AAV biology and provide support for the requirement of
further characterization of the capsid proteins in order to more efficiently design future
engineering efforts to address these obstacles. Overall, this work indicates the need to carefully
collate the available information regarding the function of capsid motifs for a given AAV of interest
in order to undertake capsid engineering efforts in a comprehensive and efficient fashion.
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Tables and Table Legends

Contact Residues
HVR

Position

V

496-NNN-498

VIII

588-QAQAQT-593
Occluded residues

HVR

Position

IV

G455, Q456

V

T494, Q495, E500

VIII

N583, H584, S586, A587

Table 1. PAV9.1 epitope residues indicated by cryo-reconstruction
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Residue (AAV9 VP1 numbering)
Vector

586

587

588

589

590

S

A

Q

A

Q

AAV9.AAQAA AAV9-like N/A

A

A

Q

A

A

AAV9.QQNAA AAV8/rh10 D/E

Q

Q

N

A

A

AAV9.SSNTA AAV3B

C

S

S

N

T

A

AAV9.RGNRQ AAV2

B

R

G

N

R

Q

R

G

H

R

E

AAV9.WT

Serotype
AAV9

Clade
F

AAV9.RGHRE AAV2-like N/A

Table 2. PAV9.1 HVR-VIII epitope residue mutagenesis scheme.
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Fold reduction
Fold increase
Percent WT
Percent WT
NAb titer
EC50
transduction (293) transduction (Huh7)
WT
1
1
100
100
AAQAA
16
45
27
11
QQNAA
128
124
53
19
SSNTA
512
264
58
11
RGNRQ
8
96
233
3
RGHRE
2048
294
60
3
TQAAA
16
15
50
8
SAQAN
16
40
76
18
SAQAA
4
20
54
7
Table 3. AAV9 capsid mutant characteristics following in vitro evaluation
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Donor
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

AAV2
5
5
<5
<5
<5
160
320
<5
40
80
160
<5
<5
<5
80
80
10
5
80
160
<5
20
<5
<5
160
80
<5
<5
10
40

AAV3B
N/A
N/A
N/A
N/A
N/A
10
40
N/A
5
10
40
N/A
N/A
N/A
N/A
N/A
N/A
N/A
10
80
N/A
5
N/A
N/A
20
20
<5
<5
N/A
N/A

NAb titer
AAV8
<5
<5
<5
<5
<5
10
40
<5
<5
10
160
<5
<5
<5
5
80
<5
20
<5
20
<5
<5
<5
<5
10
20
<5
<5
<5
10

AAV9
<5
<5
<5
<5
<5
80
80
<5
<5
20
1280
<5
<5
<5
5
80
<5
10
<5
5
<5
<5
<5
<5
10
80
<5
<5
<5
5

rh10
<5
<5
<5
<5
<5
20
80
<5
<5
20
160
<5
<5
<5
10
80
<5
20
5
40
<5
10
<5
<5
40
40
<5
<5
<5
20

Table 4. Neutralizing antibody titers of normal human donors against AAV. 30 serum
samples from normal human donors were evaluated for neutralizing antibody titers against AAV2,
AAV3B, AAV8, AAV9, and AAVrh10. Titer of <(1:)5 is defined as negative (LOD of assay); N/A
indicates titer was not determined for that sample against that serotype.
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Chain
VH
Validated
Total
Vκ
Validated
Total
Vλ
Validated
Total

Total
0.93
0.87
Total
1.74
1.21
Total
1.67
1.89

R/S
FWR1 CDR2 FWR2 CDR2 FWR3
0.32
1.52
0.89
2.33
0.79
0.34
1.81
0.89
2.18
0.79
FWR1 CDR2 FWR2 CDR2 FWR3
1.50
5.75
0.90
1.00
1.76
0.92
4.27
0.61
1.67
1.02
FWR1 CDR2 FWR2 CDR2 FWR3
1.57
2.00
1.11
6.50
1.11
1.75
2.17
1.17
7.50
1.42

Table 5. Summary of R/S ratios of variable region sequences from AAV memory B cells
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N35
N57
N94
N254*
N255*
N263
N305
N385
N410
N459
N499
N514*
N517*
N540*
N630*
N653

N+1
residue Structural topology
Q
N/A
G
N/A
H
N/A
N
Surface exposed
H
Surface exposed
G
Surface exposed
N
Buried
G
Surface exposed
N
Buried
T
Surface exposed
N
Surface exposed
G
Surface exposed
S
Surface exposed
G
Buried
F
Buried
T
Surface exposed

Average % Temperature
Structural motif deamidation factor (Å^2)
N/A
1
N/A
N/A
80
N/A
N/A
7
N/A
Not assigned
9
35
Not assigned
N/A
42
HVR I
99
51
Alpha helix
8
33
HVR III
88
41
Not assigned
3
33
HVR IV
7
65
HVR V
17
45
HVR V
84
36
HVR V
4
40
HVR VII
79
40
Not assigned
1
32
HI loop
1
35

Table 6. Characteristics of AAV8 deamidated residues of interest. Asterisks represent
residues selected for further analysis
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N57
N94
N253
N254
N270
N304
N329
N409
N452
N477
N512
N515
N651
N663
N668
N704
N709

N+1
residue Structural topology
G
N/A
H
N/A
N
Surface exposed
H
Surface exposed
D
Surface exposed
N
Buried
G
Surface exposed
N
Buried
G
Surface exposed
Y
Buried
G
Surface exposed
S
Surface exposed
T
Buried
K
Surface exposed
S
Surface exposed
Y
Surface exposed
N
Surface exposed

Average % Temperature
Structural motif deamidation factor (Å^2)
N/A
97
N/A
N/A
5
N/A
Not assigned
9
41
Not assigned
2
50
HVR I
11
65
Alpha helix
23
35
HVR II
94
89
Not assigned
9
36
HVR IV
98
64
Not assigned
2
33
HVR V
89
48
HVR V
3
47
HI loop
1
38
HI loop
4
49
HI loop
13
52
HVR IX
5
68
HVR IX
5
55

Table 7. Characteristics of AAV9 deamidated residues of interest. Conserved asparagine
residues with homologous N+1 residues (in comparison to AAV8) are denoted in italics
(determined by alignment of the full-length amino acid sequences of AAV8 and AAV9 VP1).
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Figures and Figure Legends

Figure 1. Structure of AAV1 VP3 monomer and assembled capsid. (A) Ribbon structure of an
AAV1 VP3 monomer. Orientation relative to 2-fold, 3-fold, and 5-fold axes is indicated by oval,
triangle, and pentagon, respectively. Largely conserved regions (β-barrel motif, βBIDG-βCHEF;
α-helix, αA; DE loop; HI loop) are colored in gray. Hypervariable regions (HVRs) are colored as
follows: I-purple, II-blue, III-yellow, IV-red, V-black, VI-magenta, VII-cyan, VIII-green, and IXbrown. (B) Surface model of the AAV1 capsid utilizing color scheme from (A) and the HI loop in
wheat. Figure from Tseng, 2014 Front Microbiol (50)
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Figure 2. Characterization of the AAV9 binding and neutralizing properties of PAV9.1 mAb.
(A) Determination of PAV9.1 binding to native and denatured capsids of a panel of AAV
serotypes. (B) Luciferase expression from liver in mice intravenously administered AAV9 +/passive transfer of α-AAV mAb (n=3).
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A.

D.

496-NNN-498

588-QAQAQT-593

B.

E.
C.

Figure 3. Cryo-EM reconstruction of AAV9 in complex with PAV9.1 Fab. (A) TEM image of
frozen AAV9-PAV9.1 Fab complex (B) Depiction of the molecular surface of AAV9 capsid
(fuchsia) bound with PAV9.1 Fab (blue at the protrusion of the three-fold axis) reconstructed to a
4.2Å resolution. 3,022 particles were boxed, and reconstruction was performed in Auto3dEM. (C)
Depiction of a cross-section of the AAV9-PAV9.1 complex reconstruction. (D) Pseudo-atomic
model of AAV9-PAV9.1 trimer complex built into electron density obtained from cryo-EM
reconstruction. VP3 monomers are shown in green, wheat, and cyan. Spheres represent PAV9.1
Fab bound residues. PAV9.1 Fab heavy chain is depicted in indigo and the light chain in red. (E)
Two-dimensional “roadmap” representation of HVR-V (orange) and HVR-VIII (blue) residues
involved in PAV9.1 binding.
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(490)
AAV9(487)
AAV8(489)
rh10(489)
AAV3B(487)
AAV2(486)
Consensus(490)

490

(580)
AAV9(577)
AAV8(579)
rh10(579)
AAV3B(577)
AAV2(576)
Consensus(580)

580

500

510

520

530

QRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFF
QRVSTTTGQNNNSNFAWTAGTKYHLNGRNSLANPGIAMATHKDDEERFF
QRVSTTLSQNNNSNFAWTGATKYHLNGRDSLVNPGVAMATHKDDEERFF
QRLSKTANDNNNSNFPWTAASKYHLNGRDSLVNPGPAMASHKDDEEKFF
QRVSKTSADNNNSEYSWTGATKYHLNGRDSLVNPGPAMASHKDDEEKFF
QRVSTT QNNNSNFAWTGATKYHLNGRDSLVNPGPAMASHKDDEERFF
HVR V
590

600

610

620

YGQVATNHQSAQAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHT
YGIVADNLQQQNTAPQIGTVNSQGALPGMVWQNRDVYLQGPIWAKIPHT
YGVVADNLQQQNAAPIVGAVNSQGALPGMVWQNRDVYLQGPIWAKIPHT
YGTVANNLQSSNTAPTTRTVNDQGALPGMVWQDRDVYLQGPIWAKIPHT
YGSVSTNLQRGNRQAATADVNTQGVLPGMVWQDRDVYLQGPIWAKIPHT
YG VA NLQ NHVR
AP VIII
TG VNSQGALPGMVWQDRDVYLQGPIWAKIPHT

Figure 4. Sequence alignment of PAV9.1 epitope residues of interest. Alignment of AAV VP1
amino acid sequence generated in Vector NTI; residues selected for mutagenesis are boxed.
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Figure 5. Determining the efficiency of capsid assembly of AAV9 PAV9.1 mutant vectors.
(A). Titers of AAV9 mutant vector in small scale, unpurified lysate relative to the titer of AAV9.WT.
(B). Titers of large scale, purified AAV9 mutant vectors full scale relative to the titer of AAV9.WT.
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Figure 6. Effect of epitope mutations on the EC50 of PAV9.1 mAb for AAV9. Capsid capture
ELISA against AAV9 was used to analyze and generate binding curves for PAV9.1 mAb. Panels
A-E illustrate binding curves for the following: (A) 586-590 swap mutants; (B) 494-498 mutants;
(C) 586-590 point mutants; (D) AAV9.TQAAA and AAV9.SAQAN single and combination
mutants; (E) AAV9.TQAAA and AAV9.SAQAA single and combination mutants. Absorbance was
normalized to maximum observed for each capsid; line of best fit and EC50 were determined
using the dose response function in Prism.
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Figure 7. Characterizing the impact of PAV9.1 epitope mutations on in vitro vector
transduction. Transduction efficiency of AAV9 mutant vectors relative to AAV9.WT transduction
was determined in (A) HEK293 cells using a β-galactosidase reporter gene and (B) Huh7 cells
using a firefly luciferase reporter gene. Significance was determined using a two-sided onesample t-test and compared the percent transduction of each mutant to the transduction of
AAV9.WT (defined as 100%). P-values indicated as follows: p*<0.05, p***<0.001. All data are
reported as mean + SD.
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Figure 8. Characterizing the impact of PAV9.1 epitope mutations on in vitro vector
transduction and effective PAV9.1 mAb neutralizing titer. (A) Determining the neutralizing
titer of PAV9.1 when transducing HEK293 cells with AAV9.WT.CMV.LacZ; (B) AAV9.AAQAA; (C)
AAV9.QQNAA; (D) AAV9.SSNTA; (E) AAV9.RGNRQ; (F) AAV9.RGHRE; (G) AAV9.TQAAA; (H)
AAV9.AANNN; (I) AAV9.SAQAN; or (J) AAV9.SAQAA. Neutralizing titer was defined as the
dilution prior to the point where transduction levels of 50% or greater than the vector without mAb
were achieved (levels measured in relative light units with a β-galactosidase reporter system). All
data are reported as mean ± SD.
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Figure 9. Correlation between PAV9.1 EC50 and neutralizing titer for AAV9 mutant panel.
Fold reduction in PAV9.1 neutralizing titer against each mutant relative to PAV9.1 neutralizing
titer against AAV9.WT was determined. Data was plotted on a log scale against the fold increase
in PAV9.1 EC50 for each mutant relative to PAV9.1 EC50 for AAV9.WT on a linear scale (semi2
log plot), using GraphPad Prism to determine the semi-log line of best fit; R = 0.8474.
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Figure 10. In vivo analysis of AAV9 PAV9.1 mutant vector biodistribution and transgene
expression. C57BL/6 mice received intravenous injections of either 1e11 GC per mouse (panels
A-C) or 1e12 GC per mouse (panels D-F) AAV9.CMV.LacZ (WT or mutant; n=3). Mice were
122

sacrificed on day 14 and tissues were harvested for biodistribution analysis (panels A, D) using
Taqman qPCR. Values are reported as mean ± SD. We also harvested liver (panels B, E), heart
(panels C, F) and muscle (panel G) for β-galactosidase histochemistry to determine enzyme
activity. Representative 10X images are shown; scale bars=200µm.
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Figure 11. Effect of epitope mutations on EC50 of injected mouse plasma for AAV9-based
vectors. Using capsid capture ELISA, day 56 plasma of mice that received intravenous injections
of either (A) 7.5e8 GC/mouse; or (B) 7.5e9 GC/mouse wtAAV9.LSP.hFIX was analyzed for
124

AAV9.WT or AAV9 PAV9.1 mutant binding. Absorbance was normalized to the maximum
absorbance achieved for each capsid. The line of best fit and EC50 were determined using the
dose response function in Prism. Each graph corresponds to a single animal. EC50 values were
compiled for (C) 7.5e8 GC/mouse; or (D) 7.5e9 GC/mouse dose groups in order to determine the
average for each mutant. A two-sided one-sample t-test was used to determine if there was a
significant difference between the EC50 of plasma for each mutant relative to the EC50 of plasma
for AAV9.WT (defined as 1). P-values are represented as follows: ** = p<0.01, *** = p<0.001.
EC50 data are reported as mean ± SD.
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Figure 12. Effect of epitope mutations on EC50 of NHP polyclonal serum for AAV9-based
vectors. Using capsid capture ELISA, sera from (A) NHPs treated with AAV9.WT or hu68.WT
vector; or (B) naïve NHPs that are AAV9 NAb (+) were analyzed for AAV9.WT or AAV9 PAV9.1
mutant binding. Absorbance was normalized to the maximum absorbance achieved for each
126

capsid using the dose response function in Prism to determine the line of best fit and EC50. Each
graph corresponds to a single animal. EC50 values for (C) vector-treated NHPs; and (D) naïve
NAb (+) NHPs were compiled to determine the average for each mutant. A two-sided one-sample
t-test was used to determine if there is a significant difference between the EC50 of plasma for
each mutant relative to the EC50 of plasma for AAV9.WT (defined as 1). EC50 data are reported
as mean ± SD.
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Figure 13. Effect of epitope mutations on EC50 of human donor polyclonal sera for AAV9based vectors. (A) Sera from naïve human donors that were AAV9 NAb (+) were evaluated for
AAV9.WT or AAV9 PAV9.1 mutant binding using capsid capture ELISA. The line of best fit and
EC50 were determined using the dose-response function in Prism. Each graph corresponds to a
single donor. (B) The EC50 values for NAb (+) human donor serum were compiled to determine
the average for each mutant. Significance was determined by using a two-sided one-sample t-test
and compared the EC50 of plasma for each mutant relative to the EC50 of plasma for AAV9.WT
(defined as 1). P-values are represented as follows: * = p<0.05. EC50 data are reported as mean
± SD.
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Figure 14. Evaluation of human αAAV mAbs for AAV capsid binding. (A-B). Recombinant
Donor 7 mAbs were produced and evaluated for (A) AAV2 or (B) AAV3B binding by ELISA.
Samples were diluted to 100ng/mL (white bars) or 250ng/mL (gray bars) for evaluation. Some
samples could not be produced at sufficient concentration to evaluate at 250ng/mL (#); at either
concentration, AAV binding could not be detected for some mAbs (*). (C) Recombinant mAbs
(100ng/mL or 100ng/mL and 250ng/mL, where applicable) were evaluated for binding to a larger
panel of AAV serotypes, and binding relative to AAV2 was determined based on absorbance.
Data from samples for which 100ng/mL and 250ng/mL concentrations could be evaluated are
displayed as mean +SD.
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Figure 15. Evaluation of total nucleotide mutations in AAV memory B cell variable region
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Figure 16. Mutational frequency in AAV memory B cell isolated variable chain sequences.
We determined the frequency of nucleotide (nt) substitutions, defined as the percentage of
positions containing a substitution, in the total isolated sequence (“total”), framework regions
(“FWR1”, “FWR2”, “FWR3”), and complementarity determining regions (“CDR1”, “CDR2”) (as
defined by IMGT). Frequencies were determined for validated variable heavy (A), variable kappa
(C), and variable lambda (E) sequences as well as all isolated variable heavy (B), variable kappa
(D), and variable lambda (F). Data are displayed as mean ± SD.
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Figure 17. Evaluation of silent vs. replacement mutation frequency in AAV memory B cell
isolated variable chain sequences. Frequency of nucleotide substitutions resulting in amino
acid substitutions (replacement, R) and the frequency of nucleotide substitutions not resulting in
amino acid substitutions (silent, S) were quantified (based on IMGT best germline DNA/protein
sequences) for the complete isolated sequence (“total”), framework regions (“FWR1”, “FWR2”,
“FWR3”), and complementarity determining regions (“CDR1”, “CDR2”). Frequencies were
determined for validated variable heavy (A), variable kappa (C), and variable lambda (E)
sequences as well as all isolated variable heavy (B), variable kappa (D), and variable lambda (F).
R/S ratios were also calculated based on these frequencies; values indicated to the right of bars.
Data are displayed as means.
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Figure 18. Deamidation and the electrophoretic analysis of AAV8 VP isoforms. (A) Diagram
illustrating the mechanism by which asparagine residues undergo nucleophilic attack by adjacent
nitrogen atoms, forming a succinimidyl intermediate. This intermediate then undergoes
hydrolysis, resolving into a mixture of aspartic acid and isoaspartic acid. The beta carbon is
labeled as such. The diagram was generated in BIOVIA Draw 2018. (B) 1 μg of AAV8 vector was
run on a denaturing one-dimensional SDS-PAGE. (C) Isoelectric points of carbonic anhydrase pI
marker spots are shown. (D) 5 μg of AAV8 vector was analyzed by two-dimensional gel
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Figure 19. Identification of deamidated peptides by mass spectrometry. (A-B) Electrospray
ionization (ESI) mass spectrometry and theoretical and observed masses of the 3+ peptide (93103) containing Asn-94 (A) and Asp-94 (B) are shown. (C-D) ESI mass spectrometry and
theoretical and observed masses of the 3+ peptide (247-259) containing Asn-254 (C) and Asp254 (D) are shown. The observed mass shifts for Asn-94 and Asn-254 were 0.982 Da and 0.986
Da, respectively, versus a theoretical mass shift of 0.984 Da.
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Figure 20. Analysis of asparagine and glutamine deamidation in AAV8 capsid proteins.
Percent deamidation at specific asparagine and glutamine residues of interest are shown for
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Figure 21. Determination of factors influencing AAV8 capsid deamidation. An AAV8 prep
o
was (A) incubated at 70 C for three or seven days, (B) exposed to pH 2 or pH 10 for seven days,
or (C) prepared for mass spectrometry using D2O in place of H2O to determine possible sources
of deamidation not intrinsic to AAV capsid formation.
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Figure 22. Determination of deamidation frequencies in non-AAV proteins containing
frequent asparagine and glutamine residues. Deamidation percentages are shown for two
non-AAV recombinant proteins containing NG motifs likely to be deamidated, human carbonic
anhydrase (A) and rat phenylalanine-hydroxylase (B), for comparison with AAV deamidation
percentages.
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Figure 23. Comparison of AAV8 percent deamidation calculated using data analysis
pipelines from two institutions. Percent deamidation at specific asparagine and glutamine
residues of interest are shown for AAV8 tryptic peptides evaluated at two different institutions.
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Figure 24. Structural modeling of the AAV8 VP3 monomer and analysis of deamidated
sites. (A) The AAV8 VP3 monomer is shown in a coil representation. The color of the ribbon
indicates the relative degree of flexibility (blue=most rigid/low temperature factor, red=most
flexible/high temperature factor). Spheres indicate residues of interest. Expanded diagrams are
ball and stick representations of residues of interest and their surrounding residues to
demonstrate local protein structure (Blue=nitrogen, red=oxygen). Underlined residues are those
in NG motifs. B-E. Isoaspartic models of deamidated asparagines with N+1 glycines are shown.
The 2FoFc electron density map (1 sigma level) generated from refinement of the AAV8 crystal
structure with (B) an asparagine model of N410 in comparison with isoaspartic acid models of (C)
N263, (D) N514, and (E) N540. Electron density map is shown in magenta grid. All atoms are
colored by atom type: carbon=purple (B)/green (C-E), nitrogen=blue, oxygen=pink. The beta
carbon is labeled as such. Arrow indicates electron density corresponding to the R group of the
residue of interest.
139

wtAAV8
80 kDa

A
D
B

65

C
50
40
30
E

25
pH 10

pH 6

A

A

N517D

N255D

wtAAV8

D

D
B

A

D

B

B

C

C

C

A-AAV8 VP1: 87kDa
D-Conalbumin: 76kDa

E

E

E

B-AAV8 VP2: 73kDa
E-Turbonuclease: 27kDa

C-AAV8 VP3: 61kDa

Figure 25. 2D gel electrophoretic analysis of wtAAV8 and genetic deamidation mutants.
1e11 GC of (A) wtAAV8 or (B-D, insets indicated by white box in A) mutant vector were analyzed
by 2D gel electrophoresis and stained with Sypro Ruby. Protein labeling: A=VP1; B=VP2; C=VP3,
D=chicken egg white conalbumin marker, E=turbonuclease marker. Isoelectric focusing was
performed with a pI range of 6-10. Primary VP1/2/3 isoform spots are circled, and migration
distance of major spots of markers are indicated by vertical lines (turbonuclease=dashed,
conalbumin=solid).
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Figure 26. In vitro and in vivo analyses of the impact of genetic deamidation on vector
performance. (A) Titers of wtAAV8 and genetic deamidation mutant vectors were produced by
small-scale triple transfection in 293 cells, as measured by quantitative PCR (qPCR). Titers are
reported in GC/mL. Data are represented as mean ± standard deviation. (B) The transduction
efficiency of mutant AAV8 vectors producing firefly luciferase is reported in relative light units
(RLUs). A non-parametric t test (Mann-Whitney; *p<0.05) was run to determine significance
between wtAAV8 and mutant transgene expression. Data are represented as mean ± standard
deviation. (C) Luciferase expression from C57BL/6 mice injected intravenously with wtAAV8 and
deamidation mutant vectors (n=3) was measured by luciferase imaging and reported in total flux
over a 56-day study period. Data are represented as mean + standard error mean. A linear mixed
effects model was run in R to determine significance longitudinally across all timepoints, with
141

p<0.05 considered significant; N255D showed a significant difference compared to
wtAAV8.CMV.ffluc. (D) Representative luciferase images at day 56 post-injection are shown for
mice receiving wtAAV8.CMV.ffluc and N255D capsid mutant vector. (E) GC analysis of liver
tissue harvested from mice at day 56 post-injection (as measured by qPCR, reported in
GC/diploid genome). No significance was detected between wtAAV8 and mutants based on a
non-parametric t test (Mann-Whitney; p<0.05). Data are represented as mean ± standard error
mean.
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Figure 27. Analysis of asparagine and glutamine deamidation in AAV9 capsid proteins. (A)
1e11 GCs of wtAAV9 were analyzed by 2D gel electrophoresis and stained with Sypro Ruby.
Protein labeling: A=VP1; B=VP2; C=VP3, D=chicken egg white conalbumin marker,
E=turbonuclease marker. Isoelectric focusing was performed with a pI range of 6-10. (B) Percent
deamidation at specific asparagine and glutamine residues of interest are shown for AAV9 tryptic
peptides purified by different methods. Bars indicating deamidation at asparagine residues with
N+1 glycines are crosshatched. Residues determined to be at least 2% deamidated in at least
one prep analyzed were included. Data are represented as mean ± standard deviation. (C)
Isoaspartic model of N512 is shown in the 2FoFc electron density map generated by non-biased
refinement of the AAV9 crystal structure (PDB ID: 3UX1). Arrow indicates electron density
corresponding to the R group of residue N512.
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Figure 28. Determination of factors influencing AAV9 capsid deamidation. AAV9 preps were
(A) incubated at 70oC for three or seven days or (B) exposed to pH 2 or pH 10 for seven days to
determine possible sources of deamidation not intrinsic to AAV capsid formation. Data are
represented as mean + SD.
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